

DATE 6/11/07

APPLICATION NUMBER 10/671,070

DOC CODE SRNT

DOC DATE 6/10/07


DELIVER THE ATTACHED FILE/DOCUMENT TO THE TC  
SCANNING CENTER

CONTRACTOR: THE ATTACHED FILE/DOCUMENT MUST BE  
INDEXED AND SCANNED INTO IFW WITHIN 8 WORK HOURS;  
UPLOADING OF THE SCANNED IMAGES SHOULD OCCUR NO  
LATER THAN 16 WORK HOURS  
FOLLOWING RECEIPT OF THIS REQUEST

AFTER SCANNING, ORIGINAL DOCUMENTS SHOULD BE BOXED IN  
ACCORDANCE WITH INSTRUCTIONS

10/671,070

SRNT



chain nodes :

19 20 21 22 23 24 34 37 39 41

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-11 3-41 5-34 8-39 15-34 19-21 20-23 21-22 23-24

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

3-41 5-34 15-34 20-23

exact bonds :

1-11 8-39 19-21 21-22 23-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 : 7 :

G1:N,[\*1-\*2],[\*3-\*4]

G2:C,O,N,Cl,Br,F,I

G3:C,H,O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS20:CLASS21:CLASS22:CLASS23:CLASS24:CLASS34:CLASS37:CLASS38:Atom



10/671,070

=>

Uploading C:\Program Files\Stnexp\Queries\10671070 (rce).str



chain nodes :  
19 20 21 22 23 24 34 37  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
chain bonds :  
1-11 5-34 15-34 19-21 20-23 21-22 23-24  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
14-15 15-16 16-17 17-18  
exact/norm bonds :  
5-34 15-34 20-23  
exact bonds :  
1-11 19-21 21-22 23-24  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
14-15 15-16 16-17 17-18  
isolated ring systems :  
containing 1 : 7 :

G1:N, [\*1-\*2], [\*3-\*4]

G2:C,O,N,Cl,Br,F,I

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 34:CLASS 37:CLASS 38:Atom  
Page 1



L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1        STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -    AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 23:07:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        3391 TO ITERATE

59.0% PROCESSED        2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*



PROJECTED ITERATIONS:        64328 TO        71312

PROJECTED ANSWERS:            1172 TO        2286

L2        50 SEA SSS SAM L1

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (RCE 1).str



chain nodes :  
 19 20 21 22 23 24 34 37  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
 chain bonds :  
 1-11 5-34 15-34 19-21 20-23 21-22 23-24  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
 14-15 15-16 16-17 17-18  
 exact/norm bonds :  
 5-34 15-34 20-23  
 exact bonds :  
 1-11 19-21 21-22 23-24  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
 14-15 15-16 16-17 17-18  
 isolated ring systems :  
 containing 1 : 7 :

G1:N, [\*1-\*2], [\*3-\*4]

G2:C,O,N,Cl,Br,F,I

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 34:CLASS 37:CLASS 38:Atom

L3        STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -    AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam

SAMPLE SEARCH INITIATED 23:09:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        3391 TO ITERATE

59.0% PROCESSED        2000 ITERATIONS

39 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        64328 TO        71312

PROJECTED ANSWERS:            835 TO        1809

L4                39 SEA SSS SAM L3

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (RCE 2).str



chain nodes :  
 19 20 21 22 23 24 34 37 39  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
 chain bonds :  
 1-11 5-34 8-39 15-34 19-21 20-23 21-22 23-24  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
 14-15 15-16 16-17 17-18  
 exact/norm bonds :  
 5-34 15-34 20-23  
 exact bonds :  
 1-11 8-39 19-21 21-22 23-24  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
 14-15 15-16 16-17 17-18  
 isolated ring systems :  
 containing 1 : 7 :

G1:N, [\*1-\*2], [\*3-\*4]

G2:C,O,N,Cl,Br,F,I

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 34:CLASS 37:CLASS 38:Atom  
 39:CLASS

L5        STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -    AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 23:12:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        3391 TO ITERATE

59.0% PROCESSED        2000 ITERATIONS

26 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*



PROJECTED ITERATIONS:        64328 TO        71312

PROJECTED ANSWERS:            483 TO        1279

L6                26 SEA SSS SAM L5

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (RCE 3).str



chain nodes :  
 19 20 21 22 23 24 34 37 39 41  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
 chain bonds :  
 1-11 3-41 5-34 8-39 15-34 19-21 20-23 21-22 23-24  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
 14-15 15-16 16-17 17-18  
 exact/norm bonds :  
 3-41 5-34 15-34 20-23  
 exact bonds :  
 1-11 8-39 19-21 21-22 23-24  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
 14-15 15-16 16-17 17-18  
 isolated ring systems :  
 containing 1 : 7 :

G1:N, [\*1-\*2], [\*3-\*4]

G2:C,O,N,Cl,Br,F,I

G3:C,H,O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 34:CLASS 37:CLASS 38:Atom  
 39:CLASS 41:CLASS

L7           STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7           STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 17 sss sam

SAMPLE SEARCH INITIATED 23:17:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3391 TO ITERATE

59.0% PROCESSED       2000 ITERATIONS

23 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 64328 TO 71312

PROJECTED ANSWERS: 405 TO 1153

L8           23 SEA SSS SAM L7

=> => s 17 sss ful

FULL SEARCH INITIATED 23:18:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 67392 TO ITERATE

100.0% PROCESSED       67392 ITERATIONS

1049 ANSWERS

SEARCH TIME: 00.00.01

L9           1049 SEA SSS FUL L7

=> => s 19

L10           52 L9

=> d 110 1-52 bib,ab,hitstr

L10 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:538462 CAPLUS  
 TI Pyrimidine compounds and compositions for protein kinase inhibitors and their preparation and use in the treatment of diseases associated with abnormal protein kinase activity  
 IN Zhang, Qiong; Gray, Nathanael S.; Liu, Yi; Ding, Qiang; Uno, Tetsuo  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 33pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056151	A2	20070518	WO 2006-US42975	20061103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-733570P P 20051103

AB The invention provides a class of compds. of formula I, pharmaceutical compns. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Lck, IR, IGF-1R, JNK1, Flt3, Fes, EFGR (Her-1, erbB-1), cSRC, CDK1/cyclin B, c-RAF, BTK, Bmx, Axl, Aurora-A, Abl, BCR-Abl, TrkB, Tie2, Syk, SGK, SAPK2 $\alpha$ , Rsk1 and Met kinases. Compds. of formula I wherein n and m are independently 1, 2, and 3; X1 is O, NH and NMe; X3 is O and NH; Y is N and CH; R1 is C1-4 (halo)alkyl, C1-4 (halo)alkoxy, and halo; R2 is C1-4 (halo)alkyl, C1-4 (halo)alkoxy, halo, NHCOR3; R3 is cycloalkyl; and their pharmaceutically acceptable salts, hydrates, solvates and isomers thereof, are claimed. Example compound II was prepared by amination of 4,6-dichloropyrimidine; the resulting (6-chloropyrimidin-4-yl)-(3-trifluoromethylphenyl)amine underwent substitution with N-(3-aminophenyl) cyclopropanecarboxamide to give compound II. All the invention compds. were evaluated for their protein kinase inhibitory activity. From the assay, it was determined that the invention compds. exhibited IC50 values in the range of 10 nM to 2  $\mu$ M.

IT 879127-13-6P 879127-14-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrimidine compds. useful in treatment and prevention of diseases - associated with abnormal activities of protein kinases)

RN 879127-13-6 CAPLUS

CN Cyclopropanecarboxamide, N-[3-[[6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




10/671,070



RN 879127-14-7 CAPLUS

CN Cyclopropanecarboxamide, N-[3-[[6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:464386 CAPLUS  
 DN 146:455241  
 TI Dihydrogen phosphate salt of a Prostaglandin D2 receptor antagonist as allergy inhibitor.  
 IN Langevin, Beverly; Orton, Edward; Sherer, Daniel  
 PA Aventis Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 42pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007047378	A2	20070426	WO 2006-US39901	20061012
W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-726290P P 20051013

AB The present invention is directed to the dihydrogen phosphate salt of 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid, a pharmaceutical composition comprising a pharmaceutically effective amount of the compound, and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the PGD2 antagonist.


IT 885066-66-0

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(dihydrogen phosphate salt of prostaglandin D2 receptor antagonist)

RN 885066-66-0 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 934815-71-1

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(dihydrogen phosphate salt of prostaglandin D2 receptor antagonist)


RN 934815-71-1 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 885066-67-1


CMF C23 H23 Cl2 N3 O3



CM 2

CRN 7664-38-2

CMF H3 O4 P



IT 885066-67-1P, 2-[3-[6-[2-(2,4-Dichlorophenyl)ethylamino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(dihydrogen phosphate salt of prostaglandin D2 receptor antagonist)

RN 885066-67-1 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-

10/671,070

pyrimidinyl]- $\alpha,\alpha$ -dimethyl- (CA INDEX NAME)



L10 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:409487 CAPLUS  
 DN 146:380009  
 TI Preparation of phenylpyrimidinecarbonitriles as cathepsin K and S inhibitors.  
 IN Rankovic, Zoran; Cai, Jiaqiang  
 PA N. V. Organon, Neth.  
 SO PCT Int. Appl., 43pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007039470	A1	20070412	WO 2006-EP66562	20060921
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

	US 2007111992	A1	20070517	US 2006-524841	20060921
PRAI	EP 2005-108810	A	20050923		
	US 2005-719801P	P	20050923		

OS MARPAT 146:380009

AB Title compds. [I; R = 1-3 of H, alkyl, haloalkyl, alkoxy, haloalkoxy, halo; X = NR1, O, S; R1 = H, alkyl; Y = benzyl, (substituted) alkyl; R1YN = 5-8 membered saturated (substituted) heterocyclyl], were prepared Thus, 4-(piperazin-1-yl)-6-(3-trifluoromethylphenyl)pyrimidine-2-carbonitrile as the TFA salt was prepared in 5 steps from 4,6-dichloro-2-methylthiopyrimidine, N-Boc-piperazine, and 3-trifluoromethylphenylboronic acid. I inhibited cathepsin K with pIC50 >6.

IT 932046-68-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpyrimidinecarbonitriles as cathepsin K and S inhibitors)


RN 932046-68-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 932046-67-8

CMF C22 H20 F3 N5




10/671,070

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:61837 CAPLUS  
 DN 146:156236  
 TI Cellular cholesterol absorption modifiers, and their therapeutic use  
 IN Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance,  
 Daniel L.; Semple, Joseph E.  
 PA Kalypsys, Inc., USA  
 SO PCT Int. Appl., 300pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007008541	A2	20070118	WO 2006-US26242	20060705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-697659P	P	20050708		
US 2005-697686P	P	20050708		
US 2005-697814P	P	20050708		
US 2005-727646P	P	20051017		
US 2006-782303P	P	20060313		
OS MARPAT 146:156236				
AB	The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.			
IT 920527-90-8	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cholesterol absorption modifiers and therapeutic use)			
RN 920527-90-8 CAPLUS				
CN 9H-Carbazol-3-amine, 9-ethyl-N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)				



L10 ANSWER 5 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1249826 CAPLUS  
 DN 146:781  
 TI Methods of treating pain  
 IN Wabnitz, Philipp; Schauerte, Heike; Stumm, Gabriele; Freitag, Joachim  
 PA Ingenium Pharmaceuticals A.-G., Germany  
 SO PCT Int. Appl., 132pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006125616	A2	20061130	WO 2006-EP4924	20060524
	WO 2006125616	A3	20070419		
	W:	AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HW, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2005-684345P P 20050525

OS MARPAT 146:781

AB The invention relates to methods of treating any type of pain comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

IT 848636-15-7 848636-17-9 848636-18-0  
 848636-21-5 848636-22-6 848636-23-7  
 848636-25-9 848636-27-1 848636-28-2  
 848636-31-7 848636-32-8 848636-33-9  
 848636-34-0 848636-35-1 848636-41-9  
 848636-42-0 848636-43-1 848636-46-4  
 848636-47-5 848636-48-6 848636-49-7  
 848636-50-0 848636-51-1 848636-52-2  
 848636-53-3 848636-54-4 848636-55-5  
 848636-57-7 848636-58-8 848636-59-9  
 848636-60-2 848636-61-3 848636-62-4  
 848636-63-5 848636-64-6 848636-65-7  
 848636-66-8 848636-67-9 848636-68-0  
 848636-69-1 848636-70-4 848636-71-5  
 848636-72-6 848636-74-8 848636-75-9  
 848636-76-0 848636-77-1 848636-78-2  
 848636-79-3 848636-81-7 848636-82-8  
 848636-83-9 848636-84-0 848636-88-4  
 848636-94-2 848636-95-3 848636-96-4  
 848636-97-5 848636-98-6 848636-99-7  
 848637-00-3 848637-02-5 848637-03-6  
 848637-04-7 848637-08-1 848637-09-2  
 848637-10-5 848637-11-6 848637-13-8  
 848637-14-9 848637-15-0 848637-16-1  
 848637-17-2 848637-18-3 848637-20-7  
 848637-21-8 848637-22-9 848637-24-1  
 848637-25-2 848637-26-3 848637-27-4  
 848637-28-5 848637-29-6 848637-30-9




848637-31-0 848637-32-1 848637-33-2  
 848637-34-3 848637-35-4 848637-36-5  
 848637-37-6 848637-38-7 848637-39-8  
 848637-40-1 848637-41-2 848637-42-3  
 848637-43-4 848637-44-5 848637-46-7  
 848637-47-8 848637-48-9 848637-49-0  
 848637-50-3 848637-51-4 848637-52-5  
 848637-53-6 848637-54-7 848637-55-8  
 848637-56-9 848637-57-0 848637-58-1  
 848637-59-2 848637-60-5 848637-61-6  
 848637-62-7 848637-63-8 848637-64-9  
 848637-65-0 848637-66-1 848637-67-2  
 848637-68-3 848637-69-4 848637-70-7  
 848637-71-8 848637-72-9 848637-74-1  
 848637-75-2 848637-76-3 848637-77-4  
 848637-78-5 848637-80-9 848637-81-0  
 848637-82-1 848637-90-1 848637-91-2  
 848637-93-4 848637-94-5 848637-95-6  
 848637-96-7 848637-97-8 848637-98-9  
 848638-00-6 848638-02-8 848638-04-0  
 848638-05-1 848638-06-2 848638-07-3  
 848638-08-4 848638-09-5 848638-10-8  
 848638-13-1 848638-15-3 848638-16-4  
 848638-19-7 848638-21-1 848638-22-2  
 848638-23-3 848638-26-6 848638-28-8  
 848638-29-9 848638-30-2 848638-38-0  
 848638-41-5 848638-42-6 848638-43-7  
 848638-44-8 848638-45-9 848638-46-0  
 848638-47-1 848638-48-2 848638-49-3  
 848638-50-6 848638-51-7 848638-52-8  
 848638-53-9 848638-54-0 848638-55-1  
 848638-56-2 848638-57-3 848638-58-4  
 848638-59-5 848638-60-8 848638-61-9  
 848638-62-0 848638-63-1 848638-64-2  
 848638-65-3 848638-66-4 848638-67-5  
 848638-68-6 848638-69-7 848638-70-0  
 848638-71-1 848638-72-2 848638-73-3  
 848638-74-4 848638-75-5 848638-77-7  
 848638-78-8 848638-79-9 848638-80-2  
 848638-82-4 848638-83-5 848638-84-6  
 848638-86-8 848638-87-9 848638-88-0  
 848638-89-1 848638-90-4 848638-91-5  
 848638-92-6 848638-93-7 848638-95-9  
 848638-96-0 848638-97-1 848638-98-2  
 848639-00-9 848639-04-3 848639-05-4  
 848639-06-5 848639-07-6 848639-08-7  
 848639-09-8 848639-10-1 848639-11-2  
 848639-12-3 848639-13-4 848639-15-6  
 848639-16-7 848639-17-8 848639-19-0  
 848639-21-4 848639-22-5 848639-24-7  
 848639-25-8 848639-28-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (methods of treating pain)


RN 848636-15-7 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-  
 4-methyl- (CA INDEX NAME)




RN 848636-17-9 CAPLUS

CN Benzenesulfonamide, 4-amino-N-[4-[[6-(2-methoxyphenyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-18-0 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-methyl- (CA INDEX NAME)




RN 848636-21-5 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-22-6 CAPLUS

CN 2-Pyrrolidinone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-23-7 CAPLUS

CN Acetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-25-9 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848636-27-1 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848636-28-2 CAPLUS

CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848636-31-7 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-methyl-N-propyl- (CA INDEX NAME)




RN 848636-32-8 CAPLUS

CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 848636-33-9 CAPLUS

CN Benamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-34-0 CAPLUS

CN Benamide, 4-amino-N-[4-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-35-1 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 848636-41-9 CAPLUS


CN Glycine, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-N-[(4-methylphenyl)sulfonyl]-, methyl ester (CA INDEX NAME)



RN 848636-42-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848636-43-1 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-46-4 CAPLUS

CN Methanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-47-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-48-6 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-49-7 CAPLUS

CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-50-0 CAPLUS

CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-α-(1-methylethyl)- (CA INDEX NAME)




RN 848636-51-1 CAPLUS

CN Urea, N-cyclohexyl-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-52-2 CAPLUS


CN Benzamide, 4-amino-N-[4-[[6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-53-3 CAPLUS


CN 2-Propenoic acid, 3-[3-[6-[[4-[(4-methylphenyl)sulfonyl]amino]phenyl]amino]pyrimidinyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 848636-54-4 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-55-5 CAPLUS


CN Butanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3,3-dimethyl- (CA INDEX NAME)






10/671,070


RN 848636-57-7 CAPLUS  
CN Benzamide, N-cyclohexyl-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848636-58-8 CAPLUS  
CN Benzamide, 4-(1,1-dimethylethyl)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-59-9 CAPLUS  
CN Acetamide, 2-(dimethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-60-2 CAPLUS  
CN Carbamic acid, N-[1-[[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 848636-61-3 CAPLUS  
CN 1-Piperidinecarboxylic acid, 2-[2-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

INDEX NAME)




RN 848636-62-4 CAPLUS

CN Benzamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 848636-63-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-64-6 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2,6-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-65-7 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 848636-66-8 CAPLUS

CN Guanidine, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-67-9 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848636-68-0 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-69-1 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2,3-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-70-4 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-71-5 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-72-6 CAPLUS

CN 2-Piperidineacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-74-8 CAPLUS


CN Tricyclo[3.3.1.1<sup>3,7</sup>]decane-1-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME).




RN 848636-75-9 CAPLUS  
 CN 4-Pyrimidinamine, N-[4-(2-benzoxazolyl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)



RN 848636-76-0 CAPLUS  
 CN 4-Pyrimidinamine, N-[4-(1H-benzimidazol-2-yl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848636-77-1 CAPLUS  
 CN Propanamide, 3-(diethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-78-2 CAPLUS  
 CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-79-3 CAPLUS

CN Cyclohexanecarboxamide, 1-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-81-7 CAPLUS


CN Cyclopentanecarboxamide, 1-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-82-8 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-83-9 CAPLUS

CN 1H-Imidazole-4-carboxamide, 4,5-dihydro-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)




RN 848636-84-0 CAPLUS

CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-88-4 CAPLUS

CN Benzoic acid, 3-[6-[[4-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 848636-94-2 CAPLUS

CN Benzeneacetamide, alpha-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (alphaS)- (CA INDEX NAME)

10/671,070


Absolute stereochemistry.



RN 848636-95-3 CAPLUS

CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-  
α-(methylamino)-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848636-96-4 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848636-97-5 CAPLUS


CN 2-Benzothiazolecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 848636-98-6 CAPLUS

CN Propanamide, 2,2-dimethyl-N-[4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-99-7 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-3-piperidinyl- (CA INDEX NAME)




RN 848637-00-3 CAPLUS

CN 3-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)



RN 848637-02-5 CAPLUS


CN 4-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)



RN 848637-03-6 CAPLUS

CN 2-Azetidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848637-04-7 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-08-1 CAPLUS

CN Benzamide, 4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-09-2 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]methylamino]phenyl]-4-methyl- (CA INDEX NAME)




RN 848637-10-5 CAPLUS

CN Benzamide, 4-amino-N-[4-[[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-11-6 CAPLUS

CN 2-Quinolinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-13-8 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-14-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -(dimethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-


10/671,070

pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-15-0 CAPLUS

CN Propanamide, 3-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-16-1 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-(3-aminopropoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-17-2 CAPLUS

CN Acetamide, N-[3-[6-[[4-methyl-3-[(methylsulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 848637-18-3 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-20-7 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-21-8 CAPLUS

CN Methanesulfonamide, N-[3-[6-[[4-methyl-3-[(methanesulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 848637-22-9 CAPLUS

CN Benzenesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-24-1 CAPLUS

CN Urea, N-1,3-benzodioxol-5-yl-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-25-2 CAPLUS

CN Urea, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-N'-(4-methylphenyl)methyl- (CA INDEX NAME)




RN 848637-26-3 CAPLUS

CN Urea, N-(1,1-dimethylethyl)-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-27-4 CAPLUS

CN Propanamide, 2,2-dimethyl-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-28-5 CAPLUS

CN Benzamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-29-6 CAPLUS

CN 1-Propanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-30-9 CAPLUS

CN Benzenesulfonamide, 4-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-31-0 CAPLUS

CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2-methyl-2-(methylamino)- (CA INDEX NAME)




RN 848637-32-1 CAPLUS

CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-3-methylphenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 848637-33-2 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 848637-34-3 CAPLUS


CN Methanesulfonamide, N-[3-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-35-4 CAPLUS


CN Propanamide, N-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)






RN 848637-36-5 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 848637-37-6 CAPLUS

CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-38-7 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 848637-39-8 CAPLUS

CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 848637-40-1 CAPLUS  
 CN Propanamide, N-[4-[[6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 848637-41-2 CAPLUS  
 CN 2-Piperidinecarboxamide, N-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-42-3 CAPLUS  
 CN 2H-1-Benzopyran-3-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2-oxo- (CA INDEX NAME)




RN 848637-43-4 CAPLUS  
 CN 1,3-Benzodioxole-5-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

10/671,070




RN 848637-44-5 CAPLUS

CN Propanamide, N-[4-[[6-(2-ethylphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)



RN 848637-46-7 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-47-8 CAPLUS


CN Benzamide, N-[(1R,2R)-2-hydroxycyclohexyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 848637-48-9 CAPLUS

CN Benzamide, N-(4-hydroxyphenyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-49-0 CAPLUS

CN Benzamide, 4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-N-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 848637-50-3 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, N-[4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-51-4 CAPLUS


CN 2-Naphthalenecarboxamide, 1-hydroxy-N-[4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-52-5 CAPLUS


CN Pentanamide, 2-amino-N-[4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-53-6 CAPLUS

CN 1H-Indazole-3-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-54-7 CAPLUS


CN 8-Quinolinesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848637-55-8 CAPLUS


CN Butanamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-56-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-1-methyl- (CA INDEX NAME)




RN 848637-57-0 CAPLUS

CN 2-Naphthalenecarboxamide, 3-hydroxy-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-58-1 CAPLUS

CN 2-Naphthaleneacetamide, alpha-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-59-2 CAPLUS

CN Methanone, [4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 848637-60-5 CAPLUS

CN Benzamide, N-(2-aminocyclohexyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-61-6 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-62-7 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-63-8 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-hydroxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-64-9 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-65-0 CAPLUS

CN 2-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-66-1 CAPLUS


CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-67-2 CAPLUS


CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 848637-68-3 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-69-4 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[3-(dimethylamino)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-70-7 CAPLUS


CN Methanesulfonamide, N-[2-methyl-5-[[6-[2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-71-8 CAPLUS  
 CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]-N-(propylsulfonyl)- (CA INDEX NAME)




RN 848637-72-9 CAPLUS  
 CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-74-1 CAPLUS  
 CN Methanesulfonamide, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-75-2 CAPLUS  
 CN Methanesulfonamide, N-[5-[[6-(3-cyanophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848637-76-3 CAPLUS


CN 2-Piperidinecarboxamide, N-[3-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-77-4 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-formylphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848637-78-5 CAPLUS


CN Methanesulfonamide, N-[5-[[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



10/671,070


RN 848637-80-9 CAPLUS  
CN 2-Piperidinecarboxamide, N-[3-[[6-(3-formylphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-81-0 CAPLUS  
CN 2-Piperidinecarboxamide, N-[3-[[6-[3-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-82-1 CAPLUS  
CN 2-Piperidinecarboxamide, N-[3-[[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848637-90-1 CAPLUS  
CN 2-Piperidinecarboxamide, N-[4-[[6-[3-[(methylsulfonyl)amino]phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848637-91-2 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-(3-acetylphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848637-93-4 CAPLUS


CN Methanesulfonamide, N-[5-[[6-(2-hydroxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848637-94-5 CAPLUS


CN 2-Propenoic acid, 3-[3-[6-[[4-methyl-3-[(methanesulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 848637-95-6 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-96-7 CAPLUS

CN Benzenesulfonamide, N-butyl-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848637-97-8 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methanesulfonyl)phenyl]- (CA INDEX NAME)




RN 848637-98-9 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-(2,3-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

10/671,070


Absolute stereochemistry.



RN 848638-00-6 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-[2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-02-8 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848638-04-0 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-(2-chlorophenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


10/671,070



RN 848638-05-1 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-06-2 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 848638-07-3 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[3-[(methylsulfonyl)amino]phenyl]-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.






RN 848638-08-4 CAPLUS


CN Benzamide, 4-[[6-[2-(acetylamino)phenyl]-4-pyrimidinyl]amino]-N-[(1R,2R)-2-aminocyclohexyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 848638-09-5 CAPLUS


CN Methanesulfonamide, N-[5-[[6-[2-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848638-10-8 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-13-1 CAPLUS

CN Benzoic acid, 3-[6-[[4-[[[(1R,2R)-2-aminocyclohexyl]amino]carbonyl]phenyl]amino]-4-pyrimidinyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-15-3 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-[3-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-16-4 CAPLUS


CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 848638-19-7 CAPLUS

CN Benzamide, 4-[[6-[3-(acetylamino)phenyl]-4-pyrimidinyl]amino]-N-[(1R,2R)-2-aminocyclohexyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-21-1 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(3-cyanophenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-22-2 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-23-3 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-[3-[(dimethylamino)methyl]phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-26-6 CAPLUS


CN Benzenesulfonamide, 3-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848638-28-8 CAPLUS


CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-29-9 CAPLUS


CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848638-30-2 CAPLUS


CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(2-hydroxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-38-0 CAPLUS


CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-3-pyrrolidinyl- (CA INDEX NAME)



10/671,070

RN 848638-41-5 CAPLUS


CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl][3-(1-piperidinylsulfonyl)phenyl]amino]- (CA INDEX NAME)



RN 848638-42-6 CAPLUS


CN Benzamide, 4-[[6-(2-acetylphenyl)-4-pyrimidinyl]amino]-N-[(1R,2R)-2-aminocyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848638-43-7 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-3-pyridinyl- (CA INDEX NAME)



RN 848638-44-8 CAPLUS


CN Benzamide, N-(1-acetyl-3-piperidiny)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848638-45-9 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(dimethylamino)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-46-0 CAPLUS


CN L-Proline, 1-(2,2-dimethyl-1-oxopropyl)-4-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 848638-47-1 CAPLUS

CN Benzenesulfonamide, 2-chloro-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848638-48-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(1-piperidinylsulfonyl)phenyl]-  
(CA INDEX NAME)




RN 848638-49-3 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-2-  
propen-1-yl- (CA INDEX NAME)



RN 848638-50-6 CAPLUS


CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-  
(phenylmethyl)- (CA INDEX NAME)




RN 848638-51-7 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(1-pyrrolidinylsulfonyl)phenyl]-  
(CA INDEX NAME)







RN 848638-52-8 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(4-morpholinylsulfonyl)phenyl]-  
(CA INDEX NAME)


RN 848638-53-9 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-methyl-  
(CA INDEX NAME)


RN 848638-54-0 CAPLUS

CN Acetamide, N-[3-(aminosulfonyl)phenyl]-N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-  
(CA INDEX NAME)

RN 848638-55-1 CAPLUS


CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-di-2-propen-1-yl-  
(CA INDEX NAME)

RN 848638-56-2 CAPLUS

CN Benzenesulfonamide, 3-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]-  
(CA INDEX NAME)


RN 848638-57-3 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-[(4-nitrophenyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 848638-58-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 848638-59-5 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848638-60-8 CAPLUS

CN Benzenesulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4-[[6-(2-methoxyphenyl)-


4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848638-61-9 CAPLUS


CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-propyl-  
(CA INDEX NAME)

RN 848638-62-0 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA  
INDEX NAME)


RN 848638-63-1 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-  
dimethyl- (CA INDEX NAME)




RN 848638-64-2 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848638-65-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-(methylsulfonyl)phenyl]-6-[2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 848638-66-4 CAPLUS

CN Phenol, 2-[6-[[3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 848638-67-5 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848638-68-6 CAPLUS

CN Benzenesulfonic acid, 5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848638-69-7 CAPLUS

CN Ethanol, 2-[[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]sulfonyl]- (CA INDEX NAME)




RN 848638-70-0 CAPLUS

CN 4-Pyrimidinamine, N-[2-fluoro-5-(methylsulfonyl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-71-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2-aminophenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848638-72-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-[(trifluoromethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 848638-73-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-(methylsulfonyl)phenyl]-6-(2-phenoxyphenyl)- (CA INDEX NAME)




RN 848638-74-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-butoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848638-75-5 CAPLUS


CN 4-Pyrimidinamine, N-[3-(ethenylsulfonyl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-77-7 CAPLUS  
 CN Benzoic acid, 2-chloro-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848638-78-8 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[(4-phenoxyphenyl)methyl]- (CA INDEX NAME)



RN 848638-79-9 CAPLUS  
 CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-3-methyl-, methyl ester (CA INDEX NAME)




RN 848638-80-2 CAPLUS  
 CN 1H-Indol-6-amine, N-[6-(3-aminophenyl)-4-pyrimidinyl]-2,3-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)




RN 848638-82-4 CAPLUS  
 CN Benzeneacetic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)

INDEX NAME)




RN 848638-83-5 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848638-84-6 CAPLUS

CN 1-Butanone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848638-86-8 CAPLUS


CN Methanone, [4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]phenyl- (CA INDEX NAME)



RN 848638-87-9 CAPLUS


CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-N3-phenyl- (CA INDEX NAME)






RN 848638-88-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-(1,3-dioxan-2-yl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-89-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 848638-90-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 848638-91-5 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-N4-phenyl- (CA INDEX NAME)




RN 848638-92-6 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 848638-93-7 CAPLUS

CN 4-Pyrimidinamine, N-(2-fluorophenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-95-9 CAPLUS

CN 4-Pyrimidinamine, N-(4-butylphenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-96-0 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 848638-97-1 CAPLUS  
 CN Benzenesulfonamide, 4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]methyl]-  
 (CA INDEX NAME)




RN 848638-98-2 CAPLUS  
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)



RN 848639-00-9 CAPLUS  
 CN 1,4-Benzenediamine, N1-[6-(3-aminophenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-04-3 CAPLUS  
 CN Benzoic acid, 4-[[[6-[2-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-05-4 CAPLUS

CN Benzoic acid, 2-methoxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-06-5 CAPLUS

CN Benzeneacetic acid, 4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848639-07-6 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-nitrophenyl)- (CA INDEX NAME)



RN 848639-08-7 CAPLUS


10/671,070

CN Benzenemethanol, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-09-8 CAPLUS

CN 4-Pyrimidinamine, N-phenyl-6-[2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 848639-10-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-phenyl- (CA INDEX NAME)




RN 848639-11-2 CAPLUS

CN 4-Pyrimidinamine, N-(4-fluorophenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848639-12-3 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-phenoxyphenyl)- (CA INDEX NAME)




RN 848639-13-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methylthio)phenyl]- (CA INDEX NAME)




RN 848639-15-6 CAPLUS

CN Phenol, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-16-7 CAPLUS

CN Ethanone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848639-17-8 CAPLUS

CN Benzoic acid, 2-chloro-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-19-0 CAPLUS

CN 1H-Indol-6-amine, 2,3-dihydro-1-(methanesulfonyl)-N-[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-21-4 CAPLUS

CN Benzoic acid, 4-[[6-(2-aminophenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-22-5 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 848639-24-7 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 848639-25-8 CAPLUS

CN 1H-Indol-6-amine, 2,3-dihydro-N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-1-(methylsulfonyl)- (CA INDEX NAME)



RN 848639-28-1 CAPLUS

CN Ethanone, 1-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 848639-29-2 848639-30-5 848639-31-6  
 848639-32-7 848639-33-8 848639-34-9  
 848639-35-0 848639-36-1 848639-37-2  
 848639-38-3 848639-39-4 848639-40-7  
 848639-41-8 848639-42-9 848639-43-0  
 848639-44-1 848639-47-4 848639-50-9  
 848639-51-0 848639-52-1 848639-53-2  
 848639-54-3 848639-55-4 848639-56-5  
 848639-58-7 848639-60-1 848639-62-3  
 848639-65-6 848639-66-7 848639-67-8  
 848639-68-9 848639-69-0 848639-71-4  
 848639-74-7 848639-75-8 848639-76-9  
 848639-77-0 848639-78-1 848639-79-2  
 848639-83-8 848639-84-9 848639-85-0  
 848639-86-1 848639-87-2 848639-88-3  
 848639-89-4 848639-90-7 848639-91-8  
 848639-92-9 848639-93-0 848639-94-1


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL



(Biological study); USES (Uses)  
(methods of treating pain)


RN 848639-29-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 848639-30-5 CAPLUS

CN Benzoic acid, 3-hydroxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-31-6 CAPLUS

CN Benzoic acid, 2-hydroxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-32-7 CAPLUS


CN 1-Butanesulfonamide, 4-amino-N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848639-33-8 CAPLUS  
 CN Carbamic acid, N-[3-[6-[[3-[[4-(aminobutyl)sulfonyl]amino]-4-methylphenyl]amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (CA INDEX NAME)



RN 848639-34-9 CAPLUS  
 CN Benzoic acid, 3-methoxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-35-0 CAPLUS  
 CN Benzoic acid, 4-[[6-[2-[2-(1-piperidinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-36-1 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-(dimethylamino)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-37-2 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 848639-38-3 CAPLUS


CN Benzoic acid, 4-[[6-[2-[2-(diethylamino)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 848639-39-4 CAPLUS

CN L-Proline, 4-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848639-40-7 CAPLUS

CN L-Proline, 4-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848639-41-8 CAPLUS


CN Hexanoic acid, 6-[[[(2S,4S)-4-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-2-pyrrolidinyl]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848639-42-9 CAPLUS

CN Benzenesulfonamide, N-cyclopentyl-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-  
(CA INDEX NAME)




RN 848639-43-0 CAPLUS

CN Benzenesulfonamide, N-(4,6-dimethyl-2-pyrimidinyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-  
(CA INDEX NAME)




RN 848639-44-1 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-2-thiazolyl-  
(CA INDEX NAME)




RN 848639-47-4 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-phenyl-  
(CA INDEX NAME)




RN 848639-50-9 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-methyl-  
(CA INDEX NAME)




RN 848639-51-0 CAPLUS

CN 4-Pyrimidinamine, N-(1,1-dioxidobenzo[b]thien-6-yl)-6-(2-methoxyphenyl)-  
(CA INDEX NAME)




RN 848639-52-1 CAPLUS

CN Acetamide, N-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]sulfonyl]-  
(CA INDEX NAME)




RN 848639-53-2 CAPLUS

CN Benzenesulfonamide, N-(2,6-dimethyl-4-pyrimidinyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-54-3 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-piperidinylsulfonyl)phenyl]-  
(CA INDEX NAME)




RN 848639-55-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 848639-56-5 CAPLUS

CN 4-Pyrimidinamine, 6-(2-fluoro-6-methoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848639-58-7 CAPLUS

CN 4-Pyrimidinamine, 6-(5-fluoro-2-methoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848639-60-1 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-62-3 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-1-methyl- (CA INDEX NAME)



RN 848639-65-6 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(3-piperidinyloxy)phenyl]- (CA INDEX NAME)




RN 848639-66-7 CAPLUS

CN 1H-Indazol-5-amine, N,1-bis[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)







RN 848639-67-8 CAPLUS  
 CN 1H-Indol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-68-9 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methylsulfinyl)phenyl]- (CA INDEX NAME)



RN 848639-69-0 CAPLUS  
 CN 1H-Indazol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-71-4 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 848639-74-7 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 848639-75-8 CAPLUS

CN Benzenesulfonamide, N-ethyl-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-76-9 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 848639-77-0 CAPLUS

CN 1H-Indol-5-amine, N-[[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 848639-78-1 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-79-2 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-83-8 CAPLUS

CN Benzenesulfonamide, 5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848639-84-9 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848639-85-0 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848639-86-1 CAPLUS

CN 1,4-Benzenediamine, N1,N1-diethyl-N4-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-87-2 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848639-88-3 CAPLUS

CN Urea, N-cyclohexyl-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848639-89-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-pyrrolidinyl)phenyl]- (CA INDEX NAME)




RN 848639-90-7 CAPLUS

CN 1,3-Benzenediamine, 4-chloro-N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 848639-91-8 CAPLUS


CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 848639-92-9 CAPLUS


CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

10/671,070




RN 848639-93-0 CAPLUS

CN Urea, N-[2-(dimethylamino)ethyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848639-94-1 CAPLUS

CN 4-Pyrimidinamine, N-(4-chloro-3-nitrophenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)



L10 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:977961 CAPLUS  
 DN 145:356802  
 TI Preparation of pyrimidine derivatives for treatment of hyperproliferative disorders  
 IN Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei; Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen, Jianqing; Bear, Brian R.; Brands, Michael; Hillisch, Alexander; Bierer, Donald; Wang, Ming; Fu, Wenlang; Hentemann, Martin F.; Bullion, Ann-Marie; Patel, Manoj  
 PA Bayer Pharmaceuticals Corporation, USA  
 SO PCT Int. Appl., 100pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006099231	A1	20060921	WO 2006-US8779	20060309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-660561P P 20050310

OS MARPAT 145:356802


AB Title compds. represented by the formula I [wherein R1 = H; R2 = NH2; L = O; M = CH, m = 1; n = 0-2; G = Me or CF3; G' = Me or NH2; J = pyridinyl or pyrimidyl; Y = Ph, pyridinyl or pyrimidyl; and pharmaceutically acceptable salts thereof] were prepared for treatment of hyperproliferative disorders. For example, II was provided in a multi-step synthesis starting from the reaction of guanidine carbonate with Et 3-oxo-3-phenylpropanoate. Selected I were tested for cytotoxic activity using human HCT-116 cell line with IC50 values of 3 ~ 135 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of hyperproliferative diseases, such as cancer.

IT 850247-18-6P, N-Ethyl-6-(3-methoxyphenyl)-N'-[4-[(2-trifluoromethylpyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine  
 850247-19-7P, N-Ethyl-6-(3-methoxyphenyl)-N'-[4-[(2-trifluoromethylpyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine trifluoroacetate 871240-05-0P, 6-(2,6-Dimethylphenyl)-N'-[4-[(2-trifluoromethyl)pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrimidine derivs. for treatment of hyperproliferative disorders)

RN 850247-18-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-ethyl-6-(3-methoxyphenyl)-N4-[4-[(2-trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

10/671,070




RN 850247-19-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-ethyl-6-(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 850247-18-6


CMF C25 H22 F3 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 871240-05-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,6-dimethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 4


THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




L10 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:961535 CAPLUS  
DN 145:505399  
TI Efficient microwave-assisted synthesis of highly functionalized pyrimidine derivatives  
AU Hartung, Christian G.; Backes, Alexander C.; Felber, Beatrice; Missio, Andrea; Philipp, Alexander  
CS GPC Biotech AG, Martinsried/Munich, 82152, Germany  
SO Tetrahedron (2006), 62(43), 10055-10064  
CODEN: TETRA; ISSN: 0040-4020  
PB Elsevier Ltd.  
DT Journal  
LA English  
OS CASREACT 145:505399  
AB A generally applicable one-pot procedure for the rapid, easy, and diverse asym. functionalization of pyrimidines was developed that requires min. efforts for the purification of the final products. 4-Amino-6-aryl-substituted pyrimidines are prepared in good yields by combined microwave-assisted amination and Suzuki-Miyaura cross-coupling reactions. The acid-mediated amination reaction affords the products as easily separable salts in 30-40 min reaction time.  
IT 848639-10-1P 915069-53-3P 915069-54-4P  
915069-55-5P 915069-56-6P 915069-57-7P  
915069-58-8P 915069-65-7P 915069-66-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of 4-amino-6-aryl-pyrimidines by combined microwave-assisted amination and Suzuki-Miyaura cross-coupling reactions.)  
RN 848639-10-1 CAPLUS  
CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-phenyl- (CA INDEX NAME)



RN 915069-53-3 CAPLUS  
CN 4-Pyrimidinamine, 6-(2-methylphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 915069-54-4 CAPLUS  
CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-phenyl-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl


RN 915069-55-5 CAPLUS  
CN Ethanone, 1-[2-[6-(phenylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 915069-56-6 CAPLUS  
CN Benzenemethanol, 3-[6-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 915069-57-7 CAPLUS  
CN 4-Pyrimidinamine, 6-(3-nitrophenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 915069-58-8 CAPLUS  
CN 4-Pyrimidinamine, 6-(3-nitrophenyl)-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 915069-65-7 CAPLUS

CN 4-Pyrimidinamine, N-(4-bromophenyl)-6-(2-methoxyphenyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 915069-66-8 CAPLUS

CN 4-Pyrimidinamine, N-(3-bromophenyl)-6-(3-nitrophenyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)

● HCl

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:733279 CAPLUS  
 DN 145:159863  
 TI Pyrimidine compounds and compositions as Wnt signaling pathway modulators  
 IN Ding, Sheng; Liu, Jun; Schultz, Peter G.  
 PA IRM LLC, Bermuda; The Scripps Research Institute  
 SO PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006078886	A2	20060727	WO 2006-US2007	20060118
	WO 2006078886	A3	20070111		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2005-645366P P 20050118

OS MARPAT 145:159863


AB The invention provides a novel class of compds. (I; R1 = H, C1-6 alkoxy; R2-4 = H, C1-6 alkyl; R5 = C6-12 aryl-C0-4 alkyl, C5-10 heteroaryl-C0-4 alkyl; n = 1-3) and methods of using such compds. to study the activity of the Wnt signaling pathway. A method for modulating Wnt signal transduction comprises contacting a cell with an amount of a compound I, resulting in mimicking and upregulating the Wnt signaling bioactivity. The modulation of the Wnt signal pathway is used to study biol. processes that involve Wnt signaling, such as stem cell renewal, mesenchymal progenitor cell differentiation, and embryonic limb development. A composition comprising a therapeutically effective amount of a compound I for treating a disease or disorder in an animal in which modulation of the Wnt signal pathway can prevent, inhibit or ameliorate the pathol. and/or symptomol. of the disease is also described. For example, N4-benzo-[1,3]dioxol-5-yl-methyl-6-(3-methoxy-phenyl)-pyrimidine-2,4-diamine (preparation given) induced in vitro  $\beta$ -catenin and transcription factor (TCF) dependent transcriptional activity in 293T cells in a dose dependent manner with an EC50 of 0.7  $\mu$ M.

IT 853220-52-7P 901758-74-5P


RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (phenylpyrimidinediamine derivs., uses and compns. as Wnt signaling pathway modulators)

RN 853220-52-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 901758-74-5 CAPLUS  
 CN Phenol, 4-[2-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]ethyl]-  
 (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:381409 CAPLUS  
 DN 144:432829  
 TI Preparation of 2,6-substituted-4-monosubstituted amino-pyrimidines as  
 prostaglandin D2 receptor antagonists  
 IN Lim, Sungtaek; Harris, Keith John; Stefany, David; Gardner, Charles J.;  
 Cao, Bin; Boffey, Ray; Gillespy, Timothy A.; Aguiar, Joacy C.; Hunt, Hazel  
 J.; Dechaux, Elsa A.  
 PA Aventis Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 272 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044732	A2	20060427	WO 2005-US37148	20051014
WO 2006044732	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
 YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

PRAI US 2004-619272P P 20041015


OS MARPAT 144:432829

AB The invention is directed to the preparation of aminopyrimidines I [Cy1 =  
 (un)substituted cycloalkyl, heterocyclyl, hetero/aryl, etc.; Cy2 =  
 (un)substituted cycloalkenyl, heterocyclenyl, hetero/aryl, etc.; L1 =  
 cyclo/alkylene, CH2-haloalkylene; or L1Cy2 = arylcycloalkyl,  
 cycloalkylaryl; R1 = alkylthio, NH2 and derivs., alkoxy; L2 = a bond, O,  
 CH2O; provided that when R1 = OMe, L1 = CH2CH2, L2 = a bond, and Cy2 =  
 2,4-dichlorophenyl, then Cy1 is not 1-methyl-2-ethyloxycarbonylindol-5-  
 yl], and their N-oxides, ester prodrugs, and their pharmaceutically  
 acceptable salts, hydrates and solvates, and their use as prostaglandin D2  
 (PGD2) receptor antagonists in pharmaceutical compns. comprising a  
 pharmaceutically effective amount of one or more compds. I in admixt. with a  
 pharmaceutically acceptable carrier, and to a method of treating a patient  
 suffering from a PGD2-mediated disorder. E.g., a 4-step synthesis,  
 starting from 3-fluoro-4-methoxybenzaldehyde, was given for  
 pyrimidine II. Selected I produced 50% inhibition in the SPA cAMP assay  
 in human LS174T cells expressing the endogenous DP receptor at concns.  
 within the range of about 0.1 to about 30 nM. I are useful for treating  
 allergic disease (such as allergic rhinitis, allergic conjunctivitis,  
 atopic dermatitis, bronchial asthma and food allergy), systemic  
 mastocytosis, disorders accompanied by systemic mast cell activation,  
 anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema,  
 diseases accompanied by itch, diseases (such as cataract, retinal  
 detachment, inflammation, infection and sleeping disorders) which are  
 generated secondarily as a result of behavior accompanied by itch (such as  
 scratching and beating), chronic obstructive pulmonary diseases, ischemic  
 reperfusion injury, cerebrovascular accident, chronic rheumatoid  
 arthritis, pleurisy, ulcerative colitis (no data).

IT 885066-02-4P, 3-[6-[[2-(3-Fluoro-4-methoxyphenyl)ethyl]amino]-2-


methoxypyrimidin-4-yl]benzonitrile 885066-03-5P,  
 [6-(3-Aminophenyl)-2-methoxypyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine  
 885066-10-4P, [6-(3-Aminophenyl)-2-methoxypyrimidin-4-yl][2-(4-  
 trifluoromethoxyphenyl)ethyl]amine 885066-29-5P,  
 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-  
 yl]benzaldehyde 885066-30-8P, [3-[6-[[2-(2-Chloro-6-  
 fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]methanol  
 885066-31-9P, 3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]benzaldehyde 885066-61-5P,  
 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenol  
 885066-63-7P, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]benzoic acid 885066-65-9P,  
 3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-  
 yl]benzoic acid 885066-67-1P, 2-[3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-  
 methylpropionic acid 885066-86-4P, 2-[3-[2-Methoxy-6-[[2-(4-  
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenoxy]-2-methylpropionic acid  
 ethyl ester 885066-87-5P, [3-[2-Methoxy-6-[[2-(4-  
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenoxy]acetic acid methyl ester  
 885066-89-7P, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]phenol 885066-92-2P, [3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]acetonitrile  
 885066-93-3P, [3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]phenoxy]acetonitrile 885066-94-4P,  
 3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-  
 yl]phenol 885066-99-9P, 2-[3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]-2-  
 methylpropionic acid ethyl ester 885067-03-8P,  
 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-  
 yl]benzonitrile 885067-05-0P, [3-[2-Methoxy-6-[[2-(4-  
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetonitrile  
 885067-09-4P, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyri-  
 midin-4-yl]benzoic acid 885067-11-8P, 3-[6-[[2-(3,4-  
 Dimethoxyphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid  
 885067-42-5P, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyri-  
 midin-4-yl]benzamide 885067-43-6P, 1-[3-[2-Methoxy-6-[[2-(4-  
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]ethanone  
 885068-16-6P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]benzoylamino]acetic acid ethyl ester  
 885068-74-6P 885068-81-5P, [3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]acetonitrile  
 885068-82-6P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]phenyl]difluoroacetonitrile 885069-33-0P,  
 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]-4-  
 fluorophenyl]-2-methylpropionic acid  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of aminopyrimidines as prostaglandin D2  
 receptor antagonists)

RN 885066-02-4 CAPLUS  
 CN Benzonitrile, 3-[6-[[2-(3-fluoro-4-methoxyphenyl)ethyl]amino]-2-methoxy-4-  
 pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-03-5 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-2-methoxy-N-[2-(4-methoxyphenyl)ethyl]-  
(9CI) (CA INDEX NAME)




RN 885066-10-4 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-2-methoxy-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 885066-29-5 CAPLUS


CN Benzaldehyde, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 885066-30-8 CAPLUS


CN Benzenemethanol, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 885066-31-9 CAPLUS

CN Benzaldehyde, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-61-5 CAPLUS

CN Phenol, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-63-7 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-65-9 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-67-1 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl- (CA INDEX NAME)




RN 885066-86-4 CAPLUS

CN Propanoic acid, 2-[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 885066-87-5 CAPLUS

CN Acetic acid, [3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 885066-89-7 CAPLUS

CN Phenol, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-92-2 CAPLUS

CN Acetonitrile, [3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 885066-93-3 CAPLUS

CN Acetonitrile, [3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 885066-94-4 CAPLUS

CN Phenol, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-99-9 CAPLUS

CN Propanoic acid, 2-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-


10/671,070

pyrimidinyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 885067-03-8 CAPLUS

CN Benzonitrile, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-05-0 CAPLUS

CN Benzeneacetonitrile, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-09-4 CAPLUS

CN Benzoic acid, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-11-8 CAPLUS

CN Benzoic acid, 3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-42-5 CAPLUS

CN Benzamide, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 885067-43-6 CAPLUS

CN Ethanone, 1-[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885068-16-6 CAPLUS

CN Glycine, N-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 885068-74-6 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -difluoro- (9CI) (CA INDEX NAME)




RN 885068-81-5 CAPLUS

CN Benzeneacetonitrile, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885068-82-6 CAPLUS

CN Benzeneacetonitrile, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -difluoro- (9CI) (CA INDEX NAME)



RN 885069-33-0 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-4-fluoro- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)



IT 885066-12-6P, N-[3-[2-Methoxy-6-[[2-(4-trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetamide

885066-13-7P, N-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetamide  
 885066-14-8P, [3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]carbamic acid ethyl ester 885066-17-1P,  
 3-[6-[[2-(2,4-Difluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid 885066-28-4P, [3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]methanol  
 885066-35-3P, N-[2-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]methanesulfonamide  
 885066-51-3P, 4-[2-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]amino]ethyl]phenol monohydrochloride 885066-60-4P, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenol hydrochloride  
 885066-62-6P, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid monohydrochloride 885066-64-8P,  
 3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid monohydrochloride 885066-66-0P,  
 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid monohydrochloride 885066-76-2P,  
 [2-Ethyl-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine 885066-78-4P, 6-(3-Methoxyphenyl)-N'-[2-(4-methoxyphenyl)ethyl]-N,N-dimethylpyrimidine-2,4-diamine monohydrochloride 885066-88-6P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]acetic acid methyl ester 885066-95-5P, 2-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenoxy]-2-methylpropionic acid 885066-96-6P, [3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenoxy]acetic acid 885066-98-8P,  
 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]-2-methylpropionic acid 885067-04-9P,  
 [2-(4-Methoxyphenyl)ethyl][2-methoxy-6-[3-[(1H-tetrazol-5-yl)methyl]phenyl]pyrimidin-4-yl]amine monohydrochloride 885067-08-3P, N-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoyl]methanesulfonamide  
 885067-10-7P, 3-[6-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzamide  
 885067-13-0P, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzaldehyde oxime 885067-29-8P, 3-[[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]methyl]-4H-[1,2,4]oxadiazol-5-one monohydrochloride 885067-31-2P,  
 3-[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzyl]-4H-[1,2,4]oxadiazol-5-one monohydrochloride 885067-34-5P, 3-[[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]methyl]-4H-[1,2,4]oxadiazol-5-one monohydrochloride 885067-36-7P, 3-[2-Methoxy-6-[[2-(4-trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoic acid 885067-40-3P, 3-[6-[[2-(4-Fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid hydrochloride 885067-44-7P,  
 3-[6-[[2-(4-Chlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid monohydrochloride 885067-48-1P, 2-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenol 885067-58-3P,  
 1-Ethyl-3-[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]urea 885067-63-0P, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-nitrophenyl)ethyl]amine 885067-65-2P, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-trifluoromethoxyphenyl)ethyl]amine 885067-66-3P,  
 [2-(2-Chloro-6-fluorophenyl)ethyl][2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine hydrochloride 885067-72-1P, [2-(4-Aminophenyl)ethyl][2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine monohydrochloride 885067-73-2P, (4-Methoxybenzyl)[2-methoxy-6-(3-

methoxyphenyl)pyrimidin-4-yl]amine monohydrochloride 885067-74-3P  
 , [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl](3-phenylpropyl)amine  
 monohydrochloride 885067-76-5P, (2S)-2-[[2-Methoxy-6-(3-  
 methoxyphenyl)pyrimidin-4-yl]amino]-3-(4-methoxyphenyl)propionic acid  
 885067-77-6P, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-  
 methoxyphenyl)ethyl]amine 885067-86-7P, 3-[6-[[2-(2,2-  
 Difluorobenzodioxol-5-yl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid  
 885067-91-4P, N-[3-[6-[[2-[4-(Difluoromethoxy)phenyl]ethyl]amino]-  
 2-methoxypyrimidin-4-yl]phenyl]acetamide monohydrochloride  
 885067-93-6P, [2-(2,4-Dichlorophenyl)ethyl][2-methyl-6-[3-[1-  
 methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]pyrimidin-4-yl]amine  
 monohydrochloride 885067-99-2P, 2-[3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]propionic acid  
 monohydrochloride 885068-01-9P, 2-[3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-  
 methylpropionic acid 1-(ethoxycarbonyloxy)ethyl ester monohydrochloride  
 885068-02-0P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 2-dimethylaminoethyl  
 ester dihydrochloride 885068-11-1P, 3-[6-[[2-(2,6-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid  
 885068-13-3P, [[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]benzyl]oxy]acetic acid 885068-14-4P  
 885068-17-7P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]benzoylamino]acetic acid 885068-18-8P,  
 Ethylcarbamic acid 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]phenyl ester 885068-27-9P  
 885068-28-0P, N-[2-[3-[6-[[2-(2-Fluoro-4-  
 trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-  
 yl]phenyl]ethyl]acetamide monohydrochloride 885068-29-1P,  
 [2-(2-Fluoro-4-trifluoromethylphenyl)ethyl][2-methoxy-6-[3-  
 [(oxiranyl)methoxy]phenyl]pyrimidin-4-yl]amine 885068-33-7P,  
 2-[3-[2-Methoxy-6-[[2-[4-(5-methyl-[1,3,4]oxadiazol-2-  
 yl)phenyl]ethyl]amino]pyrimidin-4-yl]phenyl]-2-methylpropionic acid  
 885068-37-1P 885068-63-3P, 3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid  
 2-(morpholin-4-yl)ethyl ester 885068-64-4P, 3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid  
 2-(4-methylpiperazin-1-yl)ethyl ester 885068-65-5P,  
 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic  
 acid ethyl ester 885068-66-6P, [3-[6-[[2-(2,4-  
 Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]methanol  
 885068-67-7P, 1-[3'-Chloro-4'-[2-[6-(3-hydroxymethylphenyl)-2-  
 methoxypyrimidin-4-yl]amino]ethyl]biphenyl-3-yl]methanol  
 885068-68-8P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid methyl ester  
 885068-78-0P 885068-79-1P 885068-83-7P,  
 [2-(2,4-Dichlorophenyl)ethyl][6-[3-[difluoro(1H-tetrazol-5-  
 yl)methyl]phenyl]-2-methoxypyrimidin-4-yl]amine 885068-91-7P,  
 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-(methoxymethyl)pyrimidin-4-  
 yl]phenyl]-2-methylpropionic acid 885068-93-9P,  
 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-hydroxymethylpyrimidin-4-  
 yl]phenyl]-2-methylpropionic acid 885069-05-6P,  
 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-  
 yl]phenyl]-2-methylpropionic acid 2,3-dihydroxypropyl ester  
 885069-12-5P, 2-[3-[6-[(Benzofuran-5-yl)methyl]amino]-2-  
 methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 885069-16-9P  
 , Ethanesulfonic acid N-[2-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-  
 methoxypyrimidin-4-yl]phenyl]-2-methylpropionyl]amide 885069-17-0P  
 , N-[2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-  
 yl]phenyl]-2-methylpropionyl]-1-phenylmethanesulfonamide




885069-18-1P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methyl-1-(morpholin-4-yl)propan-1-one  
 885069-19-2P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-N-(tetrahydropyran-4-yl)isobutyramide  
 885069-20-5P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-N-(1H-tetrazol-5-yl)isobutyramide  
 885069-31-8P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]-4-fluorophenyl]-2-methylpropionic acid monohydrochloride 885069-36-3P, 4-[2-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]amino]ethyl]phenol  
 885069-38-5P, 6-(3-Methoxyphenyl)-N'-[2-(4-methoxyphenyl)ethyl]-N,N-dimethylpyrimidine-2,4-diamine 885069-40-9P, [2-(4-Methoxyphenyl)ethyl][2-methoxy-6-[3-[(1H-tetrazol-5-yl)methyl]phenyl]pyrimidin-4-yl]amine 885069-42-1P, 3-[[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]methyl]-4H-[1,2,4]oxadiazol-5-one 885069-43-2P, 3-[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzyl]-4H-[1,2,4]oxadiazol-5-one 885069-44-3P, 3-[[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]methyl]-4H-[1,2,4]oxadiazol-5-one 885069-45-4P, 3-[6-[[2-(4-Fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid 885069-46-5P, 3-[6-[[2-(4-Chlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid 885069-47-6P, [2-(2-Chloro-6-fluorophenyl)ethyl][2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine 885069-52-3P, [2-(4-Aminophenyl)ethyl][2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine 885069-53-4P, (4-Methoxybenzyl)[2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine 885069-54-5P, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl](3-phenylpropyl)amine 885069-55-6P, N-[3-[6-[[2-[4-(Difluoromethoxy)phenyl]ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]acetamide 885069-57-8P, [2-(2,4-Dichlorophenyl)ethyl][2-methyl-6-[3-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]pyrimidin-4-yl]amine 885069-60-3P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]propionic acid 885069-61-4P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 1-(ethoxycarbonyloxy)ethyl ester 885069-62-5P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 2-dimethylaminoethyl ester 885069-64-7P, N-[2-[3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]ethyl]-2-methoxyacetamide 885069-65-8P, N-[2-[3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]ethyl]acetamide 885069-72-7P, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol hydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)


RN 885066-12-6 CAPLUS

CN Acetamide, N-[3-[2-methoxy-6-[[2-[4-(trifluoromethoxy)phenyl]ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885066-13-7 CAPLUS

CN Acetamide, N-[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885066-14-8 CAPLUS

CN Carbamic acid, [3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 885066-17-1 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2,4-difluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-28-4 CAPLUS

CN Benzenemethanol, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 885066-35-3 CAPLUS


CN Methanesulfonamide, N-[2-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 885066-51-3 CAPLUS


CN Phenol, 4-[2-[[[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl


PAGE 1-B



RN 885066-60-4 CAPLUS

CN Phenol, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/671,070



● HCl

RN 885066-62-6 CAPLUS


CN Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885066-64-8 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885066-66-0 CAPLUS


CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

NAME)




● HCl

RN 885066-76-2 CAPLUS

CN 4-Pyrimidinamine, 2-ethyl-6-(3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-  
(9CI) (CA INDEX NAME)


RN 885066-78-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[2-(4-methoxyphenyl)ethyl]-  
N2,N2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 885066-88-6 CAPLUS

CN Acetic acid, [3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 885066-95-5 CAPLUS

CN Propanoic acid, 2-[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 885066-96-6 CAPLUS

CN Acetic acid, [3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 885066-98-8 CAPLUS

CN Propanoic acid, 2-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 885067-04-9 CAPLUS


CN 4-Pyrimidinamine, 2-methoxy-N-[2-(4-methoxyphenyl)ethyl]-6-[3-(1H-tetrazol-5-ylmethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 885067-08-3 CAPLUS

CN Benzamide, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 885067-10-7 CAPLUS

CN Benzamide, 3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 885067-13-0 CAPLUS

CN Benzaldehyde, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-, oxime (9CI) (CA INDEX NAME)



RN 885067-29-8 CAPLUS


CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-31-2 CAPLUS


CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[[3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-34-5 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[[3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885067-36-7 CAPLUS




10/671,070

CN Benzoic acid, 3-[2-methoxy-6-[[2-[4-(trifluoromethoxy)phenyl]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 885067-40-3 CAPLUS


CN Benzoic acid, 3-[6-[[2-(4-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-44-7 CAPLUS


CN Benzoic acid, 3-[6-[[2-(4-chlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 885067-48-1 CAPLUS

CN Phenol, 2-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-58-3 CAPLUS

CN Urea, N-ethyl-N'-[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885067-63-0 CAPLUS

CN 4-Pyrimidinamine, 2-methoxy-6-(3-methoxyphenyl)-N-[2-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 885067-65-2 CAPLUS

CN 4-Pyrimidinamine, 2-methoxy-6-(3-methoxyphenyl)-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 885067-66-3 CAPLUS


CN 4-Pyrimidinamine, N-[2-(2-chloro-6-fluorophenyl)ethyl]-2-methoxy-6-(3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-72-1 CAPLUS


CN 4-Pyrimidinamine, N-[2-(4-aminophenyl)ethyl]-2-methoxy-6-(3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-73-2 CAPLUS


CN 4-Pyrimidinamine, 2-methoxy-6-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-74-3 CAPLUS

CN 4-Pyrimidinamine, 2-methoxy-6-(3-methoxyphenyl)-N-(3-phenylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885067-76-5 CAPLUS


CN L-Tyrosine, N-[2-methoxy-6-(3-methoxyphenyl)-4-pyrimidinyl]-O-methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885067-77-6 CAPLUS

CN 4-Pyrimidinamine, 2-methoxy-6-(3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 885067-86-7 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2,2-difluoro-1,3-benzodioxol-5-yl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-91-4 CAPLUS  
 CN Acetamide, N-[3-[6-[[2-[4-(difluoromethoxy)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885067-93-6 CAPLUS  
 CN 4-Pyrimidinamine, N-[2-(2,4-dichlorophenyl)ethyl]-2-methyl-6-[3-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885067-99-2 CAPLUS  
 CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 885068-01-9 CAPLUS  
 CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl-, 1-[(ethoxycarbonyl)oxy]ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885068-02-0 CAPLUS


CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl-, 2-(dimethylamino)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 885068-11-1 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2,6-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885068-13-3 CAPLUS

CN Acetic acid, [[3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 885068-14-4 CAPLUS


CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 885068-17-7 CAPLUS

CN Glycine, N-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 885068-18-8 CAPLUS

CN Carbamic acid, ethyl-, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)




RN 885068-27-9 CAPLUS  
 CN Acetamide, N-[2-[3-[6-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]ethyl]-2-methoxy-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 885068-28-0 CAPLUS  
 CN Acetamide, N-[2-[3-[6-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885068-29-1 CAPLUS  
 CN 4-Pyrimidinamine, N-[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]-2-methoxy-6-[3-(oxiranylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 885068-33-7 CAPLUS  
 CN Benzeneacetic acid, 3-[2-methoxy-6-[[2-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]ethyl]amino]-4-pyrimidinyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)






RN 885068-37-1 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[3-[6-[[2-(3,4-difluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]methyl]-4-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)




RN 885068-63-3 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 885068-64-4 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, 2-(4-methyl-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

— Me


RN 885068-65-5 CAPLUS

CN Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 885068-66-6 CAPLUS

CN Benzenemethanol, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885068-67-7 CAPLUS

CN [1,1'-Biphenyl]-3-methanol, 3'-chloro-4'-[2-[[6-[3-(hydroxymethyl)phenyl]-2-methoxy-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 885068-68-8 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 885068-78-0 CAPLUS

CN Benzeneacetamide, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-N-(ethylsulfonyl)- $\alpha,\alpha$ -difluoro- (9CI) (CA INDEX NAME)




RN 885068-79-1 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -difluoro-, ethyl ester (9CI) (CA INDEX NAME)



RN 885068-83-7 CAPLUS


CN 4-Pyrimidinamine, N-[2-(2,4-dichlorophenyl)ethyl]-6-[3-(difluoro-1H-tetrazol-5-ylmethyl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 885068-91-7 CAPLUS


CN Benzeneacetamide, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-(methoxymethyl)-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

NAME)




RN 885068-93-9 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-(hydroxymethyl)-4-pyrimidinyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 885069-05-6 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl-, 2,3-dihydroxypropyl ester (9CI) (CA INDEX NAME)




RN 885069-12-5 CAPLUS


CN Benzeneacetic acid, 3-[6-[(5-benzofuranylmethyl)amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 885069-16-9 CAPLUS  
 CN Benzeneacetamide, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-N-(ethylsulfonyl)- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 885069-17-0 CAPLUS  
 CN Benzeneacetamide, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl-N-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 885069-18-1 CAPLUS  
 CN Morpholine, 4-[2-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 885069-19-2 CAPLUS  
 CN Benzeneacetamide, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- $\alpha,\alpha$ -dimethyl-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 885069-20-5 CAPLUS

CN Benzeneacetamide, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 885069-31-8 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-4-fluoro-α,α-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 885069-36-3 CAPLUS

CN Phenol, 4-[2-[[[3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 885069-38-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[2-(4-methoxyphenyl)ethyl]-  
 N2,N2-dimethyl- (9CI) (CA INDEX NAME)



RN 885069-40-9 CAPLUS  
 CN 4-Pyrimidinamine, 2-methoxy-N-[2-(4-methoxyphenyl)ethyl]-6-[3-(1H-tetrazol-  
 5-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 885069-42-1 CAPLUS  
 CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-  
 methoxy-4-pyrimidinyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 885069-43-2 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[[3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]methyl]- (9CI)  
(CA INDEX NAME)




RN 885069-44-3 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[[3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]methyl]- (9CI)  
(CA INDEX NAME)




RN 885069-45-4 CAPLUS

CN Benzoic acid, 3-[6-[[2-(4-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)







RN 885069-46-5 CAPLUS  
 CN Benzoic acid, 3-[6-[[2-(4-chlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885069-47-6 CAPLUS  
 CN 4-Pyrimidinamine, N-[2-(2-chloro-6-fluorophenyl)ethyl]-2-methoxy-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 885069-52-3 CAPLUS  
 CN 4-Pyrimidinamine, N-[2-(4-aminophenyl)ethyl]-2-methoxy-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 885069-53-4 CAPLUS  
 CN 4-Pyrimidinamine, 2-methoxy-6-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 885069-54-5 CAPLUS  
 CN 4-Pyrimidinamine, 2-methoxy-6-(3-methoxyphenyl)-N-(3-phenylpropyl)- (9CI)

(CA INDEX NAME)




RN 885069-55-6 CAPLUS

CN Acetamide, N-[3-[6-[[2-[4-(difluoromethoxy)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885069-57-8 CAPLUS

CN 4-Pyrimidinamine, N-[2-(2,4-dichlorophenyl)ethyl]-2-methyl-6-[3-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885069-60-3 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α-methyl- (9CI) (CA INDEX NAME)




RN 885069-61-4 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl-, 1-[(ethoxycarbonyl)oxy]ethyl ester (9CI) (CA INDEX NAME)




RN 885069-62-5 CAPLUS

CN Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl-, 2-(dimethylamino)ethyl ester (9CI)  
(CA INDEX NAME)




RN 885069-64-7 CAPLUS

CN Acetamide, N-[2-[3-[6-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 885069-65-8 CAPLUS

CN Acetamide, N-[2-[3-[6-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 885069-72-7 CAPLUS

CN Phenol, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 885067-30-1P 885067-33-4P 885067-35-6P  
 885067-53-8P, N-(1-Iminoethyl)-3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide 885067-96-9P  
 885068-19-9P 885068-25-7P, [3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]acetonitrile 885068-26-8P, [6-[3-(2-Aminoethyl)phenyl]-2-methoxypyrimidin-4-yl][2-(2-fluoro-4-trifluoromethylphenyl)ethyl]amine  
 885068-30-4P, 3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol 885068-40-6P,  
 3-[6-[[2-(3,4-Difluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)


RN 885067-30-1 CAPLUS

CN Ethanimidamide, 2-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 885067-33-4 CAPLUS

CN Benzeneethanimidamide, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 885067-35-6 CAPLUS

CN Ethanimidamide, 2-[3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenoxy]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 885067-53-8 CAPLUS

CN Benzamide, N-(1-iminoethyl)-3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-96-9 CAPLUS

CN Benzeneacetonitrile, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl- (CA INDEX NAME)




RN 885068-19-9 CAPLUS

CN Carbonic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 885068-25-7 CAPLUS

CN Benzeneacetonitrile, 3-[6-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885068-26-8 CAPLUS

CN 4-Pyrimidinamine, 6-[3-(2-aminoethyl)phenyl]-N-[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 885068-30-4 CAPLUS

CN Phenol, 3-[6-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 885068-40-6 CAPLUS

CN Phenol, 3-[6-[[2-(3,4-difluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 885067-32-3, [3-[2-Methoxy-6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetonitrile

10/671,070


885068-43-9, 3-[6-[[2-(3-Fluoro-4-methoxyphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)


RN 885067-32-3 CAPLUS

CN Benzeneacetonitrile, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 885068-43-9 CAPLUS



CN Phenol, 3-[6-[[2-(3-fluoro-4-methoxyphenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:292375 CAPLUS  
 DN 144:350703  
 TI Preparation of 4-aminomethylpyrimidines as ppar-alpha modulators  
 IN Dittrich-Wengenroth, Elke; Baerfacker, Lars; Kretschmer, Axel;  
 Hirth-Dietrich, Claudia; Ellinghaus, Peter; Raabe, Martin; Bischoff,  
 Hilmar; Pilger, Christian; Rosentreter, Ulrich; Bartel, Stephan; Lustig,  
 Klemens; Kern, Armin; Lang, Dieter; Bauser, Marcus  
 PA Bayer Healthcare AG, Germany  
 SO PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006032384	A1	20060330	WO 2005-EP9734	20050910
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	DE 102004046623	A1	20060330	DE 2004-102004046623	20040925
	CA 2582492	A1	20060330	CA 2005-2582492	20050910
PRAI	DE 2004-102004046623	A	20040925		
	WO 2005-EP9734	W	20050910		
OS	MARPAT 144:350703				
AB	Title compds. I [X = (CH <sub>2</sub> ) <sub>n</sub> ; n = 0-2; A = O, S; Z = (CH <sub>2</sub> ) <sub>m</sub> ; O, NR <sub>9</sub> ; m = 0-2; R <sub>9</sub> = H, alkyl; R <sub>1</sub> = aryl, 5 to 10-membered heteroaryl; R <sub>2</sub> = H, aryl, alkyl, etc.; R <sub>3</sub> , R <sub>4</sub> = H, alkyl, alkenyl, etc.; R <sub>5</sub> , R <sub>6</sub> = H, alkyl, alkoxy, etc.; R <sub>7</sub> = NHR <sub>16</sub> , OR <sub>17</sub> ; R <sub>16</sub> = H, alkyl, alkylsulfonyl; R <sub>17</sub> = H, O-protecting group with provisos; R <sub>8</sub> = H, alkyl; D, E = N, CH with provisos] and their pharmaceutically acceptable salts and formulations were prepared For example, HCl-mediated deprotection of of t-Bu ester II [Y = O-tBu] afforded claimed aminomethylpyrimidine II [Y = OH] in 31% yield. In ppar-α receptor EC <sub>50</sub> assays, compds. I exhibited values from 1 μM to 1 nM.				
IT	881686-45-9P 881686-46-0P 881686-47-1P 881686-49-3P 881686-50-6P 881686-51-7P 881686-53-9P 881686-54-0P 881686-56-2P 881686-64-2P 881686-65-3P 881686-77-7P 881686-78-8P 881686-79-9P 881687-05-4P 881687-07-6P 881687-09-8P 881687-12-3P 881687-15-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 4-aminomethylpyrimidines as ppar-alpha modulators)				
RN	881686-45-9 CAPLUS				
CN	Propanoic acid, 2-[[4-[[2-methoxyethyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)				







● x HCl

RN 881686-46-0 CAPLUS



CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 881686-47-1 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881686-49-3 CAPLUS


CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 881686-50-6 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl](2-furanylmethyl)amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 881686-51-7 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[4-[[[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 881686-53-9 CAPLUS  
 CN Propanoic acid, 2-[[4-[[[2-(furan-2-ylmethyl)[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881686-54-0 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-(2-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881686-56-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(2-fluoro-5-methylphenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881686-64-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl]-2-propynylamino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881686-65-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(2-thiazolylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI)  
(CA INDEX NAME)




RN 881686-77-7 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881686-78-8 CAPLUS

CN Propanoic acid, 2-[[4-[[[(3,5-dimethyl-4-isoxazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881686-79-9 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-fluoroethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881687-05-4 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881687-07-6 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(2-methyl-4-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI) (CA INDEX NAME)




RN 881687-09-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(1-methyl-1H-imidazol-2-yl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI)  
(CA INDEX NAME)




RN 881687-12-3 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881687-15-6 CAPLUS  
 CN Propanoic acid, 2-[[4-[[[(cyclopropylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





IT 881687-25-8P 881687-26-9P 881687-27-0P  
 881687-29-2P 881687-30-5P 881687-31-6P  
 881687-33-8P 881687-34-9P 881687-36-1P  
 881687-45-2P 881687-49-6P 881687-67-8P  
 881687-68-9P 881687-69-0P 881688-01-3P  
 881688-05-7P 881688-07-9P 881688-10-4P  
 881688-12-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 4-aminomethylpyrimidines as ppar-alpha modulators)

RN 881687-25-8 CAPLUS



CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881687-26-9 CAPLUS



CN Propanoic acid, 2-[[4-[[[(6-(3-chlorophenyl)-4-pyrimidinyl)(2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 881687-27-0 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-29-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-30-5 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl](2-furanylmethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-31-6 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881687-33-8 CAPLUS

CN Propanoic acid, 2-[[4-[[[2-furanylmethyl][6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-34-9 CAPLUS

CN Propanoic acid, 2-[[4-[[[2-furanylmethyl][6-(2-methylphenyl)-4-


10/671,070

pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)




RN 881687-36-1 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(2-fluoro-5-methylphenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)




RN 881687-45-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl]-2-propynylamino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)




RN 881687-49-6 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(2-thiazolylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-67-8 CAPLUS

CN Propanoic acid, 2-[[4-[[[(3,5-dimethyl-4-isoxazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881687-68-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-69-0 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-fluoroethyl)[6-[3-(trifluoromethyl)phenyl]-4-



10/671,070

pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)




RN 881688-01-3 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)




RN 881688-05-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(2-methyl-4-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881688-07-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(1-methyl-1H-imidazol-2-yl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881688-10-4 CAPLUS


CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881688-12-6 CAPLUS


CN Propanoic acid, 2-[[4-[[[(cyclopropylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/671,070



RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:242393 CAPLUS  
DN 145:371617  
TI Substrate specificity of lysophosphatidic acid acyltransferase  
 $\beta$ -evidence from membrane and whole cell assays  
AU Hollenback, David; Bonham, Lynn; Law, Laura; Rossnagle, Eddie; Romero,  
Lisa; Carew, Heather; Tompkins, Christopher K.; Leung, David W.; Singer,  
Jack W.; White, Thayer  
CS Department of Biochemistry, Cell Therapeutics, Inc., Seattle, WA, 98119,  
USA  
SO Journal of Lipid Research (2006), 47(3), 593-604  
CODEN: JLPRAW; ISSN: 0022-2275  
PB American Society for Biochemistry and Molecular Biology, Inc.  
DT Journal  
LA English  
AB Membranes of mammalian cells contain lysophosphatidic acid acyltransferase  
(LPAAT) activities that catalyze the acylation of sn-1-acyl  
lysophosphatidic acid (lysoPA) to form phosphatidic acid. As the biol.  
roles and biochem. properties of the six known LPAAT isoforms have yet to  
be fully elucidated, we have characterized human LPAAT- $\beta$  activity  
using two different assays. In a membrane-based assay, LPAAT- $\beta$  used  
lysoPA and lysophosphatidylmethanol (lysoPM) but not other  
lysophosphoglycerides as an acyl acceptor, and it preferentially  
transferred 18:1, 18:0, and 16:0 acyl groups over 12:0, 14:0, 20:0, and  
20:4 acyl groups. The fact that lysoPM could traverse cell membranes  
permitted addnl. characterization of LPAAT- $\beta$  activity in cells: PC-3  
and DU145 cells converted exogenously added lysoPM and 14C-labeled 18:1  
into 14C-labeled phosphatidylmethanol (PM). The rate of PM formation was  
higher in cells that over-expressed LPAAT- $\beta$  and was inhibited by the  
LPAAT- $\beta$  inhibitor CT-32501. In contrast, if lysoPM and 14C-labeled  
20:4 were added to PC-3 or DU145 cells, 14C-labeled PM was also formed,  
but the rate was neither higher in cells that over-expressed LPAAT- $\beta$   
nor inhibited by CT-32501. We propose that LPAAT- $\beta$  catalyzes the  
intracellular transfer of 18:1, 18:0, and 16:0 acyl groups but not 20:4  
groups to lysoPA.  
IT 774606-24-5, CT 32501  
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(inhibition of lysophosphatidic acid acyltransferase  $\beta$ ; substrate  
specificity of lysophosphatidic acid acyltransferase  $\beta$ )  
RN 774606-24-5 CAPLUS  
CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-1H-indazol-6-yl- (9CI)  
(CA INDEX NAME)




RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




L10 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:87791 CAPLUS  
 DN 144:285633  
 TI Discovery of EGFR Selective 4,6-Disubstituted Pyrimidines from a  
 Combinatorial Kinase-Directed Heterocycle Library  
 AU Zhang, Qiong; Liu, Yi; Gao, Feng; Ding, Qiang; Cho, Charles; Hur,  
 Wooyoung; Jin, Yunho; Uno, Tetsuo; Joazeiro, Claudio A. P.; Gray,  
 Nathanael  
 CS Departments of Chemistry and Cell Biology, Genomics Institute of the  
 Novartis Research Foundation, San Diego, CA, 92121, USA  
 SO Journal of the American Chemical Society (2006) 128(7), 2182-2183  
 CODEN: JACSAT; ISSN: 0002-7863  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 144:285633  
 AB The epidermal growth factor receptor (EGFR) tyrosine kinase was one of the  
 first receptor tyrosine kinases to be targeted for drug development by the  
 pharmaceutical industry due to its ubiquitous overexpression in a variety  
 of tumors. Despite the validation of several quinazoline-based scaffolds  
 in the clinic, there is a dearth of alternative chemical structure classes  
 that are capable of inhibiting EGFR kinase activity selectively. Here we  
 describe the discovery of potent and highly selective 4,6-disubstituted  
 pyrimidine inhibitors of enzymic and cellular EGFR activity and provide an  
 explanation for their exceptional degree of kinase selectivity.  
 IT 879127-13-6P 879127-14-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (4,6-disubstituted pyrimidines preparation and selective inhibition of  
 enzymic and cellular EGFR activity)  
 RN 879127-13-6 CAPLUS  
 CN Cyclopropanecarboxamide, N-[3-[[6-(2,5-dimethoxyphenyl)-4-  
 pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 879127-14-7 CAPLUS  
 CN Cyclopropanecarboxamide, N-[3-[[6-(5-chloro-2-methoxyphenyl)-4-  
 pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L10 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:49982 CAPLUS  
 DN 144:205343  
 TI Allosteric inhibitors of Bcr-abl-dependent cell proliferation  
 AU Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Dorian; Gray, Nathanael S.  
 CS Biological Chemistry Department, Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA  
 SO Nature Chemical Biology (2006), 2(2), 95-102  
 CODEN: NCBABT; ISSN: 1552-4450  
 PB Nature Publishing Group  
 DT Journal  
 LA English  
 AB Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the mol. level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clin. validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacol. agents that could target this kinase by a distinct mechanism. We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library. Compds. in this class (exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl. We propose that this new class of compds. inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.  
 IT 778270-11-4, GNF 2 875557-38-3, GNF 3  
 875557-39-4, GNF 4  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (allosteric inhibitors of Bcr-abl-dependent cell proliferation)  
 RN 778270-11-4 CAPLUS  
 CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 875557-38-3 CAPLUS  
 CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 875557-39-4 CAPLUS

CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1331285 CAPLUS  
 DN 144:69847  
 TI Preparation of 4-phenylpyridine-2-carbonitrile derivs. as inhibitors of  
 cathepsin K and cathepsin S  
 IN Cai, Jiaqiang; Rankovic, Zoran; Moir, Jennifer Helen  
 PA Akzo Nobel N.V., Neth.  
 SO PCT Int. Appl., 71 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005121106	A1	20051222	WO 2005-EP6266	20050609
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005251923	A1	20051222	AU 2005-251923	20050609
	CA 2567845	A1	20051222	CA 2005-2567845	20050609
	EP 1758870	A1	20070307	EP 2005-763140	20050609
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
	NO 2007000146	A	20070202	NO 2007-146	20070109
PRAI	EP 2004-253491	A	20040611		
	EP 2004-106949	A	20041223		
	WO 2005-EP6266	W	20050609		

OS MARPAT 144:69847


AB Title compds. I [wherein R (one to three) = (un)substituted alkyl, alkoxy, cyano, etc.; R1 = H or alkyl; R2 = (un)substituted alkyl, alkoxy, aryloxy, etc., and pharmaceutically acceptable salts thereof] were prepared as inhibitors of cathepsin K and cathepsin S. For instance, 3'-trifluoromethylacetophenone underwent successive condensation with Et butyrate (76%), cyclization with urea in the presence of HCl (72%), chlorination with POCl3 (100%) and substitution with CuCN (8%) to give II. I showed inhibition of human cathepsin K with pIC50 > 6 (pIC50 > 7 for II). Therefore, I and their pharmaceutical compns. are useful for the treatment of cathepsin K and cathepsin S related diseases, such as atherosclerosis, bone diseases, inflammation, immune disorders and pain.

IT 871793-50-9P, 4-(3-Phenylaminopropyl)-6-(3-trifluoromethylphenyl)pyrimidine-2-carbonitrile  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of phenylpyridinecarbonitrile derivs. as inhibitors of cathepsin K and cathepsin S)

RN 871793-50-9 CAPLUS

CN 2-Pyrimidinecarbonitrile, 4-[3-(phenylamino)propyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1313901 CAPLUS  
 DN 144:51598  
 TI Preparation of amino-substituted pyrimidines as antitumor agents  
 IN Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei; Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen, Jianqing; Bear, Brian R.; Brands, Michael; Hillisch, Alexander; Bierer, Donald; Wang, Ming; Fu, Wenlang; Hentemann, Martin F.; Bullion, Ann-Marie; Patel, Manoj  
 PA Bayer Pharmaceuticals Corporation, USA  
 SO U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of Appl. No. PCT/US04/033430.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005277640	A1	20051215	US 2005-78681	20050310
	WO 2005035507	A2	20050421	WO 2004-US33430	20041008
	WO 2005035507	A3	20060831		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-510804P P 20031010  
 WO 2004-US33430 A2 20041008

OS CASREACT 144:51598; MARPAT 144:51598

AB Title compds. I [R1 = H, alkyl, cyclopropyl; R2 = alkyl, cyclopropyl, O-alkyl, etc.; R3 = H, halo; M = CH, N; L = carbonyl, O, (un)substituted alkylenyl, etc.; J and Y independently = substituted aryl, heteroaryl; A = halo, CF3, CN, etc.; m = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as useful antitumor agents. Thus, coupling 6-chloro-N4-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine with 1,3-dimethylphenylboronic acid afforded 56% II which showed IC50 of 62 nM in test for cytotoxic activity on HCT-116 cells.

IT 850247-19-7P 850247-66-4P 850248-21-4P  
 850248-24-7P 850248-69-0P 850248-70-3P  
 850248-71-4P 850248-72-5P 850248-73-6P  
 850248-74-7P 850248-75-8P 850248-76-9P  
 850248-77-0P 850248-78-1P 850248-82-7P  
 850248-84-9P 850248-85-0P 850248-90-7P  
 850249-08-0P 850249-09-1P 850249-10-4P  
 850249-13-7P 850249-14-8P 850249-16-0P  
 850249-17-1P 850249-18-2P 850249-21-7P  
 850249-22-8P 850249-28-4P 850249-31-9P  
 850249-32-0P 850249-35-3P 850249-42-2P  
 850249-47-7P 850249-61-5P 850249-63-7P  
 850249-70-6P 850249-73-9P 850249-75-1P  
 850249-78-4P 850249-79-5P 850249-80-8P  
 850249-81-9P 850249-83-1P 850249-85-3P  
 850249-89-7P 850249-91-1P 850249-93-3P  
 850249-97-7P 850249-98-8P 850249-99-9P  
 850250-01-0P 850250-04-3P 850250-06-5P

850250-09-8P 850250-10-1P 850250-11-2P  
 850250-12-3P 850250-13-4P 850250-14-5P  
 850250-15-6P 850250-17-8P 850250-19-0P  
 850250-21-4P 850250-22-5P 850250-24-7P  
 850250-25-8P 850250-26-9P 850250-27-0P  
 850250-28-1P 850250-32-7P 850250-35-0P  
 850250-36-1P 850250-41-8P 850250-42-9P  
 850250-45-2P 850250-47-4P 850250-50-9P  
 850250-51-0P 850250-55-4P 850250-57-6P  
 850250-59-8P 850250-60-1P 850252-01-6P  
 871240-05-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of amino-substituted pyrimidines as antitumor agents)


RN 850247-19-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-ethyl-6-(3-methoxyphenyl)-N4-[4-[[2-  
 (trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 850247-18-6


CMF C25 H22 F3 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 850247-66-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-methoxyphenyl)-4-  
 pyrimidinyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 850248-21-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 850248-24-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-69-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 850248-70-3 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)






RN 850248-71-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME) .




RN 850248-72-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-ethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-73-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-fluoro-5-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-74-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,3-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-75-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-76-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-77-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-78-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 850248-82-7 CAPLUS  
 CN Phenol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-84-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-85-0 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 850248-90-7 CAPLUS  
 CN Benzenemethanol, 2-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-08-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-09-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-10-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-13-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-14-8 CAPLUS

CN Benzonitrile, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-16-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-17-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-methoxy-5-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-18-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-21-7 CAPLUS

CN Benzenemethanol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-22-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-28-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-31-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-32-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-35-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-42-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-47-7 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-61-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-63-7 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-70-6 CAPLUS


CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-73-9 CAPLUS


CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)






RN 850249-75-1 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-78-4 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-79-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-80-8 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-81-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-83-1 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-85-3 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-89-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-91-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-93-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-97-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-98-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-99-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-01-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-04-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-06-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-09-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-10-1 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-11-2 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-12-3 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-13-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-14-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-15-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-17-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-19-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-21-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-22-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-24-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-25-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-26-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-27-0 CAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-28-1 CAPLUS


CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)






RN 850250-32-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-35-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-36-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-41-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[3-(dimethylamino)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-42-9 CAPLUS

CN Phenol, 3-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850250-45-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-47-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-50-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-51-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-55-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-57-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-59-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[3-(1-methylethoxy)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-60-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850252-01-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 871240-05-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,6-dimethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1168931 CAPLUS  
 DN 143:440430  
 TI Pyrimidin-4-yl-1H-indazol-5-yl-amines as CHK-1 kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy  
 IN Birault, Veronique; Woodland, Christopher Andrew  
 PA Biofocus Discovery Ltd., UK  
 SO PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005103036	A1	20051103	WO 2005-GB1566	20050422
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2004-9080 A 20040423

OS CASREACT 143:440430; MARPAT 143:440430

AB The invention relates to compds. of formula I, which are useful in the inhibition of protein kinases, in particular serine/threonine kinases, more particularly CHK-1 kinase. In compds. I, R1 is H, OH, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, carboxy, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted aryloxy, etc.; and R2 is (un)substituted aryl or (un)substituted heteroaryl; including pharmaceutically acceptable salts, hydrates, solvates, geometrical isomers, tautomers, optical isomers, or prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising compound

I and a pharmaceutically acceptable diluent or carrier, as well as to the use of the compns. in the prevention and/or treatment of a wide variety of diseases including cancer, and disease states associated with angiogenesis and/or cellular proliferation. Substitution of 4,6-dichloropyrimidine with 1H-indazol-5-ylamine gave secondary amine II, which underwent Suzuki coupling with 4-(aminomethyl)phenylboronic acid resulting in the formation of indazolyl(pyrimidinyl)amine III. Several compds. of the invention express an IC50 towards CHK-1 kinase of <10 µM and three compds., e.g., III, express <1 µM. The compds. of the invention also show selectivity for CHK-1 kinase with compound I (R1 = H; R2 = 4-(Me2NCH2)C6H4) expressing a 50-fold selectivity for CHK-1 over CDK-1 kinase.


IT 868545-65-7P, [6-(5-(Dimethylaminomethyl)-2-methoxyphenyl)pyrimidin-4-yl](1H-indazol-5-yl)amine 868545-66-8P, N-[3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]phenyl]methanesulfonamide 868545-69-1P, 3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]benzamide 868545-72-6P, [3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]phenyl]methanol 868545-76-0P, 3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]-phenol 868545-77-1P, [6-(3-((Dimethylamino)methyl)phenyl)pyrimidin-4-yl](1H-indazol-5-yl)amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

## (Uses)

(drug candidate; preparation of pyrimidinylindazolylamines as CHK-1 kinase inhibitors and therapeutic agents for treatment of cancer, angiogenesis- and cellular proliferation-associated disorders)


RN 868545-65-7 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-66-8 CAPLUS

CN Methanesulfonamide, N-[3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 868545-69-1 CAPLUS

CN Benzamide, 3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 868545-72-6 CAPLUS


CN Benzenemethanol, 3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 868545-76-0 CAPLUS


CN Phenol, 3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/671,070



RN 868545-77-1 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[3-[(dimethylamino)methyl]phenyl]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1123789 CAPLUS  
 DN 143:427366  
 TI Compositions and methods for treatment of inflammatory conditions using steroid sparing agents  
 IN Lieberburg, Ivan  
 PA Elan Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 782 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005097162	A2	20051020	WO 2005-US11307	20050401
	WO 2005097162	A3	20060406		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005231467	A1	20051020	AU 2005-231467	20050401
	CA 2561164	A1	20051020	CA 2005-2561164	20050401
	US 2006004019	A1	20060105	US 2005-95822	20050401
	EP 1763361	A2	20070321	EP 2005-763852	20050401
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRAI	US 2004-558121P	P	20040401		
	WO 2005-US11307	W	20050401		
OS	MARPAT 143:427366				
AB	This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft vs. host disease (GVHD), host vs. graft disease, and various spondyloarthropathies, comprising administering a steroid sparing Ig that modulates $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins, or an amino acid-based small (heterocyclic) mol. to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions, including an immunosuppressant, an anti-TNF compound, and a 5-ASA compound. For example, a steroid sparing agent was prepared by converting L-tyrosine tert-Bu ester to L-4-(N,N-dimethylcarbamyloxy)-phenylalanine tert-Bu ester and coupling it to 4,6-dichloro-5-piperidin-1-yl-pyrimidine to give N-(5-piperidin-yl)pyrimidin-4-yl-L-4-(N,N-dimethylcarbamyloxy)phenylalanine. Also, Natalizumab, a humanized monoclonal IgG4 antibody to $\alpha 4$ integrin, was evaluated in subjects with Chron's disease. Monthly administration of Natalizumab for 6 mo was well tolerated and enabled subjects to be successfully withdrawn from steroids.				
IT	285139-60-8P 285139-62-0P				
	RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of steroid sparing agents for treatment of inflammatory conditions)				
RN	285139-60-8 CAPLUS				



10/671,070

CN L-Tyrosine, N-[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 285139-62-0 CAPLUS

CN L-Tyrosine, N-[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L10 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1024910 CAPLUS  
 DN 143:381701  
 TI Diamino-C,N-diarylpyridine positional isomers as inhibitors of  
 lysophosphatidic acid acyltransferase- $\beta$   
 AU Hong, Feng; Hollenback, David; Singer, Jack W.; Klein, Peter  
 CS Cell Therapeutics, Inc., Seattle, WA, 98119, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(21), 4703-4707  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 143:381701  
 AB 2,6-Diamino-4,N-diarylpyridines were identified as potent, isoform  
 selective inhibitors of the enzymic activity of lysophosphatidic acid  
 acyltransferase- $\beta$  (LPAAT- $\beta$ ).  
 IT 710334-85-3 710336-16-6  
 RL: PAC (Pharmacological activity); BIOL (Biological study)  
 (diamino-C,N-diarylpyridine isomers preparation and inhibition of  
 LPAAT- $\beta$ )  
 RN 710334-85-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-chlorophenyl)-  
 (9CI) (CA INDEX NAME)



RN 710336-16-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)-  
 (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1004351 CAPLUS  
 DN 143:306328  
 TI Preparation of 4-pyrimidinamines as neuroprotectants.  
 IN Benjamin, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael Kurt; Zhong, Zhong; Reitz, Allen B.; Ross, Tina Morgan  
 PA USA  
 SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 922,874, abandoned.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

*Same as #45*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005203092	A1	20050915	US 2004-987562	20041112
	US 2003008883	A1	20030109	US 2001-922874	20010806
	US 2003212079	A1	20031113	US 2003-396158	20030325
	US 2004006094	A1	20040108	US 2003-395971	20030325
PRAI	US 2000-223791P	P	20000808		
	US 2001-922874	B2	20010806		

OS MARPAT 143:306328


AB This invention provides novel neuroprotective 4-pyrimidineamine derivs. (I, variables defined below) and neuroprotective pharmaceutical compns. comprising 4-pyrimidinamines. This invention also provides methods of using these compns. to prevent ischemic cell death, particularly neuronal cell death, and reduce the likelihood of neuronal cell death in a subject due to a traumatic event. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbonyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07  $\mu$ M to >1  $\mu$ M. For I the variables are: R20 = disubstituted amino; R21 = H, alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl, wherein the aryl portion is optionally substituted; p = 0-3; q = 0-3; R22 and R23 = halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, nitro, cyano, carboxy, alkoxycarbonyl, aryloxy, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl.

IT 397851-08-0 397851-15-9 397851-16-0  
 397851-18-2 397851-20-6 397851-24-0  
 397851-26-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of 4-pyrimidinamines as neuroprotectants)


RN 397851-08-0 CAPLUS

CN 1,4-Benzenediamine, N'-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 397851-15-9 CAPLUS

CN Ethanol, 2-[[4-[[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-16-0 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(3-nitrophenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-18-2 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(2-phenoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 397851-20-6 CAPLUS


CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-(2-phenoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-24-0 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/671,070



RN 397851-26-2 CAPLUS  
CN Ethanol, 2-[[4-[[6-[3-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenyl]ethoxy]- (9CI) (CA INDEX NAME)



L10 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:696886 CAPLUS  
 DN 143:194017  
 TI Preparation of heteroaryl-substituted pyrimidinylaminophenylbenzenesulfonamides as kinase inhibitors  
 IN Barsig, Johannes; Baudler, Monika; Bundschuh, Daniela; Gantner, Florian; Graedler, Ulrich; Heit, Isabelle; Martin, Thomas; Schaefer, Michaela; Schlemminger, Imre; Stadlwieser, Josef; Ulrich, Wolf-Ruediger  
 PA Altana Pharma A.-G., Germany  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070900	A1	20050804	WO 2005-EP50206	20050119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2553513	A1	20050804	CA 2005-2553513	20050119
	EP 1709007	A1	20061011	EP 2005-701549	20050119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRAI	EP 2004-1310	A	20040122		
	WO 2005-EP50206	W	20050119		
OS	CASREACT 143:194017; MARPAT 143:194017				
AB	Title compds. I [R1-2 = (un)substituted Ph, naphthyl, etc.] are prepared For instance, 2,6-difluoro-N-[4-[[6-(4-fluorophenyl)pyrimidin-4-yl]amino]phenyl]benzenesulfonamide is prepared from N-[6-(4-fluorophenyl)pyrimidin-4-yl]benzene-1,4-diamine (preparation given) and 2,6-difluorobenzenesulfonyl chloride. Included in the biol. results are inhibition of protein kinases like p90 ribosomal S6 kinase (Rsk) family, Src family kinases and protein kinase C isoforms; in the Rsk kinase assay selected example compds. have IC50 < 1 µM. I are useful in the treatment of, e.g., acute or chronic rejection of organ or tissue all- or xenografts.				
IT	861846-87-9P, N-[4-[[6-(3-Methoxyphenyl)pyrimidin-4-yl]amino]phenyl]-4-trifluoromethylbenzenesulfonamide 861846-88-0P, 2,4-Difluoro-N-[4-[[6-(3-methoxyphenyl)pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861846-89-1P, 4-Cyano-N-[4-[[6-(3-methoxyphenyl)pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861846-90-4P, 2-Fluoro-N-[4-[[6-(3-methoxyphenyl)pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861846-94-8P, 2,4-Difluoro-N-[4-[[6-(3-fluorophenyl)pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861846-96-0P, 2,6-Difluoro-N-[4-[[6-(3-fluorophenyl)pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861847-04-3P, N-[4-[[6-(3-Fluorophenyl)pyrimidin-4-yl]amino]phenyl]-4-methylbenzenesulfonamide 861847-09-8P, 2,6-Difluoro-N-[4-[[6-[3-[3-(morpholin-4-yl)propoxy]phenyl]pyrimidin-4-				

yl]amino]phenyl]benzenesulfonamide 861847-12-3P,  
 2-Fluoro-N-[4-[[6-[3-[2-(morpholin-4-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861847-13-4P,  
 2-Fluoro-N-[4-[[6-[3-[3-(morpholin-4-yl)propoxy]phenyl]pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861847-16-7P,  
 4-Methoxy-N-[4-[[6-[3-[3-(morpholin-4-yl)propoxy]phenyl]pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861847-18-9P,  
 2,6-Difluoro-N-[4-[[6-[3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861847-20-3P,  
 2-Fluoro-N-[4-[[6-[3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861847-31-6P,  
 2,4-Difluoro-N-[4-[[6-[3-[2-(morpholin-4-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]phenyl]benzenesulfonamide 861847-33-8P,  
 4-Methyl-N-[4-[[6-[3-[2-(morpholin-4-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]phenyl]benzenesulfonamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl-substituted pyrimidinylaminophenylbenzenesulfonamides as kinase inhibitors)


RN 861846-87-9 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 861846-88-0 CAPLUS

CN Benzenesulfonamide, 2,4-difluoro-N-[4-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 861846-89-1 CAPLUS

CN Benzenesulfonamide, 4-cyano-N-[4-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 861846-90-4 CAPLUS

CN Benzenesulfonamide, 2-fluoro-N-[4-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 861846-94-8 CAPLUS

CN Benzenesulfonamide, 2,4-difluoro-N-[4-[[6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 861846-96-0 CAPLUS


CN Benzenesulfonamide, 2,6-difluoro-N-[4-[[6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 861847-04-3 CAPLUS


CN Benzenesulfonamide, N-[4-[[6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenyl]-4-methyl- (9CI) (CA INDEX NAME)






RN 861847-09-8 CAPLUS

CN Benzenesulfonamide, 2,6-difluoro-N-[4-[[6-[3-[3-(4-morpholinyl)propoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 861847-12-3 CAPLUS

CN Benzenesulfonamide, 2-fluoro-N-[4-[[6-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 861847-13-4 CAPLUS

CN Benzenesulfonamide, 2-fluoro-N-[4-[[6-[3-[3-(4-morpholinyl)propoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 861847-16-7 CAPLUS


CN Benzenesulfonamide, 4-methoxy-N-[4-[[6-[3-[3-(4-morpholinyl)propoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 861847-18-9 CAPLUS

CN Benzenesulfonamide, 2,6-difluoro-N-[4-[[6-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 861847-20-3 CAPLUS


CN Benzenesulfonamide, 2-fluoro-N-[4-[[6-[3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 861847-31-6 CAPLUS


CN Benzenesulfonamide, 2,4-difluoro-N-[4-[[6-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/671,070



RN 861847-33-8 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[4-[[6-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:638854 CAPLUS  
 DN 143:153392  
 TI Preparation of aryl pyrimidines as protein kinase C inhibitors  
 IN Fleming, Paul E.; Shi, Zhan; Chen, Shaowu; Schmidt, Jane F.; Reader, John  
 C.; Hone, Neal D.; Ciavarri, Jeffrey P.  
 PA Millennium Pharmaceuticals, Inc., USA; Millennium Pharm Inc  
 SO PCT Int. Appl., 177 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066139	A2	20050721	WO 2005-US663	20050110
	WO 2005066139	A3	20051013		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005204060	A1	20050721	AU 2005-204060	20050110
	CA 2559888	A1	20050721	CA 2005-2559888	20050110
	US 2006040968	A1	20060223	US 2005-32299	20050110
	EP 1701944	A2	20060920	EP 2005-726205	20050110
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
	IN 2006KN02154	A	20070518	IN 2006-KN2154	20060731
PRAI	US 2004-534898P	P	20040108		
	WO 2005-US663	W	20050110		

OS MARPAT 143:153392

AB Title compds. I [R1 and R2 independently = H, alkyl, cycloalkyl; R3 = H or F; R4 = H, F, C(O)R, etc., or R3 and R4 together = carbonyl; R = H, alkyl, cycloalkyl; ring A is optionally substituted with R5; R5 = halo, CN, aliphatic, etc.; Cyl = (un)substituted 6-membered aryl or heteroaryl, 5-membered heteroaryl; Q = bond, CH2, CO; Cy2 = (un)substituted aryl, heteroaryl, heterocycle] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase C (PKC) inhibitors. Thus, e.g., II was prepared by coupling of (3-([3-(2-chloro-pyrimidin-4-yl)-benzyl]-ethyl-amino)-propyl)carbamic acid tert-Bu ester (preparation given) with tyramine and subsequent deprotection. The inhibitory activity of I against PKC-theta isoform was evaluated in an enzyme assay following the emission of europium cryptate (at 615 nm) and streptavidin-allophycocyanin (at 665 nm) and it was revealed that selected compds. of the invention display IC50 values less than 100 nM. I as PKC inhibitor should prove useful in the treatment of inflammatory diseases such as, but not limited to, rheumatoid arthritis, asthma, and multiple sclerosis. Pharmaceutical compns. comprising I are disclosed.

IT 859519-16-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl pyrimidines as protein kinase C inhibitors)

10/671,070

RN 859519-16-7 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[6-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:585317 CAPLUS

DN 143:399001

TI Induction of Apoptosis Using Inhibitors of Lysophosphatidic Acid  
Acyltransferase- $\beta$  and Anti-CD20 Monoclonal Antibodies for  
Treatment of Human Non-Hodgkin's Lymphomas

AU Pagel, John M.; Laugen, Christian; Bonham, Lynn; Hackman, Robert C.;  
Hockenbery, David M.; Bhatt, Rama; Hollenback, David; Carew, Heather;  
Singer, Jack W.; Press, Oliver W.

CS Fred Hutchinson Cancer Research Center, Univ. Washington, Seattle, WA, USA

SO Clinical Cancer Research (2005), 11(13), 4857-4866

CODEN: CCREF4; ISSN: 1078-0432

PB American Association for Cancer Research

DT Journal

LA English

AB PURPOSE: Lysophosphatidic acid acyltransferase- $\beta$  (LPAAT- $\beta$ ) is a  
transmembrane enzyme critical for the biosynthesis of phosphoglycerides whose  
product, phosphatidic acid, plays a key role in raf and AKT/mTor-mediated  
signal transduction. Exptl. Design: LPAAT- $\beta$  may be a novel target  
for anticancer therapy, and, thus, we examined the effects of a series of  
inhibitors of LPAAT- $\beta$  on multiple human non-Hodgkin's lymphoma cell  
lines in vitro and in vivo. RESULTS: We showed that five LPAAT- $\beta$   
inhibitors at doses of 500 nmol/L routinely inhibited growth in a panel of  
human lymphoma cell lines in vitro by >90%, as measured by [3H]thymidine  
incorporation. Apoptotic effects of the LPAAT- $\beta$  inhibitors were  
evaluated either alone or in combination with the anti-CD20 antibody,  
Rituximab. The LPAAT- $\beta$  inhibitors induced caspase-mediated apoptosis  
at 50 to 100 nmol/L in up to 90% of non-Hodgkin's lymphoma cells. The  
combination of Rituximab and an LPAAT- $\beta$  inhibitor resulted in a  
2-fold increase in apoptosis compared with either agent alone. To assess  
the combination of Rituximab and a LPAAT- $\beta$  inhibitor in vivo, groups  
of athymic mice bearing s.c. human Ramos lymphoma xenografts were treated  
with the LPAAT- $\beta$  inhibitor CT-32228 i.p. (75 mg/kg) daily for 5 d/wk  
x 4 wk (total 20 doses), Rituximab i.p. (10 mg/kg) weekly x 4 wk (4 doses  
total), or CT-32228 plus Rituximab combined. Treatment with either  
CT-32228 or Rituximab alone showed an approx. 50% xenograft growth delay;  
however, complete responses were only observed when the two agents were  
delivered together. CONCLUSIONS: These data suggest that Rituximab,  
combined with a LPAAT- $\beta$  inhibitor, may provide enhanced therapeutic  
effects through apoptotic mechanisms.


IT 710334-99-9, CT 32521

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)


(CT-32521 in combination with rituximab induced caspase-mediated  
apoptosis and inhibited tumor growth than alone in human and mouse  
model of non-Hodgkin's lymphoma)

RN 710334-99-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[4-  
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 710335-06-1, CT 32615  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(CT-32615 in combination with rituximab induced caspase-mediated  
apoptosis and inhibited tumor growth than alone in human and mouse  
model of non-Hodgkin's lymphoma)  
RN 710335-06-1 CAPLUS  
CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-  
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:367661 CAPLUS  
 DN 143:618  
 TI Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- $\beta$  inhibitors  
 AU Hideshima, Teru; Chauhan, Dharminder; Ishitsuka, Kenji; Yasui, Hiroshi; Raje, Noopur; Kumar, Shaji; Podar, Klaus; Mitsiades, Constantine; Hideshima, Hiromasa; Bonham, Lynn; Munshi, Nikhil C.; Richardson, Paul G.; Singer, Jack W.; Anderson, Kenneth C.  
 CS Jerome Lipper, Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA  
 SO Oncogene (2005), 24(19), 3121-3129  
 CODEN: ONCNES; ISSN: 0950-9232  
 PB Nature Publishing Group  
 DT Journal  
 LA English  
 AB PS-341 (bortezomib, Velcade) is a promising novel agent for treatment of advanced multiple myeloma (MM); however, 65% of patients with relapsed refractory disease in a phase II study do not respond to PS-341. We have previously shown that lysophosphatidic acid acyltransferase (LPAAT)- $\beta$  inhibitor CT-32615 triggers caspase-dependent apoptosis, and can overcome resistance to conventional therapeutics (i.e., dexamethasone, doxorubicin, melphalan) in MM cells. In this study, we therefore determined whether CT-32615 could also overcome resistance to PS-341. We first characterized mol. mechanisms of resistance to PS-341 in DHL-4 cells. DHL-4 cells express low levels of caspase-3 and caspase-8; furthermore, no cleavage in caspase-8, caspase-9, caspase-3, poly ADP-ribose polymerase (PARP), or DNA fragmentation factor 45 was triggered by PS-341 treatment. We have previously shown that PS-341 treatment triggers phosphorylation of c-Jun NH2-terminal kinase (JNK), which subsequently induces caspase-dependent apoptosis; conversely, JNK inhibition blocks PS-341-induced apoptosis. We here show that phosphorylation of SEK-1, JNK, and c-Jun are not induced by PS-341 treatment, suggesting that PS-341 does not trigger a stress response in DHL-4 cells. Importantly, CT-32615 inhibits growth of DHL-4 cells in a time- and dose-dependent fashion: a transient G2/M cell cycle arrest induced by CT-32615 is mediated via down-regulation of cdc25c and cdc2. CT-32615 triggered swelling and lysis of DHL-4 cells, without caspase/PARP cleavage or TUNEL-positivity, suggesting a necrotic response. Our studies therefore demonstrate that LPAAT- $\beta$  inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clin. PS-341 resistance and improve patient outcome.  
 IT 710335-06-1, CT 32615  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (mol. characterization of PS-341 (bortezomib) resistance and treatment using lysophosphatidic acid acyltransferase (LPAAT)- $\beta$  inhibitors)  
 RN 710335-06-1 CAPLUS  
 CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



10/671,070



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:346995 CAPLUS  
 DN 142:411371  
 TI Preparation of pyrimidine derivatives as antitumor agents  
 IN Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei; Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen, Jianqing; Bear, Brian; Brands, Michael; Hillisch, Alexander; Bierer, Donald; Wang, Ming; Fu, Wenlang; Hentemann, Martin F.; Bullion, Ann-Marie  
 PA Bayer Pharmaceuticals Corporation, USA  
 SO PCT Int. Appl., 276 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005035507	A2	20050421	WO 2004-US33430	20041008
	WO 2005035507	A3	20060831		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2542031	A1	20050421	CA 2004-2542031	20041008
	EP 1689722	A2	20060816	EP 2004-809919	20041008
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007508321	T	20070405	JP 2006-534438	20041008
	US 2005277640	A1	20051215	US 2005-78681	20050310
	US 2007117817	A1	20070524	US 2006-573227	20060324
PRAI	US 2003-510804P	P	20031010		
	WO 2004-US33430	W	20041008		

OS MARPAT 142:411371

AB Title compds. I [R1 = H, alkyl, cyclopropyl; R2 = alkyl, cyclopropyl, O-alkyl, etc.; R3 = H, halo; M = CH, N; L = carbonyl, O, (un)substituted-alkylenyl, etc.; J and Y independently = (un)substituted-aryl, -heteroaryl; A = halo, CF3, CN, etc.; m = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as useful antitumor agents. Thus, e.g., II was prepared by etherification of 4-chloro-picoline with 4-aminophenol followed by amination of 4-chloro-6-phenylpyrimidin-2-amine (preparation given). The cytotoxic activity of I towards HCT116 cells was evaluated and selected compds. of the invention displayed IC50 values of less than or equal to 500 nM. I should prove useful in the treatment of hyperproliferative disorders.

IT 850247-19-7P 850247-66-4P 850248-21-4P  
 850248-24-7P 850248-69-0P 850248-70-3P  
 850248-71-4P 850248-72-5P 850248-73-6P  
 850248-74-7P 850248-75-8P 850248-76-9P  
 850248-77-0P 850248-78-1P 850248-82-7P  
 850248-84-9P 850248-85-0P 850248-90-7P  
 850249-08-0P 850249-09-1P 850249-10-4P  
 850249-13-7P 850249-14-8P 850249-16-0P  
 850249-17-1P 850249-18-2P 850249-21-7P  
 850249-22-8P 850249-28-4P 850249-31-9P

850249-32-0P 850249-35-3P 850249-42-2P  
 850249-47-7P 850249-61-5P 850249-63-7P  
 850249-70-6P 850249-73-9P 850249-75-1P  
 850249-78-4P 850249-79-5P 850249-80-8P  
 850249-81-9P 850249-83-1P 850249-85-3P  
 850249-89-7P 850249-91-1P 850249-93-3P  
 850249-97-7P 850249-98-8P 850249-99-9P  
 850250-01-0P 850250-04-3P 850250-06-5P  
 850250-09-8P 850250-10-1P 850250-11-2P  
 850250-12-3P 850250-13-4P 850250-14-5P  
 850250-15-6P 850250-17-8P 850250-19-0P  
 850250-21-4P 850250-22-5P 850250-24-7P  
 850250-25-8P 850250-26-9P 850250-27-0P  
 850250-28-1P 850250-32-7P 850250-35-0P  
 850250-36-1P 850250-41-8P 850250-42-9P  
 850250-45-2P 850250-47-4P 850250-50-9P  
 850250-51-0P 850250-55-4P 850250-57-6P  
 850250-59-8P 850250-60-1P 850252-01-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrimidine derivs. as antitumor agents)

RN 850247-19-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-ethyl-6-(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 850247-18-6


CMF C25 H22 F3 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 850247-66-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 850248-21-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 850248-24-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-69-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 850248-70-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-71-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-72-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-ethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-73-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-fluoro-5-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-74-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,3-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-75-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-76-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-77-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-78-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 850248-82-7 CAPLUS

CN Phenol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850248-84-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-85-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 850248-90-7 CAPLUS

CN Benzenemethanol, 2-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-08-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-09-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-10-4 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850249-13-7 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)






RN 850249-14-8 CAPLUS

CN Benzonitrile, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-16-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-17-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-methoxy-5-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-18-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-21-7 CAPLUS

CN Benzenemethanol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-22-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-28-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-31-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-32-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-35-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-42-2 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-47-7 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-61-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-63-7 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-70-6 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-73-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-75-1 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-78-4 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-79-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-80-8 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-81-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-83-1 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-85-3 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-89-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-91-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-93-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-97-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-98-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-99-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-01-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-04-3 CAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-06-5 CAPLUS


CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)






RN 850250-09-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-10-1 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-11-2 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-12-3 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-13-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-14-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-15-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-17-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-19-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-21-4 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-22-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-24-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-25-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-26-9 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-27-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-28-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-32-7 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-35-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-36-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-41-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[3-(dimethylamino)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-42-9 CAPLUS

CN Phenol, 3-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850250-45-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-47-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-50-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-51-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-55-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-57-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-59-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[3-(1-methylethoxy)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-60-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850252-01-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)





L10 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:329965 CAPLUS  
 DN 143:41343  
 TI A small-molecule agonist of the Wnt signaling pathway  
 AU Liu, Jun; Wu, Xu; Mitchell, Brian; Kintner, Chris; Ding, Sheng; Schultz, Peter G.  
 CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA  
 SO Angewandte Chemie, International Edition (2005), 44(13), 1987-1990  
 CODEN: ACIEF5; ISSN: 1433-7851  
 PB Wiley-VCH Verlag GmbH & Co. KGaA  
 DT Journal  
 LA English  
 OS CASREACT 143:41343  
 AB A new tool for developmental biol.: A screen of combinatorial chemical libraries identified the 2-amino-4,6-disubstituted pyrimidine 1 as a dose-dependent agonist of Wnt signaling. Tadpoles that developed from embryos treated with 1 had substantial head defects (see right-hand image; left=control). Compound 1 appears to mimic the effects of a Wnt ligand in a Xenopus model and may be a useful tool in the study of physiol. processes that involve the Wnt pathway.  
 IT 853220-52-7P  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (identification of substituted pyrimidine compound as small-mol. agonist of Wnt signaling pathway in human cells and Xenopus model)  
 RN 853220-52-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-(9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:324144 CAPLUS  
 DN 142:392431  
 TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase inhibitors and their preparation  
 IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia; Liu, Yi; Schoepfer, Joseph; Steensma, Ruo  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005033086	A1	20050414	WO 2004-US32473	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004278413	A1	20050414	AU 2004-278413	20040930
CA 2539339	A1	20050414	CA 2004-2539339	20040930
US 2005171105	A1	20050804	US 2004-956412	20040930
US 7189729	B2	20070313		
EP 1670771	A1	20060621	EP 2004-789483	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004014930	A	20061107	BR 2004-14930	20040930
CN 1860106	A	20061108	CN 2004-80028450	20040930
JP 2007507531	T	20070329	JP 2006-534171	20040930
PRAI US 2003-507592P	P	20030930		
WO 2004-US32473	W	20040930		

OS CASREACT 142:392431; MARPAT 142:392431

AB The invention relates to a group of pyrimidinylarylamines and pyrimidinylaryl benzamides I which are protein kinase inhibitors. In compds. I, n is 0-3; Z is CH or N; R1 is H or NR4R5; wherein R4 is selected from H and C1-6 alkyl and R5 is selected from optionally substituted aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R2 is selected from H and C1-6 alkyl; and R3 is selected from halo, cyano, C1-6 alkyl, arylamino, arylcarbonylamino, etc.; rings A and B can have up to 4 CH groups replaced by N. The invention also relates to the preparation of I, pharmaceutical compns. containing a therapeutically effective amount of I in combination with a pharmaceutically acceptable excipient, as well as to the use of the compns. to prevent, inhibit, or ameliorate the pathol. and/or symptomol. of diseases involving abnormal activation of protein kinases. Substitution of 4,6-dichloropyrimidine with 3-(dimethylamino)aniline followed by coupling with 2-aminophenylboronic acid gave II, which reacted with 3-nitrophenylboronic acid to give III. Hydrogenation of III followed by coupling with 4-(4-methylpiperazin-1-ylmethyl)benzoic acid then gave benzamide IV. Compds. of formula I inhibit protein kinases preferably showing IC50 values of 0.1 nM to 10 µM for wild type BCR-Abl and b-Raf, with IV having an IC50 of 0.667 µM for b-Raf. IV, at a concentration of 10 µM, exhibits 56-96 % inhibition

of the following kinases: Abl, c-RAF, CHK2, FGFR3, p70S6K, PDGFR $\alpha$ , and PKC $\alpha$ .


IT 850087-62-6P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide  
 850087-67-1P, N-[3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide 850087-68-2P,  
 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide  
 850087-69-3P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-hydroxymethylbenzamide 850087-70-6P,  
 N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-3-(morpholine-4-sulfonyl)benzamide  
 850087-71-7P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-(3-methyl-5-oxo-4,5-dihydropyrazol-1-yl)benzamide 850087-72-8P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-3-(4-methylpiperazin-1-ylsulfonyl)benzamide 850087-73-9P,  
 4-[Bis(2-hydroxyethyl)sulfamoyl]-N-[3-[[2-[6-(3-dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide  
 850087-75-1P, N-Cyclopropyl-3-[[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzamide  
 850087-76-2P, [6-[2-(3-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-77-3P, [6-[2-(2-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine  
 850087-78-4P, [6-[2-(4-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-79-5P, [6-[2-(2-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine  
 850087-80-8P, [6-[2-(3-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-81-9P, [6-[2-(4-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine  
 850087-82-0P, [6-(2-o-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-83-1P, [6-(2-m-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine  
 850087-84-2P, [6-(2-p-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine 850087-85-3P, 3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzaldehyde  
 850087-86-4P, 4-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzaldehyde 850087-87-5P, (4-Trifluoromethylphenyl)[6-[2-(2-trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine 850087-88-6P, (4-Trifluoromethylphenyl)[6-[2-(4-trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine  
 850087-89-7P, N,N-Dimethyl-N'-[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]benzene-1,4-diamine  
 850087-90-0P, Phenyl[6-(2-phenylaminophenyl)pyrimidin-4-yl]amine  
 850087-91-1P, [6-[2-(2,6-Dichlorophenylamino)phenyl]pyrimidin-4-yl](3,4,5-trimethoxyphenyl)amine 850087-92-2P,  
 [6-[2-(2,6-Dichlorophenylamino)phenyl]pyrimidin-4-yl][4-(4-methylpiperazin-1-yl)phenyl]amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors)

RN 850087-62-6 CAPLUS

CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 850087-67-1 CAPLUS


CN Benzamide, N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 850087-68-2 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




— Me


RN 850087-69-3 CAPLUS  
 CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-4-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 850087-70-6 CAPLUS  
 CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-3-(4-morpholinyisulfonyl)- (9CI) (CA INDEX NAME)



RN 850087-71-7 CAPLUS  
 CN Benzamide, 4-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 850087-72-8 CAPLUS  
 CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-3-[(4-methyl-1-piperazinyl)sulfonyl]-


CN(C)c1ccc(Nc2nc3ccccc3n2)cc1Nc4ccccc4NC(=O)c5ccc(cc5)S(=O)(=O)N6CCN(C)CC6

— Me

CN Benzamide, 4-[[bis(2-hydroxyethyl)amino]sulfonyl]-N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI)  
(CA INDEX NAME)


CN(C)c1ccc(Nc2ncnc3c2c(c1)Nc4ccc(NC(=O)c5ccc(S(=O)(=O)N(CCO)cc5)cc4)cc3)
$$-\text{CH}_2-\text{OH}$$

CN    Benzamide, N-cyclopropyl-3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (9CI)    (CA INDEX NAME)




RN 850087-76-2 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-77-3 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-78-4 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-79-5 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 850087-80-8 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(3-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 850087-81-9 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(4-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 850087-82-0 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-83-1 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-84-2 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-85-3 CAPLUS

CN Benzaldehyde, 3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 850087-86-4 CAPLUS

CN Benzaldehyde, 4-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 850087-87-5 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[2-


10/671,070

(trifluoromethyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 850087-88-6 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[4-(trifluoromethyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 850087-89-7 CAPLUS


CN 1,4-Benzenediamine, N,N-dimethyl-N'-[2-[[4-(trifluoromethyl)phenyl]amino]phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850087-90-0 CAPLUS  
 CN 4-Pyrimidinamine, N-phenyl-6-[2-(phenylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-91-1 CAPLUS  
 CN 4-Pyrimidinamine, 6-[2-[(2,6-dichlorophenyl)amino]phenyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 850087-92-2 CAPLUS  
 CN 4-Pyrimidinamine, 6-[2-[(2,6-dichlorophenyl)amino]phenyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




IT 850087-64-8P 850087-65-9P 850087-66-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors)  
 RN 850087-64-8 CAPLUS  
 CN 1,3-Benzenediamine, N'-[6-(2-aminophenyl)-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 850087-65-9 CAPLUS

CN 1,3-Benzenediamine, N,N-dimethyl-N'-[6-[2-[(3-nitrophenyl)amino]phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850087-66-0 CAPLUS

CN 1,3-Benzenediamine, N'-[6-[2-[(3-aminophenyl)amino]phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:260034 CAPLUS  
 DN 142:336376  
 TI Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases  
 IN Choidas, Axel; Backes, Alexander; Cotten, Matt; Engkvist, Ola; Felber, Beatrice; Freisleben, Achim; Godl, Klaus; Greff, Zoltan; Habenberger, Peter; Hafenbradl, Doris; Hartung, Christian; Herget, Thomas; Hoppe, Edmund; Klebl, Bert; Missio, Andrea; Mueller, Gerhard; Schwab, Wilfried; Zech, Birgit; Bravo, Jose; Harris, John; Le, Joelle; Macritchie, Jackie; Savic, Vladimir; Sherborne, Brad; Simpson, Don; Simpson, Don  
 PA Axxima Pharmaceuticals AG, Germany  
 SO PCT Int. Appl., 211 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026129	A1	20050324	WO 2004-EP10353	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BG, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1678147	A1	20060712	EP 2004-786953	20040915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	EP 2003-20888	A	20030915		
	US 2003-504527P	P	20030922		
	EP 2004-10308	A	20040430		
	US 2004-569806P	P	20040512		
	WO 2004-EP10353	W	20040915		


OS MARPAT 142:336376  
 AB The invention is related to the preparation of title compds. I, and/or stereoisomeric forms and/or pharmaceutically acceptable salts [wherein R1 = H, (un)substituted alk(en/yn)yl; R2, R4 = independently H, F, Cl, Br, I, CN, NH2, NO2, (un)substituted alk(en/yn)yl; R3 = F, Cl, Br, I, (un)substituted hetero/aryl, etc.; X = R5-[LR6]m; R5 = (un)substituted hetero/aryl, heterocyclyl, cycloalkyl, etc.; R6 = H, (un)substituted alkyl, hetero/aryl, heterocyclyl, etc.; L = NRSO2, NRSO; R = H, (un)substituted alkyl, SO2-alkyl, etc.] as protein kinase inhibitors for use in the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. The invention is also related to a medium comprising at least one of compds. I in an immobilized form and its use for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized I. General preparation procedures and 5 individual synthetic examples are given. I have an inhibitory effect on the protein kinase activity of various protein kinases, such as Abl, CDK1, CDK5, etc. Selected I had an inhibitory effect on CDK9 and CDK2 with IC50 values in the range of 1 to

1000 nM. I were potent inhibitors of HIV and HCMV replication in cell cultures; for example II showed inhibition of HCMV replication in HFF cells.

IT 848636-28-2P 848636-35-1P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,4-diamine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)  
 RN 848636-28-2 CAPLUS  
 CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 848636-35-1 CAPLUS  
 CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



IT 848636-15-7P, N-[4-[6-(3-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-4-methylbenzenesulfonamide 848636-17-9P, 4-Amino-N-[4-[6-(2-benzyloxyphenyl)pyrimidin-4-yl]amino]phenyl]benzamide 848636-18-0P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-4-methylbenzenesulfonamide 848636-21-5P, 4-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848636-22-6P, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]pyrrolidin-2-one 848636-23-7P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]acetamide 848636-25-9P, N-[5-[6-(3-Aminophenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide 848636-27-1P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzamide 848636-31-7P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-4-methyl-N-propylbenzenesulfonamide 848636-32-8P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2,2-dimethylpropionamide 848636-33-9P, 2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848636-34-0P, 4-Amino-N-[4-[6-(3-aminophenyl)pyrimidin-4-ylamino]phenyl]benzamide 848636-41-9P, [[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl](4-tolylsulfonyl)amino]acetic acid methyl ester 848636-42-0P, (S)-2-[[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]carbamoyl]piperidine-1-carboxylic acid tert-butyl ester 848636-43-1P, (S)-Piperidine-2-carboxylic acid

N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848636-46-4P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]methanesulfonamide 848636-47-5P,  
 Biphenyl-4-sulfonic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848636-48-6P, 4-Amino-N-[4-[6-(5-isopropyl-2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848636-49-7P,  
 Bicyclo[2.2.1]heptane-2-carboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848636-50-0P,  
 N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-methyl-2-phenylbutyramide 848636-51-1P, 1-Cyclohexyl-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]urea 848636-52-2P,  
 4-Amino-N-[4-[6-(5-chloro-2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848636-53-3P, (E)-3-[3-[6-[4-[4-Tolylsulfonyl]amino]phenyl]amino]pyrimidin-4-yl]phenyl]-2-propenoic acid  
 848636-54-4P, Cyclohexanecarboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848636-55-5P,  
 N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3,3-dimethylbutyramide 848636-57-7P, N-Cyclohexyl-4-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzamide 848636-58-8P,  
 4-tert-Butyl-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide  
 848636-59-9P, 2-Dimethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]acetamide 848636-60-2P 848636-61-3P,  
 2-[[[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]carbonyl]methyl]piperidine-1-carboxylic acid tert-butyl ester 848636-62-4P,  
 N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-4-(4-methylpiperazin-1-yl)benzamide 848636-63-5P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]isonicotinamide 848636-64-6P,  
 4-Amino-N-[4-[6-(2,6-dimethoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide  
 848636-65-7P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-phenylbenzamide 848636-66-8P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]guanidine 848636-67-9P, N-tert-Butyl-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzamide 848636-68-0P,  
 4-Amino-N-[4-[6-(2-ethoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide  
 848636-69-1P, 4-Amino-N-[4-[6-(2,3-dimethoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848636-70-4P, 4-Amino-N-[4-[6-(2,5-dimethoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848636-71-5P,  
 4-Amino-N-[4-[6-(2-isopropoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide  
 848636-72-6P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-(piperidin-2-yl)acetamide 848636-74-8P, Adamantane-1-carboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848636-75-9P, [4-(Benzoxazol-2-yl)phenyl][6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848636-76-0P,  
 [4-(1H-Benzimidazol-2-yl)phenyl][6-(2-methoxyphenyl)pyrimidin-4-yl]amine  
 848636-77-1P, 3-Diethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]propionamide 848636-78-2P, (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]phenyl]amide 848636-79-3P,  
 1-Aminocyclohexanecarboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848636-81-7P, 1-Aminocyclopentanecarboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848636-82-8P, (R)-Piperidine-2-carboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848636-83-9P 848636-84-0P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-phenylacetamide  
 848636-88-4P, 3-[6-[4-(2,2-Dimethylpropionylamino)phenyl]amino]pyrimidin-4-yl]benzoic acid 848636-94-2P, (S)-2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-phenylethanamide  
 848636-95-3P, (S)-N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-methylamino-2-phenylethanamide 848636-96-4P  
 848636-97-5P, Benzothiazole-2-carboxylic acid N-[4-[6-(2-



methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848636-98-6P,  
 N-[4-[[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]phenyl]-2,2-  
 dimethylpropionamide 848636-99-7P, 4-[6-(2-  
 Methoxyphenyl)pyrimidin-4-ylamino]-N-(piperidin-3-yl)benzamide  
 848637-00-3P, 1-Methylpiperidine-3-carboxylic acid  
 N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-02-5P, 1-Methylpiperidine-4-carboxylic acid  
 N-[4-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]phenyl]amide  
 848637-03-6P, (S)-Azetidine-2-carboxylic acid N-[4-[6-(2-  
 methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848637-04-7P,  
 (R)-Pyrrolidine-2-carboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-  
 ylamino]phenyl]amide 848637-08-1P, 4-[[6-(2-  
 Benzyloxyphenyl)pyrimidin-4-yl]amino]benzamide 848637-09-2P,  
 N-[4-[[6-(2-Methoxyphenyl)pyrimidin-4-yl](methyl)amino]phenyl]-4-  
 methylbenzenesulfonamide 848637-10-5P, 4-Amino-N-[4-[2-amino-6-  
 (2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848637-11-6P  
 , Quinoline-2-carboxylic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-  
 ylamino]phenyl]amide 848637-13-8P, N-[5-[6-(3-  
 Methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide  
 848637-14-9P, 2-Dimethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-  
 ylamino]phenyl]-2-phenylacetamide 848637-15-0P,  
 3-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]propionamide  
 848637-16-1P, 4-Amino-N-[4-[[6-[2-(3-aminopropoxy)phenyl]pyrimidin-  
 4-yl]amino]phenyl]benzamide 848637-17-2P, N-[3-[6-[[3-  
 [(Methylsulfonyl)amino]-4-methylphenyl]amino]pyrimidin-4-  
 yl]phenyl]acetamide 848637-18-3P, N-[5-[6-(3-  
 Hydroxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide  
 848637-20-7P, N-[2-Methyl-5-[6-(3-trifluoromethylphenyl)pyrimidin-  
 4-ylamino]phenyl]methanesulfonamide 848637-21-8P,  
 N-[5-[6-[3-[(Methylsulfonyl)amino]phenyl]pyrimidin-4-yl]amino]-2-  
 methylphenyl]methanesulfonamide 848637-22-9P,  
 N-[5-[6-(3-Aminophenyl)pyrimidin-4-ylamino]-2-  
 methylphenyl]benzenesulfonamide 848637-24-1P,  
 1-(Benzodioxol-5-yl)-3-[4-[[6-(2-methoxyphenyl)pyrimidin-4-  
 yl]amino]phenyl]urea 848637-25-2P, 1-[4-[6-(2-  
 Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-(4-methylbenzyl)urea  
 848637-26-3P, 1-tert-Butyl-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-  
 ylamino]phenyl]urea 848637-27-4P, 2,2-Dimethyl-N-[4-[6-(2-  
 trifluoromethylphenyl)pyrimidin-4-ylamino]phenyl]propionamide  
 848637-28-5P, 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzamide  
 848637-29-6P, Propane-1-sulfonic acid N-[5-[6-(3-  
 aminophenyl)pyrimidin-4-ylamino]-2-methylphenyl]amide 848637-30-9P  
 , 4-[6-(3-Aminophenyl)pyrimidin-4-ylamino]benzenesulfonamide  
 848637-31-0P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-  
 2-methyl-2-methylaminopropionamide 848637-32-1P,  
 N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-3-methylphenyl]-2,2-  
 dimethylpropionamide 848637-33-2P, N-[5-[6-(3-  
 Aminophenyl)pyrimidin-4-ylamino]-2-benzyloxyphenyl]methanesulfonamide  
 848637-34-3P, N-[3-[6-(3-Aminophenyl)pyrimidin-4-  
 ylamino]phenyl]methanesulfonamide 848637-35-4P,  
 N-[3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2,2-  
 dimethylpropionamide 848637-36-5P, N-[6-(2-  
 Methoxyphenyl)pyrimidin-4-yl]-2-methylbenzene-1,4-diamine  
 848637-37-6P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,3-  
 diamine 848637-38-7P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-  
 N-[4-(morpholin-4-yl)phenyl]benzamide 848637-39-8P,  
 2,2-Dimethyl-N-[4-[6-(2-vinylphenyl)pyrimidin-4-  
 ylamino]phenyl]propionamide 848637-40-1P, N-[4-[6-(2-  
 Fluorophenyl)pyrimidin-4-ylamino]phenyl]-2,2-dimethylpropionamide  
 848637-41-2P, (S)-Piperidine-2-carboxylic acid

N-[3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-42-3P, 2-Oxo-2H-chromene-3-carboxylic acid  
 N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-43-4P, Benzodioxole-5-carboxylic acid N-[4-[6-(2-  
 methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848637-44-5P,  
 N-[4-[6-(2-Ethylphenyl)pyrimidin-4-ylamino]phenyl]-2,2-  
 dimethylpropionamide 848637-46-7P, 1H-Indole-3-carboxylic acid  
 N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848637-47-8  
 P 848637-48-9P, N-(4-Hydroxyphenyl)-4-[[6-(2-  
 methoxyphenyl)pyrimidin-4-yl]amino]benzamide 848637-49-0P,  
 N-(4-Isopropylphenyl)-4-[[6-(2-methoxyphenyl)pyrimidin-4-  
 yl]amino]benzamide 848637-50-3P, 1H-Benzimidazole-5-carboxylic  
 acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-51-4P, 1-Hydroxynaphthalene-2-carboxylic acid  
 N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-52-5P, (2S,3S)-2-Amino-3-methylpentanoic acid  
 N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-53-6P, 1H-Indazole-3-carboxylic acid N-[4-[6-(2-  
 methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848637-54-7P,  
 Quinoline-8-sulfonic acid N-[5-[6-(3-aminophenyl)pyrimidin-4-ylamino]-2-  
 methylphenyl]amide 848637-55-8P, (S)-2-Amino-N-[4-[6-(2-  
 methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-methylbutanamide  
 848637-56-9P, 1-Methyl-1H-imidazole-4-sulfonic acid  
 N-[5-[6-(3-aminophenyl)pyrimidin-4-ylamino]-2-methylphenyl]amide  
 848637-57-0P, 3-Hydroxynaphthalene-2-carboxylic acid  
 N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-58-1P, 2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-  
 yl]amino]phenyl]-2-(naphthalen-2-yl)acetamide 848637-59-2P,  
 [4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]morpholin-4-ylmethanone  
 848637-60-5P 848637-61-6P, 4-Amino-N-[4-[6-(2-  
 methoxyphenyl)-5-methylpyrimidin-4-ylamino]phenyl]benzamide  
 848637-62-7P, 3-[6-(2-Methoxyphenyl)pyrimidin-4-  
 yl]amino]benzenesulfonamide 848637-63-8P, 4-Amino-N-[4-[6-(2-  
 hydroxyphenyl)pyrimidin-4-ylamino]phenyl]benzamide 848637-64-9P,  
 N-[6-(2-Methoxyphenyl)-5-methylpyrimidin-4-yl]benzene-1,4-diamine  
 848637-65-0P, Propane-2-sulfonic acid N-[4-[6-(2-  
 methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848637-66-1P,  
 Propane-1-sulfonic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-  
 yl]amino]phenyl]amide 848637-67-2P, N-[4-[6-(2-  
 Methoxyphenyl)pyrimidin-4-ylamino]phenyl]benzenesulfonamide  
 848637-68-3P, N-[5-[[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]-2-  
 methylphenyl]methanesulfonamide 848637-69-4P,  
 N-[5-[[6-(3-Dimethylaminophenyl)pyrimidin-4-yl]amino]-2-  
 methylphenyl]methanesulfonamide 848637-70-7P,  
 N-[5-[6-(2-Isopropoxyphenyl)pyrimidin-4-ylamino]-2-  
 methylphenyl]methanesulfonamide 848637-71-8P  
 848637-72-9P, Propane-1-sulfonic acid N-[4-[6-(2-methoxyphenyl)-5-  
 methylpyrimidin-4-ylamino]phenyl]amide 848637-74-1P,  
 N-[5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-  
 methylphenyl]methanesulfonamide 848637-75-2P,  
 N-[5-[6-(3-Cyanophenyl)pyrimidin-4-ylamino]-2-  
 methylphenyl]methanesulfonamide 848637-76-3P,  
 (S)-Piperidine-2-carboxylic acid N-[3-[[6-(2-benzyloxyphenyl)pyrimidin-4-  
 yl]amino]phenyl]amide 848637-77-4P, N-[5-[6-(3-  
 Formylphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide  
 848637-78-5P, N-[5-[6-(2-Hydroxymethylphenyl)pyrimidin-4-ylamino]-  
 2-methylphenyl]methanesulfonamide 848637-80-9P,  
 (S)-Piperidine-2-carboxylic acid N-[3-[6-(3-formylphenyl)pyrimidin-4-  
 yl]amino]phenyl]amide 848637-81-0P, (S)-Piperidine-2-carboxylic  
 acid N-[3-[[6-(3-dimethylaminophenyl)pyrimidin-4-yl]amino]phenyl]amide

848637-82-1P, (S)-Piperidine-2-carboxylic acid  
 N-[3-[6-(2-hydroxymethylphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-90-1P, (S)-Piperidine-2-carboxylic acid  
 N-[4-[6-[3-[(methylsulfonyl)amino]phenyl]pyrimidin-4-yl]amino]phenyl]amide 848637-91-2P, (S)-Piperidine-2-carboxylic acid N-[4-[6-(3-acetylphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848637-93-4P, N-[5-[6-(2-Hydroxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide 848637-94-5P,  
 (E)-3-[3-[6-[3-[(Methylsulfonyl)amino]-4-methylphenyl]amino]pyrimidin-4-yl]phenyl]-2-propenoic acid methyl ester 848637-95-6P,  
 N-[5-[6-(3-Hydroxymethylphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide 848637-96-7P,  
 N-Butyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide  
 848637-97-8P, (3-Methylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848637-98-9P,  
 (S)-Piperidine-2-carboxylic acid N-[4-[6-(2,3-dimethoxyphenyl)pyrimidin-4-ylamino]phenyl]amide 848638-00-6P, (S)-Piperidine-2-carboxylic acid N-[4-[6-(2-isopropoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848638-02-8P, (S)-Piperidine-2-carboxylic acid  
 N-[4-[6-(2-trifluoromethoxyphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848638-04-0P, (S)-Piperidine-2-carboxylic acid  
 N-[4-[6-(2-chlorophenyl)pyrimidin-4-ylamino]phenyl]amide  
 848638-05-1P, (S)-Piperidine-2-carboxylic acid  
 N-[4-[6-(3-hydroxymethylphenyl)pyrimidin-4-ylamino]phenyl]amide  
 848638-06-2P 848638-07-3P 848638-08-4P  
 848638-09-5P, N-[5-[6-(2-Methoxymethylphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide 848638-10-8P  
 848638-13-1P 848638-15-3P, (S)-Piperidine-2-carboxylic acid N-[4-[6-[3-(3-methoxymethylphenyl)pyrimidin-4-yl]amino]phenyl]amide  
 848638-16-4P, N-[6-(2-Methoxyphenyl)-2-methylpyrimidin-4-yl]benzene-1,4-diamine 848638-19-7P 848638-21-1P  
 848638-22-2P 848638-23-3P, (S)-Piperidine-2-carboxylic acid N-[4-[6-[3-[(dimethylamino)methyl]phenyl]pyrimidin-4-yl]amino]phenyl]amide 848638-26-6P, 3-[6-(3-Aminophenyl)pyrimidin-4-ylamino]benzenesulfonamide 848638-28-8P,  
 N-((R,R)-2-Aminocyclohexyl)-4-[6-(2-hydroxymethylphenyl)pyrimidin-4-yl]amino]benzamide 848638-29-9P, N-(2-Diethylaminoethyl)-4-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzamide 848638-30-2P,  
 (R,R)-N-(2-Aminocyclohexyl)-4-[6-(2-hydroxyphenyl)pyrimidin-4-yl]amino]benzamide 848638-38-0P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-(pyrrolidin-3-yl)benzamide 848638-41-5P  
 848638-42-6P, (R,R)-4-[6-(2-Acetylphenyl)pyrimidin-4-ylamino]-N-(2-aminocyclohexyl)benzamide 848638-43-7P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-(pyridin-3-yl)benzamide  
 848638-44-8P, N-(1-Acetylpiperidin-3-yl)-4-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzamide 848638-45-9P,  
 (R,R)-N-(2-Aminocyclohexyl)-4-[6-(2-dimethylaminophenyl)pyrimidin-4-yl]amino]benzamide 848638-46-0P 848638-47-1P,  
 2-Chloro-5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide  
 848638-48-2P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][3-[(piperidin-1-yl)sulfonyl]phenyl]amine 848638-49-3P, N-Allyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide 848638-50-6P  
 , N-Benzyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide  
 848638-51-7P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][3-[(pyrrolidin-1-yl)sulfonyl]phenyl]amine 848638-52-8P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][3-[(morpholin-4-yl)sulfonyl]phenyl]amine  
 848638-53-9P, 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-methylbenzenesulfonamide 848638-54-0P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-N-(3-sulfamoylphenyl)acetamide  
 848638-55-1P, N,N-Diallyl-3-[6-(2-methoxyphenyl)pyrimidin-4-

ylamino]benzenesulfonamide 848638-56-2P, 3-[[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide 848638-57-3P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-(4-nitrophenylsulfonyl)phenyl]amine 848638-58-4P, [6-(2-Methoxyphenyl)pyrimidin-4-yl](4-trifluoromethylsulfonylphenyl)amine 848638-59-5P, (4-Methylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-60-8P, N-(3,4-Dimethylisoxazol-5-yl)-4-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide 848638-61-9P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-propylbenzenesulfonamide 848638-62-0P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide 848638-63-1P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N,N-dimethylbenzenesulfonamide 848638-64-2P, N-(2-Methoxyethyl)-4-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide 848638-65-3P, [6-(2-Benzyloxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine 848638-66-4P, 2-[6-[(3-Methylsulfonylphenyl)amino]pyrimidin-4-yl]phenol 848638-67-5P, [6-(3-Aminophenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine 848638-68-6P, 5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylbenzenesulfonic acid 848638-69-7P, 2-[[3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]sulfonyl]ethanol 848638-70-0P, (2-Fluoro-5-methylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-71-1P, [6-(2-Aminophenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine 848638-72-2P, [6-(2-Methoxyphenyl)pyrimidin-4-yl](3-trifluoromethylsulfonylphenyl)amine 848638-73-3P, (3-Methylsulfonylphenyl)[6-(2-Phenoxyphenyl)pyrimidin-4-yl]amine 848638-74-4P, [6-(2-Butoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine 848638-75-5P, (3-Ethenylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-77-7P, 2-Chloro-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester 848638-78-8P, [6-(2-Methoxyphenyl)pyrimidin-4-yl](4-phenoxybenzyl)amine 848638-79-9P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-3-methylbenzoic acid methyl ester 848638-80-2P, [6-(3-Aminophenyl)pyrimidin-4-yl](1-methylsulfonyl-2,3-dihydro-1H-indol-6-yl)amine 848638-82-4P, 848638-83-5P, (1H-Indazol-6-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-84-6P, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]butan-1-one 848638-86-8P, [4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]phenylmethanone 848638-87-9P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-N'-phenylbenzene-1,3-diamine 848638-88-0P, [3-([1,3]Dioxan-2-yl)phenyl][6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-89-1P, (3-Methoxyphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-90-4P, (4-Methoxyphenyl)[6-(2-Methoxyphenyl)pyrimidin-4-yl]amine 848638-91-5P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-N'-phenylbenzene-1,4-diamine 848638-92-6P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-(morpholin-4-yl)phenyl]amine 848638-93-7P, (2-Fluorophenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-95-9P, (4-Butylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848638-96-0P, [6-(2-Methoxyphenyl)pyrimidin-4-yl](4-phenoxyphenyl)amine 848638-97-1P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]methylbenzenesulfonamide 848638-98-2P, 1-Dimethylamino-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenoxy]-3-propan-2-ol 848639-00-9P, N-[6-(3-Aminophenyl)-5-methylpyrimidin-4-yl]benzene-1,4-amine 848639-04-3P, 4-[[6-[2-[2-(Morpholin-4-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester


848639-05-4P, 2-Methoxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester 848639-06-5P, [4-[[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]phenyl]acetic acid 848639-07-6P, [6-(2-Methoxyphenyl)pyrimidin-4-yl] (3-nitrophenyl)amine 848639-08-7P, [3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]methanol 848639-09-8P, N-[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]phenylamine 848639-10-1P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]phenylamine 848639-11-2P, (4-Fluorophenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848639-12-3P, [6-(2-Methoxyphenyl)pyrimidin-4-yl] (3-phenoxyphenyl)amine 848639-13-4P, [6-(2-Methoxyphenyl)pyrimidin-4-yl] (3-methylsulfonylphenyl)amine 848639-15-6P, 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenol 848639-16-7P, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]ethanone 848639-17-8P, 2-Chloro-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid 848639-19-0P, [6-(2-Benzyloxyphenyl)pyrimidin-4-yl] (1-methylsulfonyl-2,3-dihydro-1H-indol-6-yl)amine 848639-21-4P, 4-[6-(2-Aminophenyl)pyrimidin-4-ylamino]benzoic acid methyl ester 848639-22-5P, [6-(2-Methoxyphenyl)pyrimidin-4-yl] (4-methylsulfonylphenyl)amine 848639-24-7P, 1-[4-[[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]phenoxy]-3-dimethylaminopropan-2-ol 848639-25-8P, (1-Methylsulfonyl-2,3-dihydro-1H-indol-6-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848639-28-1P, 1-[3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]ethanone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848636-15-7 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-methyl- (CA INDEX NAME)




RN 848636-17-9 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-18-0 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-methyl- (CA INDEX NAME)




RN 848636-21-5 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-22-6 CAPLUS

CN 2-Pyrrolidinone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-23-7 CAPLUS

CN Acetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-25-9 CAPLUS


CN Methanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848636-27-1 CAPLUS  
 CN Benamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848636-31-7 CAPLUS  
 CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-methyl-N-propyl- (CA INDEX NAME)



RN 848636-32-8 CAPLUS  
 CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 848636-33-9 CAPLUS  
 CN Benamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-34-0 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]phenyl]-  
(CA INDEX NAME)



RN 848636-41-9 CAPLUS

CN Glycine, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-N-[(4-methylphenyl)sulfonyl]-, methyl ester (CA INDEX NAME)




RN 848636-42-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)-  
(CA INDEX NAME)

Absolute stereochemistry.






RN 848636-43-1 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-46-4 CAPLUS

CN Methanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-47-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-48-6 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-methoxy-5-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-49-7 CAPLUS

CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-50-0 CAPLUS

CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-α-(1-methylethyl)- (CA INDEX NAME)




RN 848636-51-1 CAPLUS

CN Urea, N-cyclohexyl-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-52-2 CAPLUS


CN Benzamide, 4-amino-N-[4-[[6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-53-3 CAPLUS


CN 2-Propenoic acid, 3-[3-[6-[[4-[[4-(4-methylphenyl)sulfonyl]amino]phenyl]amino]-4-pyrimidinyl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 848636-54-4 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-55-5 CAPLUS

CN Butanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3,3-dimethyl- (CA INDEX NAME)




RN 848636-57-7 CAPLUS

CN Benzamide, N-cyclohexyl-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848636-58-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-59-9 CAPLUS


CN Acetamide, 2-(dimethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-60-2 CAPLUS


CN Carbamic acid, N-[1-[[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl

ester (CA INDEX NAME)




RN 848636-61-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[2-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 848636-62-4 CAPLUS

CN Benzamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 848636-63-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-64-6 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2,6-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-65-7 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 848636-66-8 CAPLUS

CN Guanidine, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-67-9 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848636-68-0 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-69-1 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2,3-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-70-4 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-71-5 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-72-6 CAPLUS

CN 2-Piperidineacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-74-8 CAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-75-9 CAPLUS

CN 4-Pyrimidinamine, N-[4-(2-benzoxazolyl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)



RN 848636-76-0 CAPLUS


CN 4-Pyrimidinamine, N-[4-(1H-benzimidazol-2-yl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)



RN 848636-77-1 CAPLUS

CN Propanamide, 3-(diethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 848636-78-2 CAPLUS


CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-79-3 CAPLUS

CN Cyclohexanecarboxamide, 1-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-81-7 CAPLUS


CN Cyclopentanecarboxamide, 1-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-82-8 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-83-9 CAPLUS

CN 1H-Imidazole-4-carboxamide, 4,5-dihydro-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)




RN 848636-84-0 CAPLUS

CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848636-88-4 CAPLUS


CN Benzoic acid, 3-[6-[[4-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 848636-94-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848636-95-3 CAPLUS

CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- $\alpha$ -(methylamino)-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848636-96-4 CAPLUS


CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 848636-97-5 CAPLUS

CN 2-Benzothiazolecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-98-6 CAPLUS

CN Propanamide, 2,2-dimethyl-N-[4-[[6-(2-phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848636-99-7 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-3-piperidinyl- (CA INDEX NAME)




RN 848637-00-3 CAPLUS

CN 3-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)



RN 848637-02-5 CAPLUS


CN 4-Piperidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)



RN 848637-03-6 CAPLUS

CN 2-Azetidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848637-04-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848637-08-1 CAPLUS


CN Benzamide, 4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (CA

INDEX NAME)




RN 848637-09-2 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]methylamino]phenyl]-4-methyl- (CA INDEX NAME)




RN 848637-10-5 CAPLUS

CN Benzenesulfonamide, N-[4-[[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-methyl- (CA INDEX NAME)




RN 848637-11-6 CAPLUS

CN 2-Quinolinecarboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-13-8 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-14-9 CAPLUS

CN Benzeneacetamide, α-(dimethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-15-0 CAPLUS

CN Propanamide, 3-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-16-1 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-(3-aminopropoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-17-2 CAPLUS

CN Acetamide, N-[3-[6-[[4-methyl-3-[(methylsulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 848637-18-3 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-20-7 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-21-8 CAPLUS


CN Methanesulfonamide, N-[3-[6-[[4-methyl-3-[(methanesulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)






RN 848637-22-9 CAPLUS

CN Benzenesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-24-1 CAPLUS

CN Urea, N-1,3-benzodioxol-5-yl-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-25-2 CAPLUS

CN Urea, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-N'-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 848637-26-3 CAPLUS


CN Urea, N-(1,1-dimethylethyl)-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-27-4 CAPLUS  
 CN Propanamide, 2,2-dimethyl-N-[4-[[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-28-5 CAPLUS  
 CN Benzamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-29-6 CAPLUS  
 CN 1-Propanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848637-30-9 CAPLUS  
 CN Benzenesulfonamide, 4-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-31-0 CAPLUS  
 CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2-methyl-2-(methylamino)- (CA INDEX NAME)




RN 848637-32-1 CAPLUS

CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-3-methylphenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 848637-33-2 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 848637-34-3 CAPLUS

CN Methanesulfonamide, N-[3-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-35-4 CAPLUS

CN Propanamide, N-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 848637-36-5 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 848637-37-6 CAPLUS

CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-38-7 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 848637-39-8 CAPLUS

CN Propanamide, N-[4-[[6-(2-ethenylphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)



RN 848637-40-1 CAPLUS


CN Propanamide, N-[4-[[6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)



RN 848637-41-2 CAPLUS


CN 2-Piperidinecarboxamide, N-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-42-3 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2-oxo- (CA INDEX NAME)




RN 848637-43-4 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-44-5 CAPLUS

CN Propanamide, N-[4-[[6-(2-ethylphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (CA INDEX NAME)



RN 848637-46-7 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-47-8 CAPLUS


CN Benzamide, N-[(1R,2R)-2-hydroxycyclohexyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 848637-48-9 CAPLUS

CN Benzamide, N-(4-hydroxyphenyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-49-0 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 848637-50-3 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-51-4 CAPLUS


CN 2-Naphthalenecarboxamide, 1-hydroxy-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-52-5 CAPLUS


CN Pentanamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-53-6 CAPLUS

CN 1H-Indazole-3-carboxamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-54-7 CAPLUS

CN 8-Quinolinesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-55-8 CAPLUS

CN Butanamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.






RN 848637-56-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-1-methyl- (CA INDEX NAME)




RN 848637-57-0 CAPLUS

CN 2-Naphthalenecarboxamide, 3-hydroxy-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-58-1 CAPLUS

CN 2-Naphthaleneacetamide, alpha-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-59-2 CAPLUS

CN Methanone, [4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 848637-60-5 CAPLUS

CN Benzamide, N-(2-aminocyclohexyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-61-6 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-62-7 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848637-63-8 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-hydroxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-64-9 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-65-0 CAPLUS

CN 2-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-66-1 CAPLUS

CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-67-2 CAPLUS

CN Benzenesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-68-3 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-69-4 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[3-(dimethylamino)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-70-7 CAPLUS


CN Methanesulfonamide, N-[2-methyl-5-[[6-[2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848637-71-8 CAPLUS  
 CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]-N-(propylsulfonyl)- (CA INDEX NAME)




RN 848637-72-9 CAPLUS  
 CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 848637-74-1 CAPLUS  
 CN Methanesulfonamide, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-75-2 CAPLUS  
 CN Methanesulfonamide, N-[5-[[6-(3-cyanophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848637-76-3 CAPLUS


CN 2-Piperidinecarboxamide, N-[3-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-77-4 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-formylphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-78-5 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-80-9 CAPLUS  
 CN 2-Piperidinecarboxamide, N-[3-[[6-(3-formylphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-81-0 CAPLUS  
 CN 2-Piperidinecarboxamide, N-[3-[[6-[3-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-82-1 CAPLUS  
 CN 2-Piperidinecarboxamide, N-[3-[[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848637-90-1 CAPLUS  
 CN 2-Piperidinecarboxamide, N-[4-[[6-[3-[(methylsulfonyl)amino]phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848637-91-2 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-(3-acetylphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848637-93-4 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(2-hydroxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-94-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[6-[[4-methyl-3-[(methanesulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.






RN 848637-95-6 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848637-96-7 CAPLUS

CN Benzenesulfonamide, N-butyl-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848637-97-8 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methanesulfonyl)phenyl]- (CA INDEX NAME)




RN 848637-98-9 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-(2,3-dimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

10/671,070


Absolute stereochemistry.



RN 848638-00-6 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-[2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-02-8 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-04-0 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-(2-chlorophenyl)-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-05-1 CAPLUS

CN 2-Piperidinecarboxamide, N-[4-[[6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-06-2 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-07-3 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[3-(methylsulfonyl)amino]phenyl]-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-08-4 CAPLUS


CN Benzamide, 4-[[6-[2-(acetylamino)phenyl]-4-pyrimidinyl]amino]-N-[(1R,2R)-2-aminocyclohexyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 848638-09-5 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[2-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848638-10-8 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/671,070



RN 848638-13-1 CAPLUS

CN Benzoic acid, 3-[6-[[4-[[[(1R,2R)-2-aminocyclohexyl]amino]carbonyl]phenyl]amino]-4-pyrimidinyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-15-3 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-[3-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-16-4 CAPLUS


CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 848638-19-7 CAPLUS

CN Benzamide, 4-[[6-[3-(acetylamino)phenyl]-4-pyrimidinyl]amino]-N-[(1R,2R)-2-aminocyclohexyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-21-1 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(3-cyanophenyl)-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-22-2 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 848638-23-3 CAPLUS


CN 2-Piperidinecarboxamide, N-[4-[[6-[3-[(dimethylamino)methyl]phenyl]-4-pyrimidinyl]amino]phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-26-6 CAPLUS


CN Benzenesulfonamide, 3-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848638-28-8 CAPLUS


CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-29-9 CAPLUS


CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848638-30-2 CAPLUS


CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-(2-hydroxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 848638-38-0 CAPLUS


CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-3-pyrrolidinyl- (CA INDEX NAME)






10/671,070

RN 848638-41-5 CAPLUS  
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl][3-(1-piperidinylsulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 848638-42-6 CAPLUS  
CN Benzamide, 4-[[6-(2-acetylphenyl)-4-pyrimidinyl]amino]-N-[(1R,2R)-2-aminocyclohexyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-43-7 CAPLUS  
CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-3-pyridinyl- (CA INDEX NAME)




RN 848638-44-8 CAPLUS  
CN Benzamide, N-(1-acetyl-3-piperidiny)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848638-45-9 CAPLUS

CN Benzamide, N-[(1R,2R)-2-aminocyclohexyl]-4-[[6-[2-(dimethylamino)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 848638-46-0 CAPLUS


CN L-Proline, 1-(2,2-dimethyl-1-oxopropyl)-4-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 848638-47-1 CAPLUS

CN Benzenesulfonamide, 2-chloro-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848638-48-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(1-piperidinylsulfonyl)phenyl]-  
(CA INDEX NAME)




RN 848638-49-3 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-2-  
propen-1-yl- (CA INDEX NAME)




RN 848638-50-6 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-  
(phenylmethyl)- (CA INDEX NAME)




RN 848638-51-7 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(1-pyrrolidinylsulfonyl)phenyl]-  
(CA INDEX NAME)




RN 848638-52-8 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(4-morpholinylsulfonyl)phenyl]-  
(CA INDEX NAME)


RN 848638-53-9 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-methyl-  
(CA INDEX NAME)


RN 848638-54-0 CAPLUS

CN Acetamide, N-[3-(aminosulfonyl)phenyl]-N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-  
(CA INDEX NAME)


RN 848638-55-1 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-di-2-propen-1-yl-  
(CA INDEX NAME)


RN 848638-56-2 CAPLUS  
 CN Benzenesulfonamide, 3-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]-  
 (CA INDEX NAME)




RN 848638-57-3 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-[(4-nitrophenyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 848638-58-4 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 848638-59-5 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 848638-60-8 CAPLUS  
 CN Benzenesulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4-[[6-(2-methoxyphenyl)-


10/671,070

4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848638-61-9 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 848638-62-0 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848638-63-1 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 848638-64-2 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848638-65-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-(methylsulfonyl)phenyl]-6-[2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 848638-66-4 CAPLUS

CN Phenol, 2-[6-[[3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 848638-67-5 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848638-68-6 CAPLUS

CN Benzenesulfonic acid, 5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848638-69-7 CAPLUS

CN Ethanol, 2-[[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]sulfonyl]- (CA INDEX NAME)



RN 848638-70-0 CAPLUS


CN 4-Pyrimidinamine, N-[2-fluoro-5-(methanesulfonyl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-71-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2-aminophenyl)-N-[3-(methanesulfonyl)phenyl]- (CA INDEX NAME)







RN 848638-72-2 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-[(trifluoromethyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 848638-73-3 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-(methylsulfonyl)phenyl]-6-(2-phenoxyphenyl)- (CA INDEX NAME)




RN 848638-74-4 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-butoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848638-75-5 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-(ethenylsulfonyl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-77-7 CAPLUS  
 CN Benzoic acid, 2-chloro-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848638-78-8 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[(4-phenoxyphenyl)methyl]- (CA INDEX NAME)



RN 848638-79-9 CAPLUS  
 CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-3-methyl-, methyl ester (CA INDEX NAME)




RN 848638-80-2 CAPLUS  
 CN 1H-Indol-6-amine, N-[6-(3-aminophenyl)-4-pyrimidinyl]-2,3-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)




RN 848638-82-4 CAPLUS  
 CN Benzeneacetic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)

INDEX NAME)




RN 848638-83-5 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848638-84-6 CAPLUS

CN 1-Butanone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848638-86-8 CAPLUS

CN Methanone, [4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]phenyl- (CA INDEX NAME)




RN 848638-87-9 CAPLUS


CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-N3-phenyl- (CA INDEX NAME)




RN 848638-88-0 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-(1,3-dioxan-2-yl)phenyl]-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-89-1 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 848638-90-4 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 848638-91-5 CAPLUS  
 CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-N4-phenyl- (CA INDEX NAME)




RN 848638-92-6 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 848638-93-7 CAPLUS  
 CN 4-Pyrimidinamine, N-(2-fluorophenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-95-9 CAPLUS  
 CN 4-Pyrimidinamine, N-(4-butylphenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848638-96-0 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 848638-97-1 CAPLUS  
 CN Benzenesulfonamide, 4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]methyl]-  
 (CA INDEX NAME)




RN 848638-98-2 CAPLUS  
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)



RN 848639-00-9 CAPLUS  
 CN 1,4-Benzenediamine, N1-[6-(3-aminophenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-04-3 CAPLUS  
 CN Benzoic acid, 4-[[[6-[2-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-05-4 CAPLUS

CN Benzoic acid, 2-methoxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-06-5 CAPLUS

CN Benzeneacetic acid, 4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-07-6 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-nitrophenyl)- (CA INDEX NAME)




RN 848639-08-7 CAPLUS


CN Benzenemethanol, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-09-8 CAPLUS  
CN 4-Pyrimidinamine, N-phenyl-6-[2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 848639-10-1 CAPLUS  
CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-phenyl- (CA INDEX NAME)




RN 848639-11-2 CAPLUS  
CN 4-Pyrimidinamine, N-(4-fluorophenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




RN 848639-12-3 CAPLUS  
CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-phenoxyphenyl)- (CA INDEX NAME)






RN 848639-13-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methylthio)phenyl]- (CA INDEX NAME)




RN 848639-15-6 CAPLUS

CN Phenol, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-16-7 CAPLUS

CN Ethanone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 848639-17-8 CAPLUS

CN Benzoic acid, 2-chloro-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-19-0 CAPLUS

CN 1H-Indol-6-amine, 2,3-dihydro-1-(methanolsulfonyl)-N-[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-21-4 CAPLUS

CN Benzoic acid, 4-[[6-(2-aminophenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-22-5 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 848639-24-7 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 848639-25-8 CAPLUS

CN 1H-Indol-6-amine, 2,3-dihydro-N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-1-(methylsulfonyl)- (CA INDEX NAME)



RN 848639-28-1 CAPLUS

CN Ethanone, 1-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 848639-29-2P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-(piperidin-1-yl)phenyl]amine 848639-30-5P, 3-Hydroxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester 848639-31-6P, 2-Hydroxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester 848639-32-7P, 4-Aminobutane-1-sulfonic acid N-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]amide 848639-33-8P, [3-[6-[[3-(4-Aminobutan-1-ylsulfonylamino)-4-methylphenyl]amino]pyrimidin-4-yl]phenyl]carbamic acid 9H-fluoren-9-ylmethyl ester 848639-34-9P, 3-Methoxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester 848639-35-0P, 4-[[6-[2-[2-(Piperidin-1-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester 848639-36-1P, 4-[[6-[2-(2-Dimethylaminoethoxy)phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester 848639-37-2P, 4-[[6-[2-(2-Diisopropylaminoethoxy)phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester 848639-38-3P, 4-[[6-[2-(2-Diethylaminoethoxy)phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester 848639-39-4P, (S,S)-4-[4-[6-(2-Methoxyphenyl)pyrimidin-4-

ylamino]benzoylamino]pyrrolidine-2-carboxylic acid methyl ester  
 848639-40-7P, (S,S)-4-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzoylamino]pyrrolidine-2-carboxylic acid 848639-41-8P,  
 (S,S)-6-[[4-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzoylamino]pyrrolidin-2-yl]carbonyl]amino]hexanoic acid  
 848639-42-9P, N-Cyclopentyl-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzamide 848639-43-0P, N-(4,6-Dimethylpyrimidin-2-yl)-4-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide  
 848639-44-1P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-(thiazol-2-yl)benzenesulfonamide 848639-47-4P,  
 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-phenylbenzenesulfonamide 848639-50-9P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-methylbenzenesulfonamide 848639-51-0P, (1,1-Dioxo-1H-benzo[b]thiophen-6-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine  
 848639-52-1P, N-Acetyl-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide 848639-53-2P, N-(2,6-Dimethylpyrimidin-4-yl)-4-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide 848639-54-3P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-[(piperidin-1-yl)sulfonyl]phenyl]amine  
 848639-55-4P, 3-[3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenoxy]piperidine-1-carboxylic acid tert-butyl ester 848639-56-5P,  
 [6-(2-Fluoro-6-methoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine 848639-58-7P, [6-(5-Fluoro-2-methoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine  
 848639-60-1P, 2-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]ethanol 848639-62-3P, [6-(2-Methoxyphenyl)pyrimidin-4-yl](1-methyl-1H-indazol-6-yl)amine  
 848639-65-6P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][3-[(piperidin-3-yl)oxy]phenyl]amine 848639-66-7P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][1-[6-(2-methoxyphenyl)pyrimidin-4-yl]-1H-indazol-5-yl]amine  
 848639-67-8P, (1H-Indol-5-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848639-68-9P, (3-Methylsulfinylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848639-69-0P,  
 (1H-Indazol-5-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848639-71-4P, (4-Methylsulfonylbenzyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine 848639-74-7P,  
 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N,N-dimethylbenzenesulfonamide 848639-75-8P, N-Ethyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide 848639-76-9P, 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-propylbenzenesulfonamide  
 848639-77-0P, [6-(2-Methoxyphenyl)pyrimidin-4-yl](2-methyl-1H-indol-5-yl)amine 848639-78-1P, N-(2-Methoxyethyl)-3-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide 848639-79-2P,  
 N-tert-Butyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide 848639-83-8P, 5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylbenzenesulfonamide  
 848639-84-9P, N-(2-Methoxyethyl)-5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylbenzenesulfonamide 848639-85-0P,  
 N-(2-Hydroxyethyl)-5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylbenzenesulfonamide 848639-86-1P, N,N-Diethyl-N'-[6-(2-methoxyphenyl)pyrimidin-4-yl]benzene-1,4-diamine 848639-87-2P,  
 1-(4-Chloro-3-trifluoromethylphenyl)-3-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]urea 848639-88-3P, 1-Cyclohexyl-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea  
 848639-89-4P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-(pyrrolidin-1-yl)phenyl]amine 848639-90-7P, 4-Chloro-N-[6-(2-methoxyphenyl)pyrimidin-4-yl]benzene-1,3-diamine 848639-91-8P,  
 1-Isopropyl-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea 848639-92-9P, 1-[5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]-3-[2-(morpholin-4-


yl)ethyl]urea 848639-93-0P, 1-(2-Dimethylaminoethyl)-3-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]urea  
848639-94-1P, (4-Chloro-3-nitrophenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848639-29-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 848639-30-5 CAPLUS

CN Benzoic acid, 3-hydroxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-31-6 CAPLUS

CN Benzoic acid, 2-hydroxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-32-7 CAPLUS

CN 1-Butanesulfonamide, 4-amino-N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848639-33-8 CAPLUS

CN Carbamic acid, N-[3-[6-[[3-[(4-aminobutyl)sulfonyl]amino]-4-methylphenyl]amino]-4-pyrimidinyl]phenyl-, 9H-fluoren-9-ylmethyl ester (CA INDEX NAME)




RN 848639-34-9 CAPLUS

CN Benzoic acid, 3-methoxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-35-0 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-(1-piperidinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-36-1 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-(dimethylamino)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 848639-37-2 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 848639-38-3 CAPLUS


CN Benzoic acid, 4-[[6-[2-[2-(diethylamino)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 848639-39-4 CAPLUS

CN L-Proline, 4-[[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848639-40-7 CAPLUS

CN L-Proline, 4-[[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848639-41-8 CAPLUS

CN Hexanoic acid, 6-[[[(2S,4S)-4-[[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]benzoyl]amino]-2-pyrrolidinyl]carbonyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.






RN 848639-42-9 CAPLUS

CN Benzenesulfonamide, N-cyclopentyl-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-  
(CA INDEX NAME)




RN 848639-43-0 CAPLUS

CN Benzenesulfonamide, N-(4,6-dimethyl-2-pyrimidinyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-  
(CA INDEX NAME)




RN 848639-44-1 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-2-thiazolyl-  
(CA INDEX NAME)




RN 848639-47-4 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-phenyl-  
(CA INDEX NAME)




RN 848639-50-9 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-methyl-  
(CA INDEX NAME)




RN 848639-51-0 CAPLUS

CN 4-Pyrimidinamine, N-(1,1-dioxidobenzo[b]thien-6-yl)-6-(2-methoxyphenyl)-  
(CA INDEX NAME)




RN 848639-52-1 CAPLUS

CN Acetamide, N-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]sulfonyl]-  
(CA INDEX NAME)




RN 848639-53-2 CAPLUS

CN Benzenesulfonamide, N-(2,6-dimethyl-4-pyrimidinyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-  
(CA INDEX NAME)




RN 848639-54-3 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-piperidinylsulfonyl)phenyl]-  
(CA INDEX NAME)




RN 848639-55-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 848639-56-5 CAPLUS

CN 4-Pyrimidinamine, 6-(2-fluoro-6-methoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848639-58-7 CAPLUS

CN 4-Pyrimidinamine, 6-(5-fluoro-2-methoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 848639-60-1 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-62-3 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-1-methyl- (CA INDEX NAME)




RN 848639-65-6 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(3-piperidinyloxy)phenyl]- (CA INDEX NAME)




RN 848639-66-7 CAPLUS

CN 1H-Indazol-5-amine, N,1-bis[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-67-8 CAPLUS

CN 1H-Indol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-68-9 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 848639-69-0 CAPLUS

CN 1H-Indazol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848639-71-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 848639-74-7 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 848639-75-8 CAPLUS

CN Benzenesulfonamide, N-ethyl-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-76-9 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 848639-77-0 CAPLUS

CN 1H-Indol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 848639-78-1 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-79-2 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848639-83-8 CAPLUS

CN Benzenesulfonamide, 5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848639-84-9 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848639-85-0 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 848639-86-1 CAPLUS

CN 1,4-Benzenediamine, N1,N1-diethyl-N4-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 848639-87-2 CAPLUS


CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 848639-88-3 CAPLUS

CN Urea, N-cyclohexyl-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)







RN 848639-89-4 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-pyrrolidinyl)phenyl]- (CA INDEX NAME)




RN 848639-90-7 CAPLUS  
 CN 1,3-Benzenediamine, 4-chloro-N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 848639-91-8 CAPLUS  
 CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-(1-methylethyl)- (CA INDEX NAME)




RN 848639-92-9 CAPLUS  
 CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-(2-(4-morpholinyl)ethyl)- (CA INDEX NAME)




RN 848639-93-0 CAPLUS

CN Urea, N-[2-(dimethylamino)ethyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 848639-94-1 CAPLUS

CN 4-Pyrimidinamine, N-(4-chloro-3-nitrophenyl)-6-(2-methoxyphenyl)- (CA INDEX NAME)




IT 848640-00-6P, 4-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)butane-1-sulfonic acid N-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]amide 848640-01-7P, [3-[6-[3-[4-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)butan-1-ylsulfonyl]amino]-4-methylphenyl]amino]pyrimidin-4-yl]phenyl]carbamic acid 9H-fluoren-9-ylmethyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848640-00-6 CAPLUS

CN 2H-Isoindole-2-butan-sulfonamide, 1,3-dihydro-N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-1,3-dioxo- (9CI) (CA INDEX NAME)



RN 848640-01-7 CAPLUS

CN Carbamic acid, [3-[6-[[3-[[[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]sulfonyl]amino]-4-methylphenyl]amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




IT 848640-07-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848640-07-3 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-[2-(3-aminopropoxy)phenyl]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


IT 848639-98-5, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzoic acid 848640-02-8, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-4-methylbenzene-1,3-diamine 848640-03-9, [3-[6-(3-Amino-4-methylphenylamino)pyrimidin-4-yl]phenyl]carbamic acid 9H-fluoren-9-ylmethyl ester  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)  
 RN 848639-98-5 CAPLUS  
 CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848640-02-8 CAPLUS  
 CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 848640-03-9 CAPLUS  
 CN Carbamic acid, [3-[6-[(3-amino-4-methylphenyl)amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



IT 848639-99-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 4,6-disubstituted aminopyrimidines as modulators of protein  
 kinases)  
 RN 848639-99-6 CAPLUS  
 CN Carbamic acid, [[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]carbon  
 imidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:99484 CAPLUS  
 DN 142:198089  
 TI Preparation of azinyl aryl amines as vanilloid receptor ligands.  
 IN Blum, Charles A.; Brielmann, Harry; Hodgetts, Kevin J.  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2


DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009977	A1	20050203	WO 2004-US22820	20040715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004259712	A1	20050203	AU 2004-259712	20040715
	CA 2531490	A1	20050203	CA 2004-2531490	20040715
	EP 1651619	A1	20060503	EP 2004-778364	20040715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1823048	A	20060823	CN 2004-80020429	20040715
	US 2006229308	A1	20061012	US 2006-564583	20060406
PRAI	US 2003-487405P	P	20030715		
	WO 2004-US22820	W	20040715		
OS	CASREACT 142:198089; MARPAT 142:198089				
AB	Title compds. [I; X = CRx, N; Rx = H, halo, NO <sub>2</sub> , alkyl, amino, cyano, alkylsulfonfyl, (di)alkylsulfonamido, (di)alkylamino; A1 = CH, N; A2-A4 = CH, CRa, N; ≤2 of A1-A4 = N; B1, B5 = CH, N; B2-B4 = CH, CRb; ≥1 of B2-B4 = CRb; Ra, Rb = halo, OH, amino, cyano, CO <sub>2</sub> H, alkyl, cycloalkyl, alkoxy, alkoxy, alkanoyl, haloalkyl, haloalkoxy, (di)alkylamino, alkylsulfonfyl, etc.; R2 = alkyl, cycloalkyl, haloalkyl, alkylsulfonfyl; R3 = cyano, alkyl, LNR5R6, MOR7; L, M = bond, alkylene; R5, R6 = H, alkyl, alkenyl, cycloalkyl, etc.; R7 = H, alkyl, alkenyl, cycloalkyl, alkanoyl, etc.], were prepared Thus, [4-(tert-butyl)phenyl][6-(3-methoxyphenyl)pyrimidin-4-yl]amine was prepared in 2 steps from 4,6-dichloropyrimidine, 3-methoxyphenylboronic acid, and 4-tert-butylaniline. In a capsaicin receptor binding assay, I showed Ki values of <1 μM.				
IT	837382-71-5P 837382-73-7P 837382-75-9P 837382-76-0P 837382-77-1P 837382-78-2P 837382-79-3P 837382-81-7P 837382-82-8P 837382-83-9P 837382-84-0P 837382-85-1P 837382-86-2P 837382-87-3P 837382-88-4P 837382-89-5P 837382-90-8P 837382-91-9P 837382-95-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of azinyl aryl amines as vanilloid receptor ligands)				
RN	837382-71-5 CAPLUS				


10/671,070

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 837382-73-7 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-2,5-dimethyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-75-9 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)-2-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 837382-76-0 CAPLUS

CN Phenol, 2-[[6-(3-methoxyphenyl)-5-nitro-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 837382-77-1 CAPLUS

CN Phenol, 2-[[6-(3-methoxyphenyl)-5-nitro-4-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 837382-78-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-5-ethyl-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-79-3 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 837382-81-7 CAPLUS


CN 4-Pyrimidinamine, 5-ethyl-6-(3-methoxyphenyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 837382-82-8 CAPLUS


CN 4,5-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 837382-83-9 CAPLUS

CN 4,5-Pyrimidinediamine, N4-(4-cyclohexylphenyl)-6-(3-methoxyphenyl)- (9CI)  
(CA INDEX NAME)




RN 837382-84-0 CAPLUS

CN 4,5-Pyrimidinediamine, N4-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-85-1 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 837382-86-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-87-3 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-88-4 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-89-5 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 837382-90-8 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-91-9 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 837382-95-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-bromo-4-(trifluoromethyl)phenyl]-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:14169 CAPLUS  
 DN 142:114470  
 TI Preparation of sulfonylated peptide derivatives for treating rheumatoid arthritis  
 IN Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth  
 PA Elan Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 736 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000246	A2	20050106	WO 2004-US20280	20040625
	WO 2005000246	A3	20051124		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:		BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2004251754	A2	20050106	AU 2004-251754	20040625
	AU 2004251754	A1	20050106		
	CA 2529873	A1	20050106	CA 2004-2529873	20040625
	US 2005065192	A1	20050324	US 2004-875282	20040625
	US 2005074451	A1	20050407	US 2004-875469	20040625
	EP 1635822	A2	20060322	EP 2004-777033	20040625
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR		
PRAI	US 2003-482211P	P	20030625		
	WO 2004-US20280	W	20040625		

OS MARPAT 142:114470

AB The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to  $\alpha 4$  integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is -(CH2)1-4-Ar-R5', where R5' is -O-Z-NR8R8' or -O-Z-R8'', Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is -C(X)NR7-, where R7 is H or alkyl and X is O or S] are claimed for use in combination therapy. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to  $\alpha 4\beta 1$  (IC50  $\leq 15 \mu\text{M}$ ).

IT 285139-60-8P 285139-62-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


10/671,070

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 285139-60-8 CAPLUS

CN L-Tyrosine, N-[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-62-0 CAPLUS

CN L-Tyrosine, N-[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:14167 CAPLUS  
 DN 142:114469  
 TI Preparation of sulfonylated peptide derivatives for treating rheumatoid arthritis  
 IN Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth  
 PA Elan Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 647 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000244	A2	20050106	WO 2004-US20240	20040625
	WO 2005000244	A3	20050929		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004251750	A2	20050106	AU 2004-251750	20040625
	AU 2004251750	A1	20050106		
	CA 2528723	A1	20050106	CA 2004-2528723	20040625
	US 2005065192	A1	20050324	US 2004-875282	20040625
	US 2005074451	A1	20050407	US 2004-875469	20040625
	EP 1635871	A2	20060322	EP 2004-777008	20040625
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-482211P	P	20030625		
	WO 2004-US20240	W	20040625		

AB The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to  $\alpha 4$  integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. include those described by formula R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is -(CH2)1-4-Ar-R5', where R5' is -O-Z-NR8R8' or -O-Z-R8'', Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is -C(X)NR7-, where R7 is H or alkyl and X is O or S]. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to  $\alpha 4\beta 1$  (IC50  $\leq 15 \mu\text{M}$ ).

IT 285139-60-8P 285139-62-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of sulfonylated peptide derivs. for treating rheumatoid


10/671,070

arthritis)

RN 285139-60-8 CAPLUS

CN L-Tyrosine, N-[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-,  
dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-62-0 CAPLUS

CN L-Tyrosine, N-[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-,  
4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:878265 CAPLUS  
 DN 141:366255  
 TI Preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors  
 IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray, Nathanael S.; Schultz, Peter G.  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089286	A2	20041021	WO 2004-US10083	20040402
	WO 2004089286	A3	20050421		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005014753	A1	20050120	US 2004-817328	20040401
	AU 2004227943	A1	20041021	AU 2004-227943	20040402
	CA 2521184	A1	20041021	CA 2004-2521184	20040402
	EP 1613595	A2	20060111	EP 2004-758738	20040402
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009173	A	20060411	BR 2004-9173	20040402
	CN 1798734	A	20060705	CN 2004-80015433	20040402
	JP 2006522143	T	20060928	JP 2006-509594	20040402
PRAI	US 2003-460838P	P	20030404		
	US 2004-817328	A	20040401		
	WO 2004-US10083	W	20040402		

OS MARPAT 141:366255

AB The title compds. [I; X1, X2 = N, CR4 (wherein R4 = H, alkyl); L = a bond, O, NR5 (R5 = H, alkyl); R1 = X3NR6R7, X3OR7, X3R7 (X3 = a bond, alkylene; R6 = H, alkyl; R7 = aryl, heteroaryl); R2 = H, halo, NH2, etc.; R3 = (heterocycloalkyl)alkyl, heteroarylalkyl, arylalkyl, etc.], useful for treating or preventing diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl, were prepared E.g., a multi-step synthesis of II, starting from 4,6-dichloropyrimidine and p-trifluoromethoxyaniline, was given. The compds. I preferably show an IC50 in the range of 1x10<sup>-10</sup> to 1x10<sup>-5</sup>M for Bcr-abl (specific data for one of the exemplified compds. I are given). The pharmaceutical composition comprising the compound I is claimed.

IT 714962-06-8P 778270-11-4P 778270-17-0P  
 778271-72-0P 778271-79-7P 778273-82-8P  
 778273-90-8P 778274-04-7P 778274-14-9P  
 778274-20-7P 778274-28-5P 778274-34-3P  
 778274-38-7P 778274-42-3P 778274-49-0P  
 778274-58-1P 778274-65-0P 778274-74-1P  
 778274-89-8P 778275-58-4P 778275-64-2P



10/671,070


778275-72-2P 778275-86-8P 778275-92-6P  
778276-48-5P 778276-89-4P 778277-15-9P  
778277-22-8P 778277-24-0P 778277-31-9P  
778277-37-5P 778277-54-6P 778279-08-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of substituted pyrimidinamines and triazinamines as protein  
kinase inhibitors for treating tumors)


RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-  
4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 778270-11-4 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 778270-17-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (9CI)  
(CA INDEX NAME)




RN 778271-72-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[4-(trifluoromethoxy)phenyl]-  
(9CI) (CA INDEX NAME)




RN 778271-79-7 CAPLUS

CN Benzenemethanol, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 778273-82-8 CAPLUS

CN Ethanone, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 778273-90-8 CAPLUS

CN Acetamide, N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 778274-04-7 CAPLUS

CN Benzamide, N-(1-methylethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-14-9 CAPLUS

CN Benzamide, N-4-morpholinyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-20-7 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-28-5 CAPLUS

CN Benzamide, N-(2-furanylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-34-3 CAPLUS

CN Morpholine, 4-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 778274-38-7 CAPLUS


CN Piperazine, 1-ethyl-4-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778274-42-3 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 778274-49-0 CAPLUS  
 CN Benzamide, N-[(tetrahydro-2-furanyl)methyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-58-1 CAPLUS  
 CN Benzamide, N-(3-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 778274-65-0 CAPLUS  
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778274-74-1 CAPLUS  
 CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-89-8 CAPLUS  
 CN 2-Pyrrolidinemethanol, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 778275-58-4 CAPLUS  
 CN Benzamide, 2-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 778275-64-2 CAPLUS  
 CN Morpholine, 4-[3-amino-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 778275-72-2 CAPLUS  
 CN 4-Pyrimidinamine, 6-(2-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (9CI)  
 (CA INDEX NAME)




RN 778275-86-8 CAPLUS  
 CN Morpholine, 4-[4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778275-92-6 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778276-48-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778276-89-4 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-15-9 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-22-8 CAPLUS

CN Benzamide, N-(4-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-24-0 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-31-9 CAPLUS

CN 1-Piperazineethanol, 4-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 778277-37-5 CAPLUS


CN Benzamide, N-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 778277-54-6 CAPLUS


CN Benzamide, 3-amino-N-methyl-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/671,070



RN 778279-08-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)





L10 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:857162 CAPLUS

DN 141:350185

TI Preparation of pyrimidine derivatives with lysophosphatidic acid acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity

IN Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J. Peter; Kohm, Cory T.; Tulinsky, John

PA Cell Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 80 pp., which  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

*Appl.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204386	A1	20041014	US 2003-671070	20030924
PRAI	US 2002-419694P	P	20021017		
	US 2003-460776P	P	20030404		

OS MARPAT 141:350185


AB The title compds. I [X, Y, Z = N, CH, or CR with the proviso that two of X, Y and Z are N; R = alkyl, alkoxy, Cl, Br, (substituted)amino; Q = NR', R'-N-(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>n</sub>-NR', O, O-(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>n</sub>-O, S, S-(CH<sub>2</sub>)<sub>n</sub>, or (CH<sub>2</sub>)<sub>n</sub>-S; n = 1-10; R' = H or alkyl; R1 = H, OH, alkyl, alkoxy, Cl, F, Br, etc.; R2, R7 = H, OH, alkyl, alkoxy, Cl, F, Br, I, etc.; R3 = H, alkyl, alkoxy, Cl, CCl<sub>3</sub>, (substituted)amino; R4, R5, R6 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, etc. or R4, R5 or R5, R6 are taken together with benzene ring to form a heterocycle] are prepared as lysophosphatidic acid acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitors for the treatment of diseases related to cell proliferation, such as cancer. For example, reaction of 6-chloro-N4-(4-methylphenyl)-pyrimidine-2,4-diamine (preparation given) with 5-chloro-2-methoxy-Ph boronic acid yielded compound II. The latter exhibits an IC<sub>50</sub> = 0.12  $\mu$ M in the LPAAT- $\beta$  assay.

IT 710335-06-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)

RN 710335-06-1 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 710334-85-3P 710334-87-5P 710334-94-4P  
710334-96-6P 710334-97-7P 710334-99-9P  
710335-00-5P 710335-01-6P 710335-03-8P  
710335-05-0P 710335-07-2P 710335-08-3P  
710335-10-7P 710335-12-9P 710335-21-0P  
710335-25-4P 710336-16-6P 774606-08-5P  
774606-09-6P 774606-10-9P 774606-11-0P

774606-12-1P 774606-13-2P 774606-14-3P  
 774606-15-4P 774606-16-5P 774606-17-6P  
 774606-18-7P 774606-19-8P 774606-20-1P  
 774606-21-2P 774606-22-3P 774606-23-4P  
 774606-24-5P 774606-25-6P 774606-26-7P  
 774606-28-9P 774606-29-0P 774606-30-3P  
 774606-31-4P 774606-32-5P 774606-33-6P  
 774606-34-7P 774606-35-8P 774606-36-9P  
 774606-37-0P 774606-38-1P 774606-39-2P  
 774606-40-5P 774606-41-6P 774606-42-7P  
 774606-43-8P 774606-44-9P 774606-45-0P  
 774606-46-1P 774606-47-2P 774606-48-3P  
 774606-49-4P 774606-50-7P 774606-51-8P  
 774606-52-9P 774606-53-0P 774606-54-1P  
 774606-55-2P 774606-56-3P 774606-57-4P  
 774606-58-5P 774606-61-0P 774606-62-1P  
 774606-63-2P 774606-64-3P 774606-65-4P  
 774606-66-5P 774606-67-6P 774606-68-7P  
 774606-69-8P 774606-70-1P 774606-71-2P  
 774606-72-3P 774606-73-4P 774606-74-5P  
 774606-75-6P 774606-76-7P 774606-77-8P  
 774606-78-9P 774606-79-0P 774606-80-3P  
 774606-81-4P 774606-82-5P 774606-83-6P  
 774606-84-7P 774606-85-8P 774606-86-9P  
 774606-87-0P 774606-88-1P 774606-89-2P  
 774606-90-5P 774606-91-6P 774606-92-7P  
 774606-93-8P 774606-95-0P 774606-96-1P  
 774606-97-2P 774606-98-3P 774606-99-4P  
 774607-00-0P 774607-01-1P 774607-02-2P  
 774607-03-3P 774607-04-4P 774607-05-5P  
 774607-06-6P 774607-07-7P 774607-08-8P  
 774607-09-9P 774607-10-2P 774607-11-3P  
 774607-12-4P 774607-15-7P 774607-16-8P  
 774607-17-9P 774607-18-0P 774607-19-1P  
 774607-20-4P 774607-21-5P 774607-22-6P  
 774607-23-7P 774607-24-8P 774607-25-9P  
 774607-26-0P 774607-27-1P 774607-28-2P  
 774607-29-3P 774607-31-7P 774607-32-8P  
 774607-33-9P 774607-34-0P 774607-35-1P  
 774607-36-2P 774607-37-3P 774607-38-4P  
 774607-39-5P 774607-40-8P 774607-41-9P  
 774607-42-0P 774607-43-1P 774607-44-2P  
 774607-45-3P 774607-46-4P 774607-47-5P  
 774607-48-6P 774607-49-7P 774607-50-0P  
 774607-51-1P 774607-52-2P 774607-53-3P  
 774607-54-4P 774607-55-5P 774607-56-6P  
 774607-57-7P 774607-58-8P 774607-59-9P  
 774607-60-2P 774607-61-3P 774607-62-4P  
 774607-63-5P 774607-64-6P 774607-65-7P  
 774607-66-8P 774607-67-9P 774607-69-1P  
 774607-70-4P 774607-71-5P 774607-72-6P  
 774607-73-7P 774607-74-8P 774607-75-9P  
 774607-76-0P 774607-77-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrimidine derivs. with lysophosphatidic acid  
 acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)


RN 710334-85-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-chlorophenyl)-


(9CI) (CA INDEX NAME)




RN 710334-87-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)

RN 710334-94-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,5-dichlorophenyl)- (9CI)  
(CA INDEX NAME)


RN 710334-96-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)

RN 710334-97-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-

(9CI) (CA INDEX NAME)




RN 710334-99-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 710335-00-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 710335-01-6 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 710335-03-8 CAPLUS

CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-bromo- (9CI)


(CA INDEX NAME)




RN 710335-05-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(2-chlorophenyl)-  
(9CI) (CA INDEX NAME)

RN 710335-07-2 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-  
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


RN 710335-08-3 CAPLUS

CN Benzenepropanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-  
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


RN 710335-10-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-nitrophenyl)-

(9CI) (CA INDEX NAME)




RN 710335-12-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-nitrophenyl)-  
(9CI) (CA INDEX NAME)


RN 710335-21-0 CAPLUS

CN Benzamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 710335-25-4 CAPLUS


CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 710336-16-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)-

(9CI) (CA INDEX NAME)




RN 774606-08-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-methylphenyl)-  
(9CI) (CA INDEX NAME)


RN 774606-09-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-10-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methoxyphenyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




RN 774606-11-0 CAPLUS

CN Phenol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)

RN 774606-12-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)


RN 774606-13-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-6-benzothiazolyl-6-(5-chloro-2-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 774606-14-3 . CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774606-15-4 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-16-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 774606-17-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-aminophenyl)-6-(5-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)



10/671,070


RN 774606-18-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-1,3-benzodioxol-5-yl-6-(5-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774606-19-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 774606-20-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 774606-21-2 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



10/671,070


RN 774606-22-3 CAPLUS

CN Phenol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 774606-23-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-24-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-1H-indazol-6-yl- (9CI)  
(CA INDEX NAME)



RN 774606-25-6 CAPLUS


CN Benzoic acid, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



10/671,070


RN 774606-26-7 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 774606-28-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-1,3-benzodioxol-5-yl-6-(2,5-dichlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 774606-29-0 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 774606-30-3 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-nitrophenyl)- (9CI)  
(CA INDEX NAME)




RN 774606-31-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-methylphenyl)-  
 (9CI) (CA INDEX NAME)




RN 774606-32-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-methoxyphenyl)-  
 (9CI) (CA INDEX NAME)



RN 774606-33-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-1H-indazol-6-yl-  
 (9CI) (CA INDEX NAME)




RN 774606-34-7 CAPLUS  
 CN Benzonitrile, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 774606-35-8 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-36-9 CAPLUS

CN 4-Pyrimidinamine, N-(4-bromophenyl)-6-(5-chloro-2-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 774606-37-0 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(5-chloro-2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 774606-38-1 CAPLUS


CN 4-Pyrimidinamine, N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



10/671,070


RN 774606-39-2 CAPLUS

CN 4-Pyrimidinamine, 6-(5-chloro-2-methylphenyl)-N-(4-chlorophenyl)-2-methyl-  
(9CI) (CA INDEX NAME)




RN 774606-40-5 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(5-chloro-2-methylphenyl)-2-methyl-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 774606-41-6 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 774606-42-7 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)




RN 774606-43-8 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-44-9 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-45-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-1H-indazol-6-yl-5-methyl- (9CI) (CA INDEX NAME)




RN 774606-46-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-6-(5-chloro-2-methoxyphenyl)-N4-1H-indazol-6-yl- (9CI) (CA INDEX NAME)







RN 774606-47-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-methylphenyl)-  
 (9CI) (CA INDEX NAME)




RN 774606-48-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-49-4 CAPLUS  
 CN Benzonitrile, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 774606-50-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-methoxyphenyl)-  
 (9CI) (CA INDEX NAME)




RN 774606-51-8 CAPLUS  
 CN Methanone, [4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)




RN 774606-52-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774606-53-0 CAPLUS  
 CN Benzoic acid, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774606-54-1 CAPLUS  
 CN Benzenemethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



10/671,070


RN 774606-55-2 CAPLUS

CN Butanedioic acid, mono[[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl] ester (9CI) (CA INDEX NAME)



RN 774606-56-3 CAPLUS


CN Glycine, [4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-57-4 CAPLUS

CN Benzenemethanol, 4-[[6-(5-chloro-2-ethoxyphenyl)-2-(methylamino)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-58-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-[4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-61-0 CAPLUS

CN Butanedioic acid, mono[2-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 774606-62-1 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-63-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(5-methoxy-2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774606-64-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,5-dimethylphenyl)- (9CI)  
(CA INDEX NAME)


RN 774606-65-4 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(2,5-dimethylphenyl)-4-pyrimidinyl]amino]-,  
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 774606-66-5 CAPLUS

CN Benzamide, 5-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]-2-  
chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774606-67-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-fluoro-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-68-7 CAPLUS  
 CN Benzamide, 5-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-2-bromo-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-69-8 CAPLUS  
 CN Benzamide, 5-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]-2-bromo-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/671,070



● HCl

RN 774606-70-1 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 5-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-71-2 CAPLUS

CN Butanoic acid, 4-[[[4-(5-chloro-2-methylphenyl)-6-[[4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774606-72-3 CAPLUS


10/671,070

CN 2,4-Pyrimidinediamine, N4-(4-azidophenyl)-6-(5-bromo-2-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 774606-73-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774606-74-5 CAPLUS

CN 2-Oxazolepropanoic acid, 4-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774606-75-6 CAPLUS


CN Benzonitrile, 4-[[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)






RN 774606-76-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-[4-(4-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-77-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 774606-78-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[5-chloro-2-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-79-0 CAPLUS

CN Ethanol, 2-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 774606-80-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-[5-bromo-2-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-81-4 CAPLUS

CN Benzenebutanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-82-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 774606-83-6 CAPLUS

CN Benzenebutanoic acid, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-84-7 CAPLUS

CN Benzenesulfonamide, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-85-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 774606-86-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,3,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 774606-87-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(2,3,5-trichlorophenyl)- (9CI)

(CA INDEX NAME)




RN 774606-88-1 CAPLUS

CN Benzenethanol, 4-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-89-2 CAPLUS

CN Benzenepropanol, 4-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,3,5-trichlorophenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-91-6 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]- $\alpha$ -(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 774606-92-7 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 774606-93-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-95-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-chlorophenyl)-N4-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774606-96-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774606-97-2 CAPLUS  
 CN Benzenepropanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-98-3 CAPLUS  
 CN Benzenebutanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 774607-00-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(3,5-dichlorophenyl)-N4-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-01-1 CAPLUS

CN Benzenemethanol, 5-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 774607-02-2 CAPLUS

CN Benzoic acid, 3-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 774607-03-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(3-ethylphenyl)- (9CI) (CA INDEX NAME)



RN 774607-04-4 CAPLUS


CN 1,3-Propanediol, 2-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 774607-05-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,3-dichlorophenyl)- (9CI) (CA INDEX NAME)






RN 774607-06-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-bromophenyl)-N4-[4-(trifluoromethyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 774607-07-7 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 774607-08-8 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774607-09-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)-N4-methyl- (9CI) (CA INDEX NAME)




RN 774607-10-2 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774607-11-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-12-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-1H-benzotriazol-5-yl-6-(5-chloro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 774607-15-7 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-α-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774607-16-8 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro-, oxime (9CI) (CA INDEX NAME)




RN 774607-17-9 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 774607-18-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-(3,4-dimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-19-1 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-20-4 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-α-methyl- (9CI) (CA INDEX NAME)




RN 774607-21-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-propoxyphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-22-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(1-methylethoxy)phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-23-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-[4-(1-methoxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-24-8 CAPLUS

CN Benzamide, 3-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 774607-25-9 CAPLUS  
 CN Ethanone, 1-[4-[[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]amino]phenyl]-  
 (9CI) (CA INDEX NAME)



RN 774607-26-0 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(4-azidophenyl)-6-(2-ethoxy-5-iodophenyl)- (9CI)  
 (CA INDEX NAME)




RN 774607-27-1 CAPLUS  
 CN Benzeneethanol, 4-[[2-amino-6-[5-bromo-2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-28-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-(4-chlorophenyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-29-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(2-methoxyethoxy)phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 774607-31-7 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(hexyloxy)phenyl]-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-32-8 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(phenylmethoxy)phenyl]-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-33-9 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(2,3,5-trichlorophenyl)-4-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)



RN 774607-34-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-butoxyphenyl)-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 774607-35-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[2-(4-morpholinyl)ethoxy]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)






RN 774607-36-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-37-3 CAPLUS  
 CN Benzeneethanol, 4-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-38-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774607-39-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(phenylmethoxy)phenyl]-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-40-8 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 774607-41-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[5-chloro-2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-42-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[3-(dimethylamino)propoxy]phenyl]-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-43-1 CAPLUS  
 CN Benzeneethanol, 4-[[2-amino-6-[5-chloro-2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774607-44-2 CAPLUS  
 CN Boronic acid, [4-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-45-3 CAPLUS  
 CN Benzonitrile, 4-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-46-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-(4-nitrophenyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-47-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-(4-bromophenyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-48-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-ethylphenyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-49-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-50-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-51-1 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(2-phenylethoxy)phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-52-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethylphenyl)-N4-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)

RN 774607-53-3 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[5-chloro-2-(cyclohexylmethoxy)phenyl]-N4-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)

RN 774607-54-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethylphenyl)-N4-(4-nitrophenyl)-  
(9CI) (CA INDEX NAME)

RN 774607-55-5 CAPLUS


CN Benzoic acid, 3-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-,  
ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-56-6 CAPLUS

CN Benzoic acid, 3-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 774607-57-7 CAPLUS

CN 4-Pyrimidinamine, N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 774607-58-8 CAPLUS


CN Boronic acid, [4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-59-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[5-chloro-2-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-60-2 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-ethylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774607-61-3 CAPLUS

CN Benzeneethanol, 4-[[6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)






10/671,070


RN 774607-62-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(phenoxymethyl)phenyl]-N4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 774607-63-5 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(4-nitrophenyl)methoxy]phenyl]-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-64-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-chloro-3-(trifluoromethyl)phenyl]-6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-65-7 CAPLUS

CN 4-Pyrimidinamine, 6-[5-bromo-2-(methoxymethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-66-8 CAPLUS

CN 4-Pyrimidinamine, 6-[5-bromo-2-(methoxymethyl)phenyl]-N-(4-bromophenyl)-  
(9CI) (CA INDEX NAME)




RN 774607-67-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(2-methoxyphenyl)methoxy]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 774607-69-1 CAPLUS


CN Benzamide, 5-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]-2-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-70-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(4-methoxyphenyl)methoxy]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 774607-71-5 CAPLUS


CN Benzamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-72-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-chlorophenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-73-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(2-methoxyphenyl)methoxy]phenyl]-N4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 774607-74-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-chlorophenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-75-9 CAPLUS

CN 4-Pyrimidinamine, 6-(5-bromo-2-ethoxyphenyl)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-76-0 CAPLUS


CN Benzeneethanol, 4-[[6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774607-77-1 CAPLUS  
 CN 4-Pyrimidinamine, 6-(5-bromo-2-ethoxyphenyl)-N-(4-fluorophenyl)- (9CI)  
 (CA INDEX NAME)



IT 710335-15-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyrimidine derivs. with lysophosphatidic acid  
 acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)  
 RN 710335-15-2 CAPLUS  
 CN Benzoic acid, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)




IT 710335-04-9P 774607-83-9P 774608-01-4P  
 774608-04-7P 774608-16-1P 774608-20-7P  
 774608-24-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of pyrimidine derivs. with lysophosphatidic acid  
 acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)  
 RN 710335-04-9 CAPLUS  
 CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-chloro-  
 (9CI) (CA INDEX NAME)




RN 774607-83-9 CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774608-01-4 CAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, [4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 774608-04-7 CAPLUS


CN Benzoic acid, 4-[[6-(5-chloro-2-ethoxyphenyl)-2-(methylamino)-4-pyrimidinyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 774608-16-1 CAPLUS

CN 2-Oxazolepropanoic acid, 4-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 774608-20-7 CAPLUS


CN Benzenebutanoic acid, 4-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774608-24-1 CAPLUS

CN Benzeneacetic acid, 4-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 929003-17-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of pyrimidine derivs. with lysophosphatidic acid  
 acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)

RN 929003-17-8 CAPLUS

CN 4-Pyrimidinamine, 6-(5-chloro-2-methoxyphenyl)-N-(4-chlorophenyl)-2-methyl-  
(CA INDEX NAME)



IT 774606-59-6P 774606-60-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrug; preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)

RN 774606-59-6 CAPLUS

CN L-Aspartic acid, 4-[[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774606-60-9 CAPLUS

CN L-Alanine, [4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L10 ANSWER 33 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:550744 CAPLUS  
 DN 141:89118  
 TI Preparation of biaryl derivatives having differential tumor cytotoxicity  
 IN Chyba, Jason; Deveraux, Quinn; Hampton, Garret; King, Fred  
 PA IRM Llc, Bermuda  
 SO U.S. Pat. Appl. Publ., 11 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004132786	A1	20040708	US 2003-739667	20031218
	US 7125997	B2	20061024		
	WO 2004058713	A1	20040715	WO 2003-US40686	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299750	A1	20040722	AU 2003-299750	20031218
PRAI	US 2002-435853P	P	20021220		
	US 2003-491132P	P	20030729		
	WO 2003-US40686	W	20031218		

OS MARPAT 141:89118

AB Novel biaryl derivs. (I) [R1 = HO, C1-6 alkoxy, halo-substituted-C1-6 alkoxy, halo-substituted C1-6 alkyl; R2 = H, halo, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C1-6 alkyl, halo-substituted C1-6 alkyl; R3 = halo, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C1-6 alkyl, halo-substituted C1-6 alkyl, -YNR4R5 (wherein Y = a bond, C5-6 heteroarylene; R4 = H, C1-6 alkyl; R5 = C6-10 aryl substituted with one to three radicals selected from the group chosen from halo, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, halo-substituted C1-6 alkoxy, and PhO; or R4 and R5 together with the nitrogen to which R4 and R5 are attached form C3-8 heterocycloalkyl substituted with Ph optionally substituted with one to three radicals selected from the group chosen from halo, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C1-6 alkyl and halo-substituted C1-6 alkyl); Z = -XNR6CONR7- or -XS(O)2NR7- (wherein X = a bond, C1-6 alkylene; R6, R7 = H, C1-6 alkyl)] and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof are prepared This invention is also related to the uses of the compds. I in various medicinal applications, including the treatment, prevention and control of proliferative diseases such as tumors, and to pharmaceutical compns. comprising these compds. The compds. I can be used to treat or prevent diseases or disorders that involve the activity of macrophage migration inhibitory factor-1 (MIF-1) and/or adenosine kinase. Thus, 20 mL CH2Cl2 was added to a 4-(Morpholino)aniline resin (4.40 g, 3.52 mmol) and the solution was allowed to stand at room temperature for one hour, followed by adding Et3N (4.9 mL, 35 mmol) and 4-chlorobenzoyl chloride (2.24 mL, 17 mmol), and the reaction mixture was placed on a shaker and shaken overnight at room temperature The resin was then filtered and washed consecutively with MeOH, DMF, and CH2Cl2 (4+20 mL each) to give, after vacuum drying, the product, N-[4-(morpholin-4-yl)phenyl]-4-chlorobenzamide bound to


resin, which (1.0 g, .apprx.0.8 mmol) was aminated by 4-(trifluoromethoxy)aniline (0.55 mL, 4.0 mmol) in the presence of Pd2(dba)3 (0.091 g, 0.10 mmol) and IPrHCl ligand (0.085 g, 0.20 mmol) in 15 mL dioxane in a glass vial under shaking at 90°, cooled to room temperature to give, after filtering the resin and washing consecutively with MeOH, DMF, and CH2Cl2 (4+10 mL each) and cleaving the resin by treatment with a mixture of 50% CF3CO2H, 45% CH2Cl2, and 5% H2O, and purification using HPLC, N-[4-(Morpholin-4-yl)phenyl]-4-[(4-trifluoromethoxyphenyl)amino]benzamide (II). II showed IC50 of 26 nM against SW620 cell line.

IT 714962-05-7P, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]benzoic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)

RN 714962-05-7 CAPLUS

CN Benzoic acid, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 714962-03-5P, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]-N-(2-trifluoromethylbenzyl)benzamide 714962-06-8P, 4-Methoxy-N-[3-[6-[(4-trifluoromethoxyphenyl)amino]pyrimidin-4-yl]phenyl]benzenesulfonamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)


RN 714962-03-5 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

L10 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:467883 CAPLUS  
 DN 141:38627  
 TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol  
 (pi) 3-kinase inhibitors and their use in the treatment of cancer  
 IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048365	A1	20040610	WO 2003-US37294	20031121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507100	A1	20040610	CA 2003-2507100	20031121
	AU 2003295776	A1	20040618	AU 2003-295776	20031121
	US 2004176385	A1	20040909	US 2003-719896	20031121
	EP 1575940	A1	20050921	EP 2003-786980	20031121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016485	A	20051011	BR 2003-16485	20031121
	CN 1735607	A	20060215	CN 2003-80108239	20031121
	JP 2006514118	T	20060427	JP 2005-510381	20031121
	NO 2005002927	A	20050708	NO 2005-2927	20050615
	IN 2005KN01189	A	20060609	IN 2005-KN1189	20050621
PRAI	US 2002-428473P	P	20021121		
	US 2003-438568P	P	20030107		
	US 2003-523081P	P	20031119		
	WO 2003-US37294	W	20031121		

OS MARPAT 141:38627

AB Title compds. I [Y = (un)substituted alk(en/yn)yl, hetero/aryl, heterocyclyl; X = a direct link, NH and derivs., CH2 and derivs., O, S, SO, SO2, etc.; R1 = H, alkyl, CO2H, halo, OH and derivs., NH2 and derivs.; R2 = (un)substituted hetero/aryl, heterocyclyl; W = NH2 and derivs., (un)substituted alkyl, cyclyl containing at least one heteroatom; with provisos; their stereoisomers, tautomers, pharmaceutically acceptable salts, esters, or prodrugs] were prepared as phosphatidylinositol (pi) 3-kinase inhibitors for treating neoplasm. A solid phase synthesis is given for pyrimidine II•2CF3CO2H. Selected I displayed an IC50 < 20 µM in a cell proliferation assay.


IT 701243-13-2P, 3-[6-(1H-Indazol-5-ylamino)-2-[(2-methoxyethyl)amino]pyrimidin-4-yl]phenol  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)

RN 701243-13-2 CAPLUS

10/671,070

CN Phenol, 3-[6-(1H-indazol-5-ylamino)-2-[(2-methoxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 35 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:453205 CAPLUS  
 DN 141:23547  
 TI Preparation of amino heterocycles as vanilloid receptor (VR1) modulators,  
 in particular antagonists, for treating pain and/or inflammation  
 IN Blurton, Peter; Burkamp, Frank; Fletcher, Stephen Robert; Hollingworth,  
 Gregory John; Jones, A. Brian; Mciver, Edward Giles; Moyes, Christopher  
 Richard; Rogers, Lauren  
 PA Merck Sharp & Dohme Limited, UK  
 SO PCT Int. Appl., 72 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004046133	A1	20040603	WO 2003-GB4969	20031114
W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506025	A1	20040603	CA 2003-2506025	20031114
AU 2003283581	A1	20040615	AU 2003-283581	20031114
EP 1562934	A1	20050817	EP 2003-775557	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512323	T	20060413	JP 2004-552870	20031114
US 2006040947	A1	20060223	US 2005-534584	20050511
PRAI GB 2002-26724	A	20021115		
WO 2003-GB4969	W	20031114		

OS MARPAT 141:23547

AB Title compds. I [wherein V = NH and derivs., O, S, SO, SO<sub>2</sub>; W, X = independently CH or N; Y = N, CH, C-Ar<sub>2</sub>, with the proviso that at least one, but no more than two, of W, X, and Y are N; Z = CH or C-Ar<sub>2</sub> with the proviso that when Y = N or CH, then Z = C-Ar<sub>2</sub>, and when Y = Ar<sub>2</sub>, then Z = CH; Ar<sub>1</sub> = fused 9- or 10-membered heterobicyclic ring, containing 1-4 heteroatoms selected from N, O, and S wherein at least one of the rings is aromatic; Ar<sub>2</sub> = (un)substituted (un)fused Ph, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl; R<sub>1</sub> = halo, OH, oxo, CN, NO<sub>2</sub>, SH and derivs., SO<sub>2</sub>H and derivs., CONH<sub>2</sub> and derivs., halo/hydroxy/cyclo/cycloalkyl/alkyl, halo/hydroxy/cyclo/alkoxy, alkenyl, alkynyl etc.; R<sub>2</sub> = H, halo, OH, halo/cyclo/alkyl, halo/alkoxy, (un)substituted phenyl; n = 0-3; and their pharmaceutically acceptable salts, N-oxides, and prodrugs] were prepared as vanilloid receptor (VR1) modulators, in particular antagonists, for treating conditions or diseases in which pain and/or inflammation predominates. For example, 3-Methyl-7-(trifluoromethyl)isoquinolin-5-amine (preparation given) was arylated with 4-Chloro-6-(4-trifluoromethylphenyl)pyrimidine (preparation given) to give the diheterocyclyl amine II in 40% yield. I bound to the VR1 receptor with an IC<sub>50</sub> < 1 μM, and in the majority of cases, < 200 nM. I are predominantly VR1 antagonists with a few of them VR1 partial antagonists and VR1 partial agonists. Thus, I and their pharmaceutical compns. are useful for treating pain and/or inflammation.

IT 697740-23-1P, 1-[2-[6-(Isoquinolin-5-ylamino)pyrimidin-4-


yl]benzyl]piperidin-4-one 697740-24-2P, 3-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]benzaldehyde 697740-27-5P, N-[6-(3-Fluorophenyl)pyrimidin-4-yl]isoquinolin-5-amine 697740-30-0P, N-[6-(3,5-Dichlorophenyl)pyrimidin-4-yl]isoquinolin-5-amine 697740-33-3P, N-[6-[3,5-Bis(Trifluoromethyl)phenyl]pyrimidin-4-yl]isoquinolin-5-amine 697740-38-8P, 3-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]benzoic acid 697740-39-9P, N-[6-(3-Trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine 697740-40-2P, N-[6-(3-Methylphenyl)pyrimidin-4-yl]isoquinolin-5-amine 697740-42-4P, N-[6-[2-Fluoro-3-(pyridin-3-yl)phenyl]pyrimidin-4-yl]isoquinolin-5-amine 697740-46-8P, N-[6-(3-Nitrophenyl)pyrimidin-4-yl]isoquinolin-5-amine 697740-50-4P, N-[6-(3-Isopropylphenyl)pyrimidin-4-yl]isoquinolin-5-amine 697740-52-6P, N-[6-(2,5-Difluorophenyl)pyrimidin-4-yl]isoquinolin-5-amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(VR1 antagonist; preparation of amino heterocycles as vanilloid receptor (VR1) modulators, in particular antagonists, for treating pain and/or inflammation)


RN 697740-23-1 CAPLUS

CN 4-Piperidinone, 1-[[2-[6-(5-isoquinolinylamino)-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 697740-24-2 CAPLUS

CN Benzaldehyde, 3-[6-(5-isoquinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-27-5 CAPLUS

CN 5-Isoquinolinamine, N-[6-(3-fluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-30-0 CAPLUS

CN 5-Isoquinolinamine, N-[6-(3,5-dichlorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-33-3 CAPLUS

CN 5-Isoquinolinamine, N-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-38-8 CAPLUS

CN Benzoic acid, 3-[6-(5-isoquinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-39-9 CAPLUS


CN 5-Isoquinolinamine, N-[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-40-2 CAPLUS


CN 5-Isoquinolinamine, N-[6-(3-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 697740-42-4 CAPLUS

CN 5-Isoquinolinamine, N-[6-[2-fluoro-3-(3-pyridinyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-46-8 CAPLUS


CN 5-Isoquinolinamine, N-[6-(3-nitrophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-50-4 CAPLUS


CN 5-Isoquinolinamine, N-[6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/671,070



RN 697740-52-6 CAPLUS

CN 5-Isoquinolinamine, N-[6-(2,5-difluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME).



L10 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:428912 CAPLUS  
 DN 141:7437  
 TI Preparation of phenyl or heteroaryl amino acid derivatives as prostacyclin receptor (IP) antagonists  
 IN Murata, Toshiki; Umeda, Masaomi; Yoshikawa, Satoru; Urbahns, Klaus; Gupta, Jang; Sakurai, Osamu  
 PA Bayer Healthcare A.-G., Germany  
 SO PCT Int. Appl., 206 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

X 2 Diff

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043926	A1	20040527	WO 2003-EP11976	20031029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2505361	A1	20040527	CA 2003-2505361	20031029
	AU 2003276201	A1	20040603	AU 2003-276201	20031029
	EP 1575919	A1	20050921	EP 2003-810952	20031029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016191	A	20050927	BR 2003-16191	20031029
	CN 1735598	A	20060215	CN 2003-80108581	20031029
	JP 2006514110	T	20060427	JP 2005-506646	20031029
	IN 2005DN01536	A	20070420	IN 2005-DN1536	20050415
	US 2006089371	A1	20060427	US 2005-534174	20050506
	NO 2005002797	A	20050609	NO 2005-2797	20050609
PRAI	EP 2002-25024	A	20021111		
	EP 2003-11397	A	20030520		
	WO 2003-EP11976	W	20031029		
OS	MARPAT 141:7437				

AB The invention relates to amino acid derivs. I [Ar is (un)substituted phenylene or 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S; Q is CH, CR10 or N (R10 is halo, cyano, amino, nitro, formyl, hydroxymethyl, methylthio, alkyl, haloalkyl, alkoxy or phenylalkoxy); R1 is OR11 (R11 is alkoxyalkylene, a mono- or bicyclic ring, alkyl, etc.), CH2NHR11, COR11, CONHR11, SR11, SOR11, SO2R11, NHR11, NHCO2R11, NHCOR11, NHSO2R11, H, OH, halo, a mono- or bicyclic ring, alkyl, etc.; R2 is H, OH, amino, alkyl, cycloalkyl, alkylthio, alkylsulfonyl, aryl, heteroaryl, etc.; R3 is H, alkyl or haloalkyl; R4 is carboxy, tetrazolyl or N-hydroxyaminocarbonyl; R5 is H, alkoxy, aryl, heteroaryl, alkyl or haloalkyl; R6 is H, alkyl or haloalkyl] which have prostacyclin receptor (IP) antagonistic activity and can be used for the prophylaxis and treatment of diseases such urol. diseases or disorder or pain. Thus, N-[6-[4-(benzyloxy)phenyl]pyrimidin-4-yl]-D-phenylalanine was prepared by substitution reaction of 4,6-dichloropyrimidine with D-phenylalanine Me ester hydrochloride, followed by arylation with 4-(benzyloxy)phenylboronic acid and saponification IP binding/cAMP data for > 100 synthesized compds. are tabulated (IC50 values are classified as A < 0.1  $\mu$ M  $\leq$  B < 1  $\mu$ M  $\leq$  C).

10/671,070


IT 693791-40-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Ph or heteroaryl amino acid derivs. as prostacyclin receptor (IP) antagonists)

RN 693791-40-1 CAPLUS

CN Phenylalanine, N-[6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:390240 CAPLUS

DN 140:406815

TI Preparation of phenylaminopyrimidines as Rho-Kinase II (ROK $\alpha$ ) inhibitors for the treatment of cardiovascular diseases.

IN Feurer, Achim; Bennabi, Samir; Heckroth, Heike; Schirok, Hartmut; Mittendorf, Joachim; Kast, Raimund; Stasch, Johannes-peter; Gnoth, Mark Jean; Muentner, Klaus; Lang, Dieter; Figueroa, Perez Santiago; Ehmke, Heimo

PA Bayer Healthcare Ag, Germany; et al.

SO PCT Int. Appl., 203 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039796	A1	20040513	WO 2003-EP11452	20031016
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10332232	A1	20040513	DE 2003-10332232	20030716
	CA 2503646	A1	20040513	CA 2003-2503646	20031016
	AU 2003278088	A1	20040525	AU 2003-278088	20031016
	EP 1562935	A1	20050817	EP 2003-769398	20031016
	EP 1562935	B1	20060906		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006506458	T	20060223	JP 2005-501803	20031016
	US 2006241127	A1	20061026	US 2005-531889	20050419
PRAI	DE 2002-10250113	A	20021028		
	DE 2003-10332232	A	20030716		
	WO 2003-EP11452	W	20031016		

OS MARPAT 140:406815

AB Title compds. I [A = (un)substituted indazole, dihydrobenzofuran, indoline, etc.: R1 = H, halo, CN; R3, R4 = H, F, Cl; R5 = H, OH, halo, etc.] and their pharmaceutically acceptable salts were prepared. For example, condensation of 5-(4-amino-2-fluorophenoxy)-1H-indazol, e.g., prepared from 5-hydroxyindazole in 2-steps, and 4-chloro-6-(4-pyridinyl)-2-pyrimidinamine, e.g., prepared from isonicotinic acid in 3-steps, afforded phenylaminopyrimidine II in 62% yield. In Rho-Kinase II (ROK $\alpha$ ) inhibition assays, 13-examples of compds. I exhibited IC50 values ranging from 1-680 nM, e.g., the IC50 value of phenylaminopyrimidine II was 20 nM. Compds. I were claimed useful for the treatment of cardiovascular diseases.

IT 688779-97-7P 688780-01-0P 688780-05-4P

688780-81-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of phenylaminopyrimidines as Rho-Kinase II (ROK $\alpha$ ) inhibitors for the treatment of cardiovascular diseases)

RN 688779-97-7 CAPLUS

CN Benzonitrile, 3-[2-amino-6-[[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]amino]-


10/671,070

4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 688780-01-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 688780-05-4 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(3-bromophenyl)-N4-[3-chloro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 688780-81-6 CAPLUS

CN Benzenemethanol, 2-[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/671,070




L10 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:303311 CAPLUS  
 DN 141:64387  
 TI Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase- $\beta$   
 AU Gong, Baoqing; Hong, Feng; Kohm, Cory; Jenkins, Scott; Tulinsky, John; Bhatt, Rama; de Vries, Peter; Singer, Jack W.; Klein, Peter  
 CS Cell Therapeutics, Inc., Seattle, WA, 98119, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2303-2308  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 OS CASREACT 141:64387  
 AB 2,4-Diamino-N4,6-diarylpyrimidines were identified as potent, isoform specific inhibitors of lysophosphatidic acid acyltransferase- $\beta$  (LPAAT- $\beta$ ). Active inhibitors also blocked proliferation of tumor cell lines in vitro. The effect of one of the synthesized compds. (2j) in an in vivo tumor model was investigated.  
 IT 710334-85-3P 710334-86-4P 710334-87-5P  
 710334-94-4P 710334-95-5P 710334-96-6P  
 710334-97-7P 710334-98-8P 710334-99-9P  
 710335-00-5P 710335-01-6P 710335-02-7P  
 710335-03-8P 710335-04-9P 710335-05-0P  
 710335-06-1P 710335-07-2P 710335-08-3P  
 710335-09-4P 710335-10-7P 710335-11-8P  
 710335-12-9P 710335-13-0P 710335-14-1P  
 710335-15-2P 710335-16-3P 710335-17-4P  
 710335-18-5P 710335-19-6P 710335-20-9P  
 710335-21-0P 710335-23-2P 710335-24-3P  
 710335-25-4P 710335-26-5P 710335-27-6P  
 710336-16-6P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers, inhibitors of lysophosphatidic acid acyltransferase- $\beta$ )  
 RN 710334-85-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 710334-86-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)







RN 710334-87-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-bromophenyl)-  
 (9CI) (CA INDEX NAME)




RN 710334-94-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,5-dichlorophenyl)- (9CI)  
 (CA INDEX NAME)



RN 710334-95-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(5-fluoro-2-methylphenyl)-  
 (9CI) (CA INDEX NAME)




RN 710334-96-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-chlorophenyl)-  
 (9CI) (CA INDEX NAME)




RN 710334-97-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 710334-98-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-bromophenyl)-6-(5-chloro-2-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 710334-99-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 710335-00-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 710335-01-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-bromophenyl)-  
(9CI) (CA INDEX NAME)




RN 710335-02-7 CAPLUS

CN Phenol, 3-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl-  
(9CI) (CA INDEX NAME)




RN 710335-03-8 CAPLUS

CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-bromo- (9CI)  
(CA INDEX NAME)




RN 710335-04-9 CAPLUS

CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-chloro-  
(9CI) (CA INDEX NAME)




RN 710335-05-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(2-chlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 710335-06-1 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-07-2 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-08-3 CAPLUS

CN Benzenepropanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-09-4 CAPLUS

CN Benzeneacetic acid, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-10-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 710335-11-8 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 710335-12-9 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-1H-indazol-6-yl-

(9CI) (CA INDEX NAME)




RN 710335-13-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-phenyl- (9CI) (CA INDEX NAME)




RN 710335-14-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 710335-15-2 CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-16-3 CAPLUS

CN Benzeneacetic acid, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-17-4 CAPLUS

CN Boronic acid, [4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 710335-18-5 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-19-6 CAPLUS


CN Benzonitrile, 3-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-20-9 CAPLUS

CN Benzamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)


RN 710335-21-0 CAPLUS

CN Benzamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-N-  
hydroxy- (9CI) (CA INDEX NAME)

RN 710335-23-2 CAPLUS


CN Benzeneacetamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-  
pyrimidinyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)

RN 710335-24-3 CAPLUS


CN Benzenecarboximidamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-  
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-25-4 CAPLUS  
 CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 710335-26-5 CAPLUS  
 CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)



RN 710335-27-6 CAPLUS  
 CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 710336-16-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:1006976 CAPLUS  
 DN 140:59653  
 TI Preparation of phenylaminopyrimidines as rho-kinase inhibitors  
 IN Feurer, Achim; Bennabi, Samir; Heckroth, Heike; Ergueden, Jens; Schenke, Thomas; Bauser, Markus; Kast, Raimund; Stasch, Johannes-Peter; Stahl, Elke; Muentert, Klaus; Lang, Dieter; Ehmke, Heimo  
 PA Bayer Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 116 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003106450	A1	20031224	WO 2003-EP5827	20030604
	WO 2003106450	A8	20050203		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, SA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10226943	A1	20040108	DE 2002-10226943	20020617
	CA 2489452	A1	20031224	CA 2003-2489452	20030604
	AU 2003232848	A1	20031231	AU 2003-232848	20030604
	EP 1515965	A1	20050323	EP 2003-759908	20030604
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005538962	T	20051222	JP 2004-513282	20030604
PRAI	DE 2002-10226943	A	20020617		
	WO 2003-EP5827	W	20030604		
OS	MARPAT 140:59653				
AB	Title compds. [I; R1 = amino, OH; R2 = H, alkyl, cycloalkyl; R3, R4 = cyano, H, F, Cl; A = Q1-Q3; R5, R6 = H, F, Cl; D = (substituted) Ph, (iso)quinoline, indole, etc.], were prepared for treating cardiovascular diseases. Thus, 4-chloro-6-quinolin-6-yl-pyrimidin-2-amine (preparation given) and 3-fluoro-4-(4-pyridinylsulfanyl)aniline (preparation given) were treated with 37% HCl followed by stirring for over night at 100° to give 12% N-[2-amino-6-(6-quinolinyl)-4-pyrimidinyl]-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine. The latter inhibited Rho-kinase II (ROKα) with IC50 = 7 nM.				
IT	637039-07-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of phenylaminopyrimidines as rho-kinase inhibitors)				
RN	637039-07-7 CAPLUS				
CN	Acetamide, N-[3-[2-amino-6-[[3-fluoro-4-(5-isoquinolinylloxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)				

10/671,070



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:591169 CAPLUS  
 DN 139:149643  
 TI Preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses  
 IN Nagarathnam, Dhanapalan; Dumas, Jacques; Hatoum-mokdad, Holia; Boyer, Stephen; Wang, Chunguang; Pluempe, Hans; Feurer, Achim; Bennabi, Samir  
 PA Bayer Corporation, USA  
 SO PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062225	A1	20030731	WO 2003-US1839	20030123
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2473510	A1	20030731	CA 2003-2473510	20030123
	US 2004002508	A1	20040101	US 2003-349177	20030123
	US 6924290	B2	20050802		
	EP 1470121	A1	20041027	EP 2003-705858	20030123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005521659	T	20050721	JP 2003-562103	20030123
	US 2005192304	A1	20050901	US 2005-107793	20050418
PRAI	US 2002-349987P	P	20020123		
	US 2003-349177	A3	20030123		
	WO 2003-US1839	W	20030123		


OS MARPAT 139:149643

AB Disclosed are pyrimidinamines (shown as I; variables defined below; e.g. 4-[[4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl]sulfanyl]phenol), their synthesis, and their use as Rho-kinase inhibitors (no data). These compds. are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. For I: R1 and R2 = H, halo, alkyl (un)substituted by halo up to perhalo, cycloalkyl, alkenyl, alkynyl, NO2, NH2, NR6R7, or furyl, thienyl, pyridyl, trifluoromethyl or Ph each (un)substituted with NH2, NO2 trifluoromethyl or alkoxy; or R1 and R2 may be taken together to form a ring of = 5-7 members optionally interrupted by N and (un)substituted on N by benzyl. R3 = NH2 or -NH- Ph (un)substituted with halo, C1-C4 alkyl, trifluoromethyl, nitro or amino; R4 = X-A- and R5n-substituted Ph, R5n-substituted 6-X-Apyridin-3-yl or indol-5-yl (un)substituted on N with pyridyl; X is a linker substituted at the 3 or 4 position of the ring and is O, S, -S-CH2-, -(CH2)m-, or -C(O)-; A is Ph (un)substituted with alkylthio or OH, pyridyl, quinolyl or isoquinolyl. Each R5 independently is halo, alkyl (un)substituted by halo up to perhalo, cycloalkyl, alkoxy, alkenyl, alkynyl, NO2, NH2, or trifluoromethyl; n is 0-4; m is 1 or 2; and R6 and R7 are each independently H, alkyl, cycloalkyl, or Ph (un)substituted with halo, CF3, alkyl, nitro or amino; or R6 and R7 may form, together with the N atom to which they are attached, a heterocyclic ring (un)substituted with alkyl,

optionally interrupted by O, or optionally fused to phenyl; addnl. details including provisos are given in the claims. More than 30 example preps. of I plus many preps. of intermediates are included. For example, 4-[[4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl]mercapto]phenol (0.11 mmol, 51% yield) was prepared from 2-amino-4-chloro-6-ethylpyrimidine (0.23 mmol) and 4-[(4-aminophenyl)sulfanyl]phenol (0.25 mmol) suspended in a mixture of 0.01M aqueous HCl (230  $\mu$ L) and 1-butanol (230  $\mu$ L); the mixture was refluxed overnight.


IT 569658-30-6P, N-[2-Amino-6-(3-nitrophenyl)-4-pyrimidinyl]-N-[3-fluoro-4-[(4-pyridinyl)sulfanyl]phenyl]amine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses)

RN 569658-30-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(4-pyridinylthio)phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 569658-36-2P, N-[2-Amino-6-(3-aminophenyl)-4-pyrimidinyl]-N-[3-fluoro-4-[(4-pyridinyl)sulfanyl]phenyl]amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses)

RN 569658-36-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[3-fluoro-4-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 41 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:301049 CAPLUS  
 DN 138:321058  
 TI C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation  
 IN Ding, Sheng; Ding, Qiang; Gray, Nathanael S.  
 PA IRM LLC, Bermuda; The Scripps Research Institute  
 SO PCT Int. Appl., 68 pp., which which which  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003031406	A2	20030417	WO 2002-US32680	20021012
	WO 2003031406	A3	20060105		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463563	A1	20030417	CA 2002-2463563	20021012
	AU 2002342051	A1	20030422	AU 2002-342051	20021012
	US 2003191312	A1	20031009	US 2002-270030	20021012
	US 7176312	B2	20070213		
	JP 2005512972	T	20050512	JP 2003-534390	20021012
	EP 1578722	A2	20050928	EP 2002-776216	20021012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2006009642	A1	20060112	US 2005-223429	20050909
PRAI	US 2001-328763P	P	20011012		
	US 2001-331835P	P	20011120		
	US 2002-346480P	P	20020107		
	US 2002-348089P	P	20020110		
	US 2001-328741P	P	20011012		
	US 2002-346552P	P	20020107		
	US 2002-347037P	P	20020108		
	US 2002-170031	A3	20020612		
	WO 2002-US32680	W	20021012		

OS CASREACT 138:321058; MARPAT 138:321058

AB General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls, particularly C2-, C6- and 9-aryl-substituted purines (e.g. 2-(2,4-dimethoxyphenyl)-6-(4-methoxybenzylamino)-9-isopropylpurine), was demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via Pd catalyzed cross-coupling reactions. The 1st claim comprises a method of preparing a C2-substituted purine compound, said method comprising: reacting a C2-halogenated purine with A-X (X = -B(OH)<sub>2</sub>, -OH, and -NHR<sub>1</sub>; R<sub>1</sub> = H, (un)substituted alkyl; A = (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl) in the presence of a solvent, a base, a carbene ligand and a Pd catalyst. The 2nd claims narrows the 1st claim to purines I wherein R<sub>2</sub> = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl; X' = direct bond, NR<sub>1</sub> and O; X'' = direct bond, O and NR<sub>3</sub>, with the proviso that when X'' is NR<sub>3</sub>, Y is R<sub>4</sub> or A', and


when X' is O or a direct bond, Y is A'; A' = (un)substituted alkyl, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heterocyclyl; R3 = H, (un)substituted alkyl; and R4 = (un)substituted alkyl. Similar claims pertain to C6-substituted purines. Also claimed is a method of preparing a 9-aryl substituted purines, the method comprising: reacting a 2,6-dihalogenated purine with Ar-B(OH)2 (Ar = (un)substituted aryl, and (un)substituted heterocyclyl) in the presence of a solvent and a Cu catalyst. Also claimed is a method for synthesizing a substituted heteroaryl, the method comprising: providing a dihaloheteroaryl scaffold moiety and capturing the dihaloheteroaryl scaffold moiety on a resin by nucleophilic substitution of a 1st halogen by a resin-bound amine nucleophile to afford a resin-bound amine substituted monohaloheteroaryl. Substitution of the 2nd halogen is done by nucleophilic displacement (e.g. by aniline, phenol, amine, boronic acid) or coupling (e.g. palladium-mediated). An initial substitution (e.g. alkylation, acylation, coupling) can be done prior to substitution of the 1st halogen. Example procedures are included for: boronic acid coupling, aniline coupling, phenol coupling, purine N9 arylation via boronic acids/cupric acetate, reductive amination for synthesis of PAL-resin-bound amine, resin capture of dichloroheterocycles, substitution of remaining chloro group with boronic acids via Suzuki coupling and product cleavage, substitution of remaining chloro group with anilines or amines via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with phenols via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction without base and product cleavage, and substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction with KOTBu as base and product cleavage. Tables of purity and yields for various heteroaryl combinatorial libraries are included as validation of the following methods: palladium catalyzed cross-coupling reactions for derivatizing resin-bound 2-chloro-6-aminopurine with boronic acids, anilines, amines and phenols, resin-bound chloroheterocyclic scaffolds which can be derivatized via Suzuki coupling reaction, resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed amination reaction, and resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed C-O bond formation reaction.

IT 406932-44-3P, 4-(4-Methoxybenzylamino)-6-(3-methoxyphenyl)pyrimidine 406932-45-4P, 4-(4-Methoxybenzylamino)-6-(3-methoxyphenyl)pyrimidin-2-amine  
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
 (C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation)  
 RN 406932-44-3 CAPLUS  
 CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 406932-45-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

10/671,070






L10 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:98255 CAPLUS  
 DN 138:287627  
 TI Suzuki Cross-Coupling of Solid-Supported Chloropyrimidines with Arylboronic Acids  
 AU Wade, Janice V.; Krueger, Clinton A.  
 CS ChemRx Division, Discovery Partners International Inc., South San Francisco, CA, 94080, USA  
 SO Journal of Combinatorial Chemistry (2003), 5(3), 267-272  
 CODEN: JCCHFF; ISSN: 1520-4766  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 138:287627  
 AB The utility of the Suzuki cross-coupling to synthesize biaryl compds. is expanded herein to include reactions of resin-supported chloropyrimidines with boronic acids. In particular, an efficient method is described for the synthesis of a library of biaryl compds. from solid-supported chloropyrimidines. The Suzuki reaction was performed in an inert atmospheric using Pd2(dba)3/P(t-Bu)3 as catalyst, spray-dried KF as base, and THF as solvent. The reaction was allowed to proceed overnight at 50 °C. Upon cleavage with acid, a library of 4-(substituted amino)-6-arylpyrimidines, e.g. I, was obtained in moderate yield and high purity.  
 IT 503610-80-8DP, resin-supported  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (Suzuki cross-coupling of solid-supported chloropyrimidines with arylboronic acids)  
 RN 503610-80-8 CAPLUS  
 CN Ethanone, 1-[3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



IT 503610-80-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (Suzuki cross-coupling of solid-supported chloropyrimidines with arylboronic acids)  
 RN 503610-80-8 CAPLUS  
 CN Ethanone, 1-[3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:927396 CAPLUS  
 DN 138:13955  
 TI Preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase for the treatment of disease  
 IN Cao, Sheldon Xiaodong; Bounaud, Pierre-Yves; Chen, Xiaohua; Chung, Hyun-Ho; Dumas, David Paul; Kc, Sunil Kumar; Min, Changhee; Yang, Jae Young; Long, Mellissa C.  
 PA LG Biomedical Institute, USA  
 SO PCT Int. Appl., 286 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096867	A2	20021205	WO 2002-US16920	20020528
	WO 2002096867	A3	20040304		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002310187	A1	20021209	AU 2002-310187	20020528
	US 2003187007	A1	20031002	US 2002-158030	20020528
	US 2003208067	A1	20031106	US 2002-158103	20020528
	EP 1412327	A2	20040428	EP 2002-737248	20020528
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004534779	T	20041118	JP 2003-500047	20020528
	KR 2004026657	A	20040331	KR 2003-715388	20031125
PRAI	US 2001-294792P	P	20010530		
	WO 2002-US16920	W	20020528		

OS MARPAT 138:13955

AB Phenol and hydroxynaphthalene derivs. I [X = O, S, amine, alkylamine, alkynylamine, arylamine, and heteroarylamine; R1 = (un)substituted 5- or 6-membered aromatic or heteroarom. ring, -(X1)mCOX2-, wherein X1 = alkylene, alkenylene, alkynylene, aryl and heteroaryl, X2 = H, alkyl, aryl, heteroaryl, OH, alkoxy, amino, substituted amine, m = 0 or 1, or R1 = -C(X3)=N-NX4-C(=E)-NX5X6 wherein X3 = H, alkyl, aryl, alkylaryl, heteroaryl, and amino and E = O, S, and substituted amine with X4, X5, and X6 independently equal to H, alkyl, aryl, and heteroaryl; R2, R3, and R4 = H, alkyl, alkylene, halo, alkoxy, etc.; or R2 and R3 or R3 and R4 may be taken together to form an (un)substituted aromatic or heteroarom. ring; R5 = H, (un)substituted-alkyl, -aryl, -heterocycle, etc.; R6 = H, alkyl, alkene, alkyne, aryl, and heteroaryl] are prepared and disclosed as inhibitors of protein kinase. Thus, II was prepared by cyclocondensation of 5'-bromo-2'-methoxyacetophenone with N,N-dimethylformamide di-Et acetal with subsequent Suzuki coupling with 4-methoxyphenylboronic acid. In assays to determine cyclin dependent kinase activity, specifically against CDK2 and CDK5, II possessed IC50 values of 0-0.5  $\mu$ M. II proved highly specific for CDK2 and CDK5 and was further evaluated by in vitro tumor cell efficacy tests against numerous cancers. The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compds. The methods

incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compds. and pharmaceutical compns. comprising these compds.

IT 477726-95-7P 477726-96-8P 477727-07-4P  
477727-17-6P 477727-18-7P 477727-19-8P  
477727-20-1P 477727-24-5P 477727-25-6P  
477727-26-7P 477727-27-8P 477727-28-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)

RN 477726-95-7 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[ (1R)-1-(hydroxymethyl)-2-phenylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477726-96-8 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[ (1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477727-07-4 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-17-6 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[[1,1'-biphenyl]-2-ylmethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-18-7 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(3-chlorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-19-8 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-20-1 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(3-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-24-5 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[3-fluorophenyl]methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 477727-25-6 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[2-fluorophenyl]methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 477727-26-7 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[3-methoxyphenyl]methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 477727-27-8 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[4-methoxyphenyl]methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)

10/671,070



RN 477727-28-9 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2-fluoro-4-hydroxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:353449 CAPLUS  
 DN 136:369729  
 TI Preparation of N6-(2-aminopyrimidin-4-yl)-quinoline-4,6-diamines as N-type calcium channel antagonists for the treatment of pain  
 IN Chaudhari, Bipinchandra; Chapdelaine, Marc; Hostetler, Greg; Kemp, Lucius; McCauley, John  
 PA Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036586	A1	20020510	WO 2001-SE2388	20011031
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 200212894	A	20020515	AU 2002-12894	20011031
	EP 1339706	A1	20030903	EP 2001-981239	20011031
	EP 1339706	B1	20060419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513125	T	20040430	JP 2002-539345	20011031
	AT 323693	T	20060515	AT 2001-981239	20011031
	ES 2261496	T3	20061116	ES 2001-1981239	20011031
	US 2004058945	A1	20040325	US 2003-415785	20031002
	US 6815447	B2	20041109		
PRAI	SE 2000-4053	A	20001106		
	WO 2001-SE2388	W	20011031		

OS MARPAT 136:369729

AB The title compds. [I; R1 = NE1E2 (wherein E1 = H, Me; E2 = H, alkyl, phenylalkyl); R2 = E3, E4 (E3 = alkyl, alkoxy, alkoxyalkyl; E4 = substituted Ph); R3 = E5, E6 (E5 = NH2, perfluoroalkyl, alkyl, alkoxyalkyl, phenylalkoxy, phenoxyalkyl; E6 = Ph substituted at one or two positions)], useful for the treatment of pain, were prepared. Thus, reacting 2-phenylquinoline-4,6-diamine with 4-chloro-6-(4-fluorophenyl)pyrimidin-2-amine (preparation given) afforded 92% I [R1 = NH2; R2 = Ph; R3 = 4-FC6H4]. Compds. I generally had a binding affinity for the N-type calcium channel, as measured by the FLIPR assay, of  $\leq 10 \mu\text{M}$ .

IT 423182-53-0P 423182-64-3P 423182-67-6P  
 423182-68-7P 423182-69-8P 423182-72-3P  
 423182-73-4P 423182-75-6P 423182-77-8P  
 423182-81-4P 423182-82-5P 423182-85-8P  
 423182-91-6P 423182-94-9P 423182-95-0P  
 423182-97-2P 423182-99-4P 423183-00-0P  
 423183-02-2P 423183-03-3P 423183-04-4P  
 423183-08-8P 423183-09-9P 423183-12-4P  
 423183-14-6P 423183-16-8P 423183-17-9P  
 423183-18-0P 423183-19-1P 423183-24-8P  
 423183-25-9P 423183-26-0P 423183-37-3P  
 423183-39-5P 423183-40-8P 423183-41-9P  
 423183-43-1P 423183-44-2P 423183-46-4P


423183-47-5P 423183-48-6P 423183-50-0P  
 423183-52-2P 423183-53-3P 423183-54-4P  
 423183-55-5P 423183-56-6P 423183-60-2P  
 423183-62-4P 423183-63-5P 423183-64-6P  
 423183-65-7P 423183-69-1P 423183-70-4P  
 423183-71-5P 423183-73-7P 423183-75-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of N6-(2-aminopyrimidin-4-yl)-quinoline-4,6-diamines as N-type  
 calcium channel antagonists for the treatment of pain)


RN 423182-53-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-  
 phenyl- (9CI) (CA INDEX NAME)




RN 423182-64-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-  
 methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 423182-67-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-[3-(  
 trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423182-68-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-




10/671,070

pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-69-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423182-72-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 423182-73-4 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-pentyl- (9CI) (CA INDEX NAME)



RN 423182-75-6 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(2-(4-methoxyphenyl)ethyl)- (9CI) (CA INDEX NAME)

fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-77-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-81-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-82-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-85-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423182-91-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenoxyethyl)phenyl]-4-pyrimidinyl]-2-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 423182-94-9 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 423182-95-0 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(2-

fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-97-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-99-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 423183-00-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-02-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-4-phenyl- (9CI) (CA INDEX NAME)


10/671,070

pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-03-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-04-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-08-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-09-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-12-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-14-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 423183-16-8 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 423183-17-9 CAPLUS


10/671,070

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-18-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-19-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-24-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423183-25-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-26-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-37-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)



RN 423183-39-5 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)






10/671,070


RN 423183-40-8 CAPLUS  
CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423183-41-9 CAPLUS  
CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 423183-43-1 CAPLUS  
CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-44-2 CAPLUS  
CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-46-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423183-47-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-48-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-50-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-52-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-pentyl- (9CI) (CA INDEX NAME)




RN 423183-53-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-54-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-55-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-56-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-60-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-62-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-63-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-64-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-65-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-69-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-70-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-71-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-73-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)



RN 423183-75-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)-N4,N4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:122964 CAPLUS  
 DN 136:167384  
 TI Preparation of 4-pyrimidinamines as neuroprotectants.  
 IN Grant, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael; Zhong, Zhong; Scott, Malcolm; Reitz, Allen B.; Ross, Tina Morgan  
 PA Ortho-McNeil Pharmaceutical, Inc., USA  
 SO PCT Int. Appl., 92 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002012198	A2	20020214	WO 2001-US24659	20010806
	WO 2002012198	A3	20020606		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2419030	A1	20020214	CA 2001-2419030	20010806
	AU 200181120	A	20020218	AU 2001-81120	20010806
	EP 1313713	A2	20030528	EP 2001-959581	20010806
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001013165	A	20030715	BR 2001-13165	20010806
	JP 2004505952	T	20040226	JP 2002-518176	20010806
	NZ 524100	A	20050128	NZ 2001-524100	20010806
	IN 2003KN00137	A	20050311	IN 2003-KN137	20030203
	ZA 2003001868	A	20040625	ZA 2003-1868	20030306
PRAI	US 2000-223791P	P	20000808		
	WO 2001-US24659	W	20010806		

OS MARPAT 136:167384

AB Pharmaceutical compns. comprising a pharmaceutically acceptable carrier [I; R9 = H, thienyl, furanyl, pyrrolyl, (substituted) Ph, pyridinyl, pyridinyl, naphthyl, benzo[b]thien-2-yl, 2-benzofuranyl, pyrimidinyl, 2,4-bis(methoxyphenyl)-5-pyrimidinyl; R10 = cyanoalkyl, alkylamino, dialkylamino, hydroxyalkylamino, hydroxydialkylamino; R11 = H, alkyl], are claimed. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbamoyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07  $\mu$ M to >1  $\mu$ M.


IT 397851-08-0 397851-15-9 397851-16-0  
 397851-18-2 397851-20-6 397851-24-0  
 397851-26-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-08-0 CAPLUS


CN 1,4-Benzenediamine, N'-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)






RN 397851-15-9 CAPLUS

CN Ethanol, 2-[[4-[[6-(3,5-bis(trifluoromethyl)phenyl)-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-16-0 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(3-nitrophenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-18-2 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(2-phenoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-20-6 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-(2-phenoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-24-0 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 397851-26-2 CAPLUS

CN Ethanol, 2-[[4-[[6-[3-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)



L10 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:96165 CAPLUS

DN 136:294745

TI A combinatorial scaffold approach toward kinase-directed heterocycle libraries

AU Ding, Sheng; Gray, Nathanael S.; Wu, Xu; Ding, Qiang; Schultz, Peter G.

CS Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA

SO Journal of the American Chemical Society (2002), 124(8), 1594-1596

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

OS CASREACT 136:294745

AB A novel strategy for efficient synthesis of various substituted nitrogen-heterocycles, e.g., I, as kinase-directed combinatorial libraries is described. The general scheme involves capture of various dichloroheterocycles onto solid support and further elaborations by aromatic substitution with amines at elevated temperature or by anilines, boronic acids, and phenols via palladium-catalyzed cross-coupling reactions, thus the scaffold itself is transformed into a diversity element within the combinatorial scheme. Libraries consisting of discrete and highly diverse heterocyclic small mols. constructed with these chemistries are currently being evaluated in a variety of cell and protein-based assays.


IT 406932-44-3P 406932-45-4P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)

(derivatization of resin-bound chloroheterocyclic scaffolds via Suzuki coupling reaction with aryl boronic acid and subsequent cleavage of substituted heterocyclic product)

RN 406932-44-3 CAPLUS


CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



*Differs by 1 sub.  
Appl. provided  
Scripps data  
for addition of  
CH<sub>3</sub>*

RN 406932-45-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:635876 CAPLUS  
 DN 135:211049  
 TI Preparation of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders  
 IN Borroni, Edilio Maurizio; Huber-Trottmann, Gerda; Kilpatrick, Gavin John; Norcross, Roger David  
 PA F. Hoffmann La Roche A.-G., Switz.  
 SO PCT Int. Appl., 256 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062233	A2	20010830	WO 2001-EP1679	20010215
	WO 2001062233	A3	20020103		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2398274	A1	20010830	CA 2001-2398274	20010215
	EP 1261327	A2	20021204	EP 2001-927670	20010215
	EP 1261327	B1	20050427		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008611	A	20030506	BR 2001-8611	20010215
	HU 200300029	A2	20030528	HU 2003-29	20010215
	JP 2003523380	T	20030805	JP 2001-561300	20010215
	NZ 520241	A	20040528	NZ 2001-520241	20010215
	AU 780527	B2	20050324	AU 2001-54643	20010215
	AT 293962	T	20050515	AT 2001-927670	20010215
	ES 2240449	T3	20051016	ES 2001-1927670	20010215
	RU 2277911	C2	20060620	RU 2002-123338	20010215
	US 2001027196	A1	20011004	US 2001-788956	20010220
	US 6586441	B2	20030701		
	ZA 2002006077	A	20031030	ZA 2002-6077	20020730
	NO 2002004006	A	20020822	NO 2002-4006	20020822
PRAI	EP 2000-103432	A	20000225		
	WO 2001-EP1679	W	20010215		

OS MARPAT 135:211049

AB The title compds. (I) [wherein A = a bond, S, N(R), (CH<sub>2</sub>)<sub>2</sub>, CH:CH, C.tplbond.C, or O; X and Y = independently N:, :N, :CH, C(CN):, :C(CN), C(CSNH<sub>2</sub>):, or :C(CSNH<sub>2</sub>), wherein at least 1 of X or Y is N; R<sub>1</sub> = H, (cyclo)alkyl, alkenyl, alkynyl, halo, CN, (alkyl)carboxylates, (alkyl)carbamates, alkoxy(alkyl), phenoxy(alkyl), phenylamino(alkyl), (un)substituted phenyl(alkyl) or amino(alkyl), morpholinyl(alkyl), piperidinyl(alkyl), pyridinyl(alkyl), piperazinyl(alkyl), etc.; R<sub>2</sub> = H, halo, CN, NO<sub>2</sub>, acyl, carboxylate, (un)substituted alkyl, alkenyl, alkynyl, or Ph; R<sub>3</sub> = alkyl or thienyl, (dihydro)furanyl, benzodioxolyl, isoxazolyl, pyridinyl, dihydropyranyl, pyrazinyl, aryl(alkyl)oxy, pyrazolyl, (un)substituted Ph, etc.; R<sub>4</sub> and R<sub>5</sub> = independently H, benzoyl, or (un)substituted phenacyl; or A and R<sub>2</sub> taken together the with the C atoms to which they are attached may form a substituted thienyl group] were prepared as adenosine receptor modulators. For example, treating 3,4,5-trimethoxybenzoylacetonitrile with to NaH in DMSO, followed by addition

of CS<sub>2</sub> and MeI, gave the bis(methylthio) intermediate. Cycloaddn. with guanidine nitrate in the presence of TEA in DMF afforded the pyrimidinenitrile (II), which exhibited high selectivity toward the A<sub>1</sub> and A<sub>3</sub> adenosine receptors compared to the A<sub>2</sub> receptor with pK<sub>i</sub> values of 5.88, 5.71 and 7.24, resp. I are useful for the treatment of Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, and sedation, and they may be active as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants, and cardioprotective agents (no data). The most preferred indications for I are those which include disorders of the central nervous system, such as certain depressive disorders, neuroprotection, and Parkinson's disease.


IT 357288-80-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders and other diseases)

RN 357288-80-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-methoxyphenyl)-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2000:513679 CAPLUS  
 DN 133:120681  
 TI Preparation of amino acid acyl derivatives as inhibitors of leukocyte adhesion mediated by VLA-4  
 IN Konradi, Andrei; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Welmaker, Gregory S.; Kreft, Anthony; Sarantakis, Dimitrios; Dressen, Darren B.; Grant, Francine S.; Semko, Christopher; Xu, Ying-Zi  
 PA Elan Pharmaceuticals, Inc., USA; American Home Products  
 SO PCT Int. Appl., 342 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000043372	A1	20000727	WO 2000-US1686	20000121
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359115	A1	20000727	CA 2000-2359115	20000121
	EP 1144388	A1	20011017	EP 2000-913245	20000121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000007663	A	20020507	BR 2000-7663	20000121
	US 6479492	B1	20021112	US 2000-489378	20000121
	US 6492372	B1	20021210	US 2000-489377	20000121
	HU 200201213	A2	20021228	HU 2002-1213	20000121
	AU 773538	B2	20040527	AU 2000-34724	20000121
	TW 239954	B	20050921	TW 2000-89101088	20000124
	ZA 2001005314	A	20030327	ZA 2001-5314	20010627
	IN 2001CN00984	A	20050304	IN 2001-CN984	20010711
	NO 2001003600	A	20010920	NO 2001-3600	20010720
	US 2003125324	A1	20030703	US 2002-218366	20020815
	US 6911439	B2	20050628		
	US 2003144328	A1	20030731	US 2002-218445	20020815
	US 6903088	B2	20050607		
	US 2003139402	A1	20030724	US 2002-251442	20020920
	US 7049306	B2	20060523		
	HK 1046132	A1	20060504	HK 2002-107038	20020926
	NZ 529822	A	20031219	NZ 2003-529822	20031127
	US 2004147512	A1	20040729	US 2003-748089	20031229
	US 7005433	B2	20060228		
	US 2005203093	A1	20050915	US 2005-33079	20050110
	US 2005261293	A1	20051124	US 2005-145489	20050602
	US 2007099921	A1	20070503	US 2006-582293	20061016
PRAI	US 1999-116923P	A2	19990122		
	US 1999-160999P	P	19991021		
	US 1999-160199P	P	19991019		
	US 2000-489377	A3	20000121		
	US 2000-489378	A3	20000121		
	WO 2000-US1686	W	20000121		
	US 2002-218366	A3	20020815		
	US 2002-218445	A3	20020815		
	US 2002-251442	A1	20020920		

US 2005-33079

A1 20050110

OS MARPAT 133:120681

AB Disclosed are compds. R2-W:CR1-Q-CR3R3'COX and R2-W'-CHR1-Q-CR3R3'COX [R1 and R2 are joined to form a ring; R3, R3' = H, iso-Pr, -CH2Z or :CHZ, where Z = H, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxy, carboxyalkyl, etc.; Q = O, S, SO, SO2, NH or imino group; W = nitrogen, carbon; W' = nitrogen, carbon, oxygen, sulfur, SO, SO2; X = OH, (un)substituted alkoxy, alkenoxy, cycloalkoxy, cycloalkenoxy, aryloxy, heteroaryloxy or heterocyclyloxy, an amino group] which bind VLA-4. Thus, N-[5-(N-4-toluenesulfonylamino)pyrimidin-4-yl]-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester was prepared by condensation of L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester with 2,4-dichloro-5-nitropyrimidine, followed by nitro group reduction and tosylation. Compds. synthesized in the examples are expected to have a binding affinity to VLA-4 expressed by an IC50 of 15  $\mu$ M or less.

IT 285139-60-8P 285139-62-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid acyl derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 285139-60-8 CAPLUS

CN L-Tyrosine, N-[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-62-0 CAPLUS

CN L-Tyrosine, N-[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 4


THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1999:295955 CAPLUS  
 DN 131:67655  
 TI Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists  
 AU Cocuzza, Anthony J.; Chidester, Dennis R.; Culp, Steven; Fitzgerald, Lawrence; Gilligan, Paul  
 CS Chemical and Physical Sciences Department, DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA  
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(7), 1063-1066  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB The Suzuki reaction has been used to synthesize a variety of aryl-substituted heterocyclic antagonists of the CRH1 receptor. Examples with several different heterocyclic cores are potent CRH receptor ligands.  
 IT 219840-93-4P 219840-94-5P  
 RL: BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)  
 (aryl-substituted heterocycles as corticotropin-releasing hormone antagonists, and preparation thereof using Suzuki reaction)  
 RN 219840-93-4 CAPLUS  
 CN 4-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



20/88

RN 219840-94-5 CAPLUS  
 CN 4,5-Pyrimidinediamine, N4-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L10 ANSWER 50 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:48709 CAPLUS

DN 130:125084

TI Aryl- and arylamino-substituted heterocycles as corticotropin releasing hormone (CRF) antagonists

IN Cocuzza, Anthony J.; Hobbs, Frank W.; Beck, James P.; Gilligan, Paul J.

PA Du Pont Pharmaceuticals Company, USA

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901439	A1	19990114	WO 1998-US13840	19980702
	W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2296014	A1	19990114	CA 1998-2296014	19980702
	AU 9881810	A	19990125	AU 1998-81810	19980702
	EP 994860	A1	20000426	EP 1998-931783	19980702
	R: CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	US 6103737	A	20000815	US 1998-109395	19980702
	JP 2002510322	T	20020402	JP 1999-507408	19980702
PRAI	US 1997-51745P	P	19970703		
	WO 1998-US13840	W	19980702		

OS MARPAT 130:125084

AB Corticotropin releasing factor (CRF) antagonists I and their stereoisomers and pharmaceutically acceptable salts are disclosed [wherein Y = CR2 or N; Z = CH or N; K = CR5 or N; R1 = alk(en/yn)yl, Cl, F, cyano, CF3; R2R4 = E-F where E and F = CR9 and/or CR9'; or R2R4 = A:D where A and D = CH, CR10, or N, provided that A:D is oriented to form imidazole but not pyrazole; or R2R4 = A-D where A = NR9 and D = CO, oriented to form an imidazolone; R3 = Ph, naphthyl, pyridinyl, or pyrimidinyl, all substituted by R8; R4 = (un)substituted alkyl, allyl, or propargyl; R5 = 1-4 of alk(en/yn)yl, cycloalkyl, halo, NO2, cyano, NR6R7, OR7, COR7, C(:NOR9)R7, SOR7, etc.; or 2 R5 moieties may form CR9R9'CR9R9'O, CR9:CR9'O, etc.; R6, R7 = H or (un)substituted alkyl, cycloalkyl, (CH2)mPh or (CH2)m-heteroaryl; R8 = alk(en/yn)yl, cycloalkyl, Ph, heteroaryl, halo, NO2, cyano, NR6R7, OR7, etc., with provisos; R9, R9' = H, alkyl; n = 0-2; m = 0-6]. Also disclosed is their use in treating psychiatric disorders and neurol. diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders, as well as treatment of immunol., cardiovascular or heart-related diseases, and colonic hypersensitivity associated with psychopathol. disturbance and stress in mammals. For example, condensation of 2-BrC6H4COCH3 with MeC(OMe)2NMe2 gave 2-BrC6H4COCH:MeNMe2, which underwent cyclocondensation with (2-bromo-4-isopropylphenyl)guanidine-HCl, followed by N-alkylation of the resultant aminopyrimidine with EtI and NaH in DMSO, to give title compound II. Some I were active (no data) in an assay for inhibition of CRF-stimulated adenylate cyclase activity.

IT 199728-09-1P 199728-10-4P 219840-93-4P

219840-94-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists)

RN 199728-09-1 CAPLUS


10/671,070

CN 4-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 199728-10-4 CAPLUS

CN 4,5-Pyrimidinediamine, N4-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-93-4 CAPLUS

CN 4-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 219840-94-5 CAPLUS

CN 4,5-Pyrimidinediamine, N4-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

L10 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1997:772646 CAPLUS  
 DN 128:34777  
 TI Preparation of tetrahydropteridines and pyridylpiperazines for treatment  
 of neurological disorders  
 IN Wilde, Richard Gerald  
 PA Du Pont Merck Pharmaceutical Company, USA  
 SO PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9744038	A1	19971127	WO 1997-US8448	19970519
	W: AU, CA, IL, JP, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9703884	A	19981106	ZA 1997-3884	19970506
	US 6083948	A	20000704	US 1997-857349	19970516
	CA 2255650	A1	19971127	CA 1997-2255650	19970519
	AU 9731316	A	19971209	AU 1997-31316	19970519
	AU 739269	B2	20011011		
	EP 901374	A1	19990317	EP 1997-926590	19970519
	EP 901374	B1	20031210		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	NZ 332704	A	20000526	NZ 1997-332704	19970519
	JP 2000511183	T	20000829	JP 1997-542618	19970519
	AT 255896	T	20031215	AT 1997-926590	19970519
	EP 1380298	A2	20040114	EP 2003-78058	19970519
	EP 1380298	A3	20040407		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	PT 901374	T	20040430	PT 1997-926590	19970519
	ES 2213216	T3	20040816	ES 1997-926590	19970519
	MX 9809730	A	20000531	MX 1998-9730	19981119
	US 6399609	B1	20020604	US 2000-570775	20000511
	US 2003064993	A1	20030403	US 2002-59910	20020129
	US 6869955	B2	20050322		
PRAI	US 1996-18198P	P	19960523		
	US 1997-857349	A3	19970516		
	EP 1997-926590	A3	19970519		
	WO 1997-US8448	W	19970519		
	US 2000-570775	A3	20000511		

OS MARPAT 128:34777

AB The title compds. [I; A = N, CR11 (wherein R11 = H, C1-4 alkyl, halo); X = H, (un)substituted Ph, heteroaryl, etc.; R4 = H, C1-12 alkyl, allyl, etc.; R5-R8 = H, C1-4 alkyl, allyl, etc.; R4R5R6 = along with two interconnecting atoms may form (un)substituted imidazole or tetrazole ring; R5R6 = O, S, NR12 (wherein R12 = H, C1-4 alkyl, Ph); R9 = (un)substituted Ph, pyridyl, pyrimidinyl; R10 = H, C1-4 alkyl, CN], corticotropin releasing factor (CRF) antagonists useful in treating anxiety, depression, and other psychiatric and neurol. disorders, were prepared and formulated. Thus, reaction of 4,6-dichloro-2-methyl-5-nitropyrimidine with EtBuNH followed by reacting the resulting 4-chloro-6-(ethylbutylamino)-2-methyl-5-nitropyrimidine with 2-bromo-4-isopropylaniline, reduction of 6-(2-bromo-4-isopropylphenylamino)-4-(ethylbutylamino)-2-methyl-5-nitropyrimidine with sodium dithionite, treatment of 5-amino-6-(2-bromo-4-isopropylphenylamino)-4-(ethylbutylamino)-2-methylpyrimidine with NaH in DMF, and addition of BrCH2CO2Et afforded I [A = N; X = BuEtN; R4 = R7 = R8 = H; R5R6 = O; R9 = 2-Br-4-iPrC6H3; R10 = Me]. Compds. I are effective at 0.002-200

mg/kg/day.


IT 199728-09-1P 199728-10-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetrahydropteridines and pyridylpiperazines for treatment of neurol. disorders)


RN 199728-09-1 CAPLUS

CN 4-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 199728-10-4 CAPLUS

CN 4,5-Pyrimidinediamine, N4-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 52 OF 52 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1955:60839 CAPLUS

DN 49:60839

OREF 49:11726h-i,11727a-b

TI 2-Amino-4-substituted amino-6-arylpyrimidines

IN Hitchings, Geo. H.; Russell, Peter B.

PA Burroughs Wellcome and Co. (U.S.A.) Inc.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2691655		19541012	US 1952-289907	19520524
AB	2-Amino-4-substituted amino-6-arylpyrimidines, useful as growth inhibitors for rapidly growing virus are prepared from the corresponding 4-hydroxypyrimidine by conversion to the 4-chloropyrimidine and subsequent reaction with the appropriate amine. Thus, 47 g. BzCHPrCO <sub>2</sub> Et, refluxed 6 hrs. with 12 g. guanidine carbonate in 200 ml. EtOH, gives 2-amino-4-hydroxy-5-propyl-6-phenylpyrimidine (I), m. 311-13°, obtained by dilution of the reaction mixture with 500 ml. H <sub>2</sub> O and recrystn. of the precipitate from EtOH; the 5-benzyl analog (II), m. 340°, was prepared similarly from BzCH(CH <sub>2</sub> Ph)CO <sub>2</sub> Et. Refluxing 10 g. I with 50 ml. POCl <sub>3</sub> until solution was achieved, removing the excess POCl <sub>3</sub> , and suspending the residue in iced aqueous NH <sub>4</sub> OH gave 2-amino-4-chloro-5-propyl-6-phenylpyrimidine (III). Similarly, II yields the 5-benzyl analog (IV) of III; heating 5 g. III with 100 ml. of a saturated solution of MeNH <sub>2</sub> in EtOH in				

a

bomb for 16 hrs. at 150° gives 4.2 g. 4-MeNH analog of III, m.

198°, and IV gives the 4-MeNH analog of IV, m. 177°.

Refluxing 5 g. III with 25 ml. of PhNH<sub>2</sub> 5 hrs., cooling, and recrystg. the precipitate from EtOH, gives needles of the 4-PhNH analog of III, m. 171°;

4-PhNH analog of IV, m. 211°. The following compds. are obtained

by analogous procedures: 2-amino-4-methylamino-6-(2-naphthyl)pyrimidine,

m. 238-9°; 2-amino-4-methylamino-6-phenylpyrimidine, m.

195-6°, and its 4-PhNH, m. 305-6° (decomposition),

4-(p-ClC<sub>6</sub>H<sub>4</sub>NH), m. 304-5°, and 4-(p-MeOC<sub>6</sub>H<sub>4</sub>NH) analogs, m.

259-63°.


IT 859208-83-6P, Pyrimidine, 2-amino-4-p-anisidino-5-benzyl-6-(o-chlorophenyl)-

RL: PREP (Preparation)

(preparation of)

RN 859208-83-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



10/671,070

=> => d his

(FILE 'HOME' ENTERED AT 23:06:25 ON 10 JUN 2007)

FILE 'REGISTRY' ENTERED AT 23:06:44 ON 10 JUN 2007

L1           STRUCTURE UPLOADED  
L2           50 S L1 SSS SAM  
L3           STRUCTURE UPLOADED  
L4           39 S L3 SSS SAM  
L5           STRUCTURE UPLOADED  
L6           26 S L5 SSS SAM  
L7           STRUCTURE UPLOADED  
L8           23 S L7 SSS SAM  
L9           1049 S L7 SSS FUL

FILE 'CAPLUS' ENTERED AT 23:18:20 ON 10 JUN 2007

L10           52 S L9

FILE 'CAOLD' ENTERED AT 23:20:06 ON 10 JUN 2007

=> s 19

L11           0 L9

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

456.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-40.56

STN INTERNATIONAL LOGOFF AT 23:20:20 ON 10 JUN 2007